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Abstract  
Dynamic Src Tyrosine Kinase Signaling Directs Invadopodia Formation and Function in 
Head and Neck Cancer: Novel Insights into the Original Oncogene 
Laura Catherine Kelley 
 
 Cancer cell invasion and motility is mediated through actin-rich protrusions that 
facilitate migration through extracellular matrix and degradation of tissue barriers. Src 
tyrosine kinase is an essential catalyst of motile actin networks and is a potent mediator 
of the metastatic program. The Src substrate cortactin is a critical scaffold that links 
kinase signaling to cytoskeletal dynamics. Both Src and cortactin are overexpressed in 
several human cancers and their expression is associated with poor prognosis. These 
proteins are not associated with the initiation of tumorigenesis, but are thought to play a 
vital role in the metastatic process. The overall aim of my work is to determine the 
molecular mechanisms by which Src and cortactin promote the invasive cancer 
phenotype. Further understanding of these processes provided by the following studies, 
could provide clinical benefits for cancer patients with advanced disease. Study one 
demonstrates treatment with the Src-targeted small molecule inhibitor saracatinib 
impairs tumor cell invasion in vitro and lymph node metastasis in vivo. Further, we 
identify that Src inhibition decreased invadopodia formation and MMP expression in 
HNSCC cell lines. Study two identifies regulated WT Src activity as essential for 
governing invadopodia maturation in HNSCC cells and Src transformed fibroblasts. In 
addition, we establish cortactin phosphorylation downstream of Src as central to this 
process. In study three we examine the role of the EGFR/MEK pathway upstream of Src 
and cortactin in regulating cell migration and lamellipodia dynamics. Lastly, study four 
outlines an attempt to create a transgenic model of HNSCC tumor cell invasion in which 
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Introduction and significance: Cancer cell invasion and metastasis 
 Cancer is a group of diseases that arises when normal cells undergo a series of 
genetic modifications that lead to uncontrolled growth. Malignant transformation 
requires the acquisition of multiple mutations that lead to the production of oncogenes 
that actively promote tumorgenesis, or the loss of tumor suppressor genes that restrain 
tumorgenesis (Weinberg, 1994).  There are presumably hundreds of combinations of 
genetic mutations that support uncontrolled growth.  To this end, a multitude of cancers 
exist which are classified by tissue of origin, and subsequently by the genetic or 
epigenetic abnormalities they possess.  Nevertheless, it is generally accepted that for 
any tumor type to become malignant the cell must gain several distinct properties. 
These include the ability to promote uncontrolled growth, evade apoptosis, sustain 
angiogenesis, continuously replicate, and be able to invade local tissues in order to 
eventually metastasize to distant sites (Hanahan and Weinberg, 2000). This dissertation 
focuses on two proteins that are overexpressed in invasive tumor types; Src tyrosine 
kinase and the adapter protein cortactin. How these proteins contribute to dynamic, 
motile protrusions that propel the invasive/metastatic program of epithelial derived 
tumors (carcinomas) is discussed.   
 The majority of cancer deaths result from metastasis of the primary tumor (Steeg, 
2006). Metastasis- the process by which malignant cells spread from the tissue of origin 
to colonize local and/or distant organs- requires multiple discrete steps (Nguyen et al., 




respond to cues from the surrounding microenvironment, whereby it takes on a 
migratory or invasive phenotype and locally invades the surrounding tissue. Tumor cells 
then reach and invade the dense vascular-endothelial basement membrane to enter the 
circulation, a process termed intravasation. In the blood stream or lymphatic system, 
cells are required to survive anchorage independent growth (anoikis) in the circulation 
until the cells arrest and extravasate at the metastatic location. During extravasation, 
cells again invade through basement membranes and the surrounding tissue to seed 
and colonize distant sites. Tumor cell invasion, a critical step at multiple points during 
metastasis as outlined above, is a process which is dependent on temporal and spatial 
rearrangement of the actin cytoskeleton (Yamaguchi et al., 2005b).  Understanding the 
function of proteins involved in invasion is prerequisite for the development of anti-
invasive therapies that have the potential to directly improve patient outcome. To this 
end, it is critical to gain understanding of the molecular mechanisms that drive tumor 
cell invasion and metastasis.   
 Tumor cell invasion is facilitated through highly regulated changes in plasma 
membrane dynamics, resulting from reorganization of the underlying actin cytoskeleton 
(Yamaguchi et al., 2006). The ATP-binding protein actin is one of the most abundant 
proteins in eukaryotic cells. Spatial and temporal dynamic regulation of globular (G) or 
monomeric actin into filamentous (F) actin provides the structural network and the 
protrusive forces that govern cell motility and invasion (Campellone and Welch, 2010).  
Actin filaments possess a fast growing barbed (+) end and a slower growing pointed (-) 
end that have structurally and biochemically distinct properties.  Construction of a new 
actin filament is facilitated through the generation of a free barbed end, termed actin 
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nucleation. ATP bound actin monomers are then added to the + end and the dynamics 
of the growing filament are tightly coupled to ATP-hydrolysis. Regulation of this highly 
specialized cellular process is facilitated by an abundance of actin-binding (ABP) 
proteins that direct actin polymerization/depolymerization necessary for functional cell 
movement. There are several classes of ABPs that bind to G- or F-actin to control actin 
filament dynamics through numerous biochemical processes, including nucleation, 
capping, severing, crosslinking, bundling, anchoring, depolymerizing, sequestering, 
branch formation, monomer delivery, nucleotide exchange, cytoskeletal linkers, 
sidebinding, and signaling (Winder and Ayscough, 2005).  Not surprisingly, several 
actin-associated regulatory proteins are overexpressed or dysregulated in tumor cells, 
altering actin dynamics in a manner conducive to driving the invasive cancer phenotype 
(Iwaya et al., 2007; Kelley et al., 2008; Otsubo et al., 2004; Semba et al., 2006; Wang et 




 Actin-based specialized motility structures formed by cancer cells include 
lamellipodia, filopodia, podosomes and invadopodia (Buccione et al., 2004). These 
differing types of membrane protrusions are developed in response to a variety of 
extracellular chemoattractants including ECM components, growth factors and 
chemokines. Upon binding of chemoattractants to extracellular cell surface receptors, 
intracellular signaling pathways are triggered leading to specific, highly organized 
changes in cell shape that are regulated by Rho family GTPases (Ridley, 2001a; Ridley, 
2001b; Ridley, 2004; Ridley, 2006). Actin nucleation downstream of these signals is 
facilitated though activation of the actin related protein (Arp)2/3 complex,  which results 
Figure 1 Model depicting the tumor cell invasion mediated by invadopodia. 
Carcinoma cells gain an invasive phenotype and actively degrade the underlying 
basement membrane. Once the cells are detached from the primary tumor, cancer 
cells migrate along/through the ECM. Tumor cells must then invade the blood 
vessel wall in order to enter the circulatory system (intravasation) where they 
eventually arrest and extravasate before metastatic colonization at the secondary 
site. Illustration adapted from Yamaguchi et al., 2005b. 
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in the formation of de novo branched actin networks (Higgs and Pollard, 2001; Pollard 
and Beltzner, 2002). The activation of Arp2/3 complex is regulated by actin nucleation 
promoting factors (NPFs) including the WASp (Wilskott-Aldrich syndrome protein) family 
proteins and cortactin (Uruno et al., 2003; Weaver et al., 2001; Weed et al., 2000). 
Recently, additional actin nucleators including diaphanous-related formins (DRFs), WH2 
containing proteins (spire, cordon-bleu, and leimodin), and two additional WCA 
containing NPFs (WHAMM and JMY) were discovered that facilitate elongated, 
unbranched actin polymerization necessary in extended membrane protrusive 
structures such as filipodia and invadopodia (Campellone and Welch, 2010).  
 The type of protrusion formed by a motile cancer cell is highly dependent on the 
selective pressure of the environment (Wolf and Friedl, 2009; Yamaguchi and 
Condeelis, 2007). In 2D environments, such as cells plated on glass coverslips or 
coverslips coated with thin ECM such as fibronectin, tumor cells form sheet-like 
projections called lamellipodia and filopodia at the leading edge. Cancer cells plated on 
thick ECM, such as collagen and Matrigel substrates, form rod-shaped, elongated cell 
protrusions perpendicular to the cell body termed invadopodia. Invadopodia contain 
proteolytic activities that facilitate clearing of the ECM around the protrusions. 
Additionally, invadopodia produced by cancer cells also facilitate breaching of live 
basement membrane explants and invadopodia-like protrusions have been imaged in 
vivo (Condeelis and Segall, 2003; Hotary et al., 2002; Yamaguchi et al., 2005b). 
Therefore, these specialized structures are thought to be the critical machinery that 
allows cancer cells to migrate through ECM and to cross tissue barriers during multiple 




Invadopodia: Invasion machinery of cancer cells  
 Invadopodia are actin-rich ventral membrane protrusions found in oncogenic 
kinase-transformed fibroblasts and metastatic cancer cell lines (Ayala et al., 2006; 
Buccione et al., 2004; Weaver, 2006; Yamaguchi et al., 2006).  Invadopodia are most 
similar in structure to podosomes, which are produced in untransformed, non-metastatic 
cell lineages such as endothelial, smooth muscle and monocytic lines (osteoclasts, 
macrophages, monocytes, and dendritic cells)(Linder, 2009). Invadopodia and 
podosomes share similar protein components, but differ in their number, size and 
dynamics. Invadopodia are present in smaller numbers (<10 versus >100 per cell), but 
they are much larger (~8, compared to 1 µM) and more persistent than podosomes 
(lasting hours as opposed to minutes).  
 There is no unique biochemical marker for invadopodia. In vitro, invadopodia are 
identified by plating cells on top of fluorescently labeled ECM, usually collagen (gelatin), 
where invadopodia protein components colocalize with areas of degraded matrix 
(Figure 2).   In three-dimensional matrices, cancer cells develop numerous lateral 
spikes that are enriched with invadopodia markers including the matrix 
metalloproteinase MT1-MMP (Li et al., 2010; Wolf and Friedl, 2009). In vivo imaging of 
invadopodia is extremely difficult due to dynamic nature of the process and the 
inaccessible tissue environment in which they occur. However, intravital imaging of 
GFP-labeled tumor cells demonstrated “invadopodia-like” cell protrusions extending into 
the vasculature during intravasation (Wyckoff et al., 2004; Yamaguchi et al., 2005b). 
Until the imaging technology advances to the point enabling identification of 
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invadopodia markers at high resolution during the metastatic process, the question of 
whether invadopodia form, or what form they take in vivo remains unanswered. 
Recently, membrane protrusions highly resembling invadopodia structure and function 
were identified and imaged in C. elegans. In this system, cells that cross basement 
membranes during normal worm development use invadopodia-like structures to 
degrade and invade surrounding tissues. Due to the transparent nature of these worms, 
several invadpododia markers were visualized by live cell imaging including F-actin, Src 
non-receptor tyrosine kinase (Src), phospholipid phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2), and proteases (Hagedorn et al., 2009; Sherwood et al., 2005; Ziel et al., 
2009). The ability of cancer cell lines to form invadopodia and actively degrade matrix is 
associated with increased invasive capacity measured by other experimental 
parameters such as transwell invasion assays and xenograft mouse models (Ammer et 




 Invadopodia were first identified by the Chen laboratory in the 1980’s as 
specialized proteolytic surface protrusions formed in chicken embryonic fibroblasts 
(CEF) transformed by Rous sarcoma virus (RSV)(Chen, 1989; Chen et al., 1985). 
Throughout the 1990’s, the Chen laboratory further characterized these structures as 
containing integrins, fibronectin (Mueller and Chen, 1991), tyrosine phosphorylated 
proteins (YPPs)(Mueller et al., 1992), and soluble (Monsky et al., 1993; Monsky et al., 
1994) and membrane bound proteases (Nakahara et al., 1997). In addition, invadopodia 
were discovered to promote focal degradation of a variety of ECM components 
including fibronectin, laminin, type I collagen, and type IV collagen (Kelly et al., 1994). 
 During the last decade, considerable work on invadopodia biology has 
Figure 2  Invadopodia formed in Src transformed fibroblasts. Invadopodia are actin 
rich aggregates that contain cortactin and MT1-MMP. Underlying invadopodia are 
dark areas in the labeled gelatin (white) where the ECM has been degraded by 
invadopodia. Arrows point to areas with invadopodia, bar = 10µM.  
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substantially expanded our understanding of the molecular machinery within these 
organelles where protein networks coordinating cell signaling, actin polymerization, 
vesicle trafficking, and ECM hydrolysis converge to create organelles necessary for 
initiating cellular invasion.  
 It is currently unclear whether the initial trigger of invadopodia formation is 
integrin-based adhesion to ECM, or if the formation of F-actin-rich structure precedes 
and supports integrin clustering. It is clear that integrins are necessary to target and/or 
activate proteases at invadopodia (Artym et al., 2002; Deryugina et al., 2001), and the 
integrin combination that localizes to invadopodia is dependent on cell type and the 
specific ECM engaged (Badowski et al., 2008; Block et al., 2008; Mueller and Chen, 
1991). Also, Invadopodia contain several adhesion proteins that have well-characterized 
roles in focal adhesions, cell-matrix contacts that provide mechanical force during cell 
movement, including talin (Mueller et al., 1999) and paxillin (Bowden et al., 1999). 
Surprisingly, vinculin (Gimona et al., 2008) is notably absent from these structures. 
Focal adhesion kinase (FAK) does not localize to invadopodia and is not required for 
invadopodia formation or activity (Vitale et al., 2008). However, depletion of FAK 
increases the number of active invadopodia per cell and redistributes phosphotyrosine-
containing proteins from focal adhesions to invadopodia, but FAK depleted cells showed 
impaired invasion through Matrigel (Chan et al., 2009).  These results suggest that a 
balance of “adhesive” and “invasive” ECM-cell contacts is necessary for optimal cancer 
cell invasion.  
  Since invadopodia are absent in non-cancerous cell types, it is intriguing to 
speculate that cancer cells gain specific mutations that alter actin cytoskeletal signaling 
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to support the formation of invadopodia.  For instance, invadopodia can be triggered 
only at permissive temperatures when using a temperature-activated Src (See Study 1), 
supporting an inside-out mechanism of invadopodia formation. However, it is clear that 
external signals regulate invadopodia assembly and function.  Addition of epidermal 
growth factor (EGF) enhances invadopodia numbers (Yamaguchi et al., 2005a), and 
increasing substrate rigidity enhances the number and ECM degradation activity of 
invadopodia (Enderling et al., 2008; Parekh and Weaver, 2009). These results suggest 
that once tumor cells are “primed” to form invadopodia, the extracellular environment 
modulates the invasiveness of these cells. Surprisingly, addition of protease inhibitors 
blocks degradation and the formation of invadopodia in cancer cells that form 
spontaneous invadopodia (Ayala et al., 2008), suggesting that an outside-in signaling 
loop is necessary to support invadopodia biogenesis.  
 Invadopodia contain branched and bundled actin filament networks. Like the 
formation of lamellipodia, initial invadopodia protrusions are dependent on N-WASp-
activated Arp2/3-mediated actin polymerization.   Both N-WASp and Arp2/3 localize to 
invadopodia (Baldassarre et al., 2006; Clark and Weaver, 2008; Lorenz et al., 2004; 
Yamaguchi et al., 2005a) and knockdown or expression of dominant negative mutants 
of these proteins substantially decreases invadopodia formation (Mizutani et al., 2002; 
Schoumacher et al., 2010; Yamaguchi et al., 2005a). Upstream activators of N-WASp, 
including WASp-interacting protein (WIP), Nck1, Tks5 (Oikawa et al., 2008), CDC42, 
and the CDC42 GEF (guanine exchange factor that stimulates the exchange of GDP for 
GTP) Fgd1 are also necessary for invadopodia assembly (Ayala et al., 2009; Oser et 
al., 2009; Stylli et al., 2009; Yamaguchi et al., 2005a). Accordingly, CDC42 seems to be 
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the dominant member of the Ras superfamily of GTPases that is responsible for 
invadopodia assembly. CDC42 localizes to invadopodia sites whereas RhoA and Rac1 
are not detectable (Baldassarre et al., 2006). Cells with invadopodia are substantially 
decreased in cancer cell lines transfected with CDC42 siRNA or dominant-negative 
CDC42 (Yamaguchi et al., 2005a). Very recently, several papers have been published 
suggesting that the Arp2/3-N-WASp network activated downstream of CDC42 is 
necessary for the initial formation of the dendritic actin structure at invadopodia, but 
unbranched, bundled actin structures are necessary for invadopodia elongation and 
stability. Diaphanous-related formins (DRFs 1-3), which polymerize linear actin 
filaments in stress fibers and filopodia, are necessary for invadopodia formation and 
efficient degradation (Lizarraga et al., 2009). In addition, several flilopodia-associated 
proteins have been localized to elongated invadopodia tips, including fascin, α-actinin, 
VASP, T-fimbrin, and myosinX (Li et al., 2010; Schoumacher et al., 2010). In addition to 
these, several other actin binding proteins function in invadopodia assembly or stability, 
including gelsolin, zyxin (Spinardi et al., 2004), cofilin (Yamaguchi et al., 2005a), and 
cortactin (Bowden et al., 1999).  
 Early invadopodia studies identified the serine protease seprase (Monsky et al., 
1994), and the urokinase-type plasminogen activator (uPA) (Artym et al., 2002; 
Kindzelskii et al., 2004) as essential proteases regulating degradation at invadopodia. 
However, today it is widely recognized that the family of zinc-dependant matrix 
metalloproteinases (MMPs) are the key enzymes that mediate cell invasion (Deryugina 
and Quigley, 2006; Egeblad and Werb, 2002; Hotary et al., 2006; Poincloux et al., 
2009). All MMPs, which contain propetide, catalytic, and hemopexin-like-C-terminal 
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domains, are generated as proenzymes (zygomens) and become activated through 
proteolytic cleavage of the propeptide. MMP activation and protein levels are increased 
in cancer and their expression is associated with poor prognosis (Deryugina and 
Quigley, 2006; Littlepage et al., 2010; Scherer et al., 2008). The secreted proteases 
MMP-2 and MMP-9 have been localized to invadopodia in many systems and increased 
amounts or activity of these secreted proteins have been correlated to invadopodia 
activity and cell invasion (Ammer et al., 2009; Artym et al., 2006; Clark and Weaver, 
2008; Clark et al., 2007). However, the membrane-bound MT1-MMP has emerged as 
the indispensible mediator of focal degradation at invadopodia (Artym et al., 2006; 
Hotary et al., 2006; Li et al., 2008; Nakahara et al., 1997; Poincloux et al., 2009; Sabeh 
et al., 2004; Sakurai-Yageta et al., 2008; Steffen et al., 2008). MT1-MMP 
overexpression (Hotary et al., 2006; Nakahara et al., 1997; Sabeh et al., 2004) or 
knockdown (Artym et al., 2006; Hotary et al., 2006; Steffen et al., 2008) increases or 
decreases ECM degradation, accordingly.  In agreement with this, treatment of cells 
with a broad-spectrum MMP inhibitor prevents focal invadopodia ECM degradation 
activity (Ayala et al., 2008). 
 In order for invadopodia to functionally degrade the ECM, the cytoskeletal 
structure must be tethered to the cell membrane, and invadopodia must facilitate the 
focal delivery of proteases.   In this way, invadopodia are highly specialized structures in 
which actin remodeling is coupled to vesicular transport in order to deliver new 
membrane components and actively remove ECM. Delivery of MMPs to invadopodia 
and uptake of ECM most likely occurs via the trans-Golgi network (Ayala et al., 2006). 
This finding is consistent with the observation that the Golgi is often found oriented 
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towards, and in close proximity to invadopodia (Baldassarre et al., 2003). Two ADP-
ribosylation factors (Arf1 and Arf6) that regulate membrane trafficking and actin 
remodeling have been identified as contributing to invadopodia formation (Hashimoto et 
al., 2004; Onodera et al., 2005; Tague et al., 2004).  Arf1 is mainly found at the Golgi 
where it is known to act upstream and downstream of CDC42 (the main GTPase in 
invadopodia) to regulate actin polymerization (Chen et al., 2005; Dubois et al., 2005; 
Wu et al., 2000). In addition, AMAP1, a GTP-Arf6 activating protein (GAP) and known 
Src substrate, localizes to and regulates invadopodia formation (Bharti et al., 2007). The 
transport vesicle-tethering protein exocyst complex (Sakurai-Yageta et al., 2008), and 
docking/fusion protein v-SNARE TI-VAMP/VAMP7 (Steffen et al., 2008) are both 
required for the delivery of MT1-MMP to invadopodia sites. The GTPase dynamin 2 
(Dyn2) which is required for endocytosis (Hinshaw, 2000), and protein trafficking from 
the Golgi (Jones et al., 1998), is required for invadopodia formation in Src transformed 
fibroblasts (Baldassarre et al., 2003; Buccione et al., 2004; McNiven et al., 2004). 
 Until recently, the role of directional, microtubule-based vesicle trafficking in 
invadopodia formation was unknown.  IQGAP1, a protein that links actin and 
microtubule cytoskeletal networks, is critical for delivery of MT1-MMP to invadopodia 
(Sakurai-Yageta et al., 2008).  In addition, electron micrographs of elongated 
invadopodia revealed the presence of 1-2 microtubules decorated with many 
vesicles/endosomes (Schoumacher et al., 2010). Immunofluorescent staining of these 
structures confirmed the presence of tubulin throughout the length of the invadopodia, 
with tyr-tubulin (indicative of dynamic microtubule networks) concentrated the 
invadopodia base. Treatment of invadopodia with nocodazole (facilitating microtubule 
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depolymerization) did not change the number of invadopodia structures, but significantly 
decreased invadopodia length. In the same report, similar results were found for 
vimentin, suggesting a role for intermediate filaments in invadopodia elongation. In 
addition to actin, regulation of other cytoskeletal elements is an area of emerging 
interest in invadopodia biology.  
 
Cortactin: Scaffolding invasive actin networks 
 Cortactin is an essential link between kinase signaling and dynamic actin 
networks in cell adhesion, migration, endocytosis, and tumor invasion (Ammer and 
Weed, 2008). Accordingly, cortactin localizes to actin-based protrusions, including 
lamellipodia, filopodia, dorsal waves, podosomes and invadopodia.  Cortactin is a multi-
domain scaffolding protein identified by the Parsons laboratory in the early 1990s in a 
screen for prominent Src substrates (Kanner et al., 1990; Wu and Parsons, 1993; Wu et 
al., 1991). The cortactin (CTTN) gene encodes a 550 amino acid product that is highly 
conserved among vertebrate species (Schuuring et al., 1993; Wu and Parsons, 1993; 
Zhan et al., 1993). Electron microscopy studies of purified recombinant cortactin have 
proposed that cortactin is a monomeric, asymmetric, rod-shaped molecule ~220 Å in 
length (Weaver et al., 2002). However, cortactin has recently been reported to also exist 
in a partially globular conformation whereby the C-terminal region of cortactin folds back 
towards the N-terminus resulting in a “closed” conformation (Cowieson et al., 2008). 
Cortactin is predicted to have a molecular mass ~62 kDa. However, cortactin migrates 
as a doublet upon SDS/PAGE to 80kDa (p80) and 85kDa (p85)(Schuuring et al., 1993; 
Wu et al., 1991). The distinct bands are proposed to represent post-translational 
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modifications of cortactin, but the nature of these modifications remains controversial. A 
single band is formed when the proline rich region (PRR) of cortactin is deleted or when 
SDS/PAGE is performed in the presence of 5 M urea (Campbell et al., 1999; Huang et 
al., 1997a; Huang et al., 1997b). In addition, a shift from the 80 to the 85kDa form is 
seen in response to EGF treatment and the resulting upper band is associated with 
serine phosphorylation at residues S405 and S418 (Campbell et al., 1999). In this 
system, the 80 to 85kDa shift is blocked by inhibition of the Erk activating kinase MEK, 
suggesting that ERK is responsible for serine phosphorylation at these sites. However, 
prolonged treatment with MEK inhibitors alone failed to change the ratio of the 
80/85kDa forms, pointing to a model in which MEK-independent pathways may also 
regulate the shift. The p85 form was identified as the predominant form of cortactin in 
colorectal cancers compared to equal ratios of the p80 and p85 in non-cancerous 
tissues (Zhang et al., 2006), suggesting a functional preference for the p85 cortactin 
conformation in tumor cell invasion. 
 Based on primary structure analysis, cortactin predominantly consists of five 
distinct domains (see Figure 3). Cortactin activates the Arp2/3 complex via a NPF 
conserved DDW motif at the N-terminal acidic domain (NTA). Distinct from other NPF’s 
that bind actin monomers, cortactin interacts with F-actin via a tandem repeat region 
containing six and a half 37 amino acid cortactin repeats.  This F-actin binding region is 
located adjacent to the NTA (Weed et al., 2000). Cortactin is a weaker activator of 
Arp2/3 than WASp family proteins, yet it has a 20-fold higher affinity for F-actin than the 
Arp 2/3 complex (Uruno et al., 2001). In addition, cortactin preferentially binds to newly 
polymerized actin filaments with monomers containing ATP or ADP-Pi, instead of older 
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filaments consisting of ADP monomers (Bryce et al., 2005). These data suggest that 
cortactin is targeted to sites of dynamic actin remodeling where it stabilizes newly 
formed branches (Weaver et al., 2001). Accordingly, cortactin is a ubiquitously 
expressed protein that participates in diverse actin-based subcellular functions in 
several distinct cell types. These processes include cell migration, invasion, and 
metastasis (Li et al., 2001; Yamaguchi and Condeelis, 2007), axon guidance (Knoll and 
Drescher, 2004), neuronal morphogenesis (Gray et al., 2005; Martinez et al., 2003), 
integrin and cadherin-mediated signaling (Ren et al., 2009), bone reabsorption 
(Matsubara et al., 2006), endocytosis (Orth and McNiven, 2006), and pathogenic 
cellular entry of bacteria and viruses (Selbach and Backert, 2005). The regulation of 
cortactin needed to orchestrate these distinct and complex processes is mediated by 
the carboxyl-terminal end of the molecule. Specifically, cortactin is phosphorylated by 
multiple tyrosine and serine/threonine kinases within its proline rich domain (PRR), and 
interacts with several binding partners via a C-terminal Src homology 3 (SH3) domain 





 Cortactin was originally identified as a prominent substrate of the v-Src 
oncogene, and cortactin colocalizes with actin to invasive structures produced in these 
cells (Wu and Parsons, 1993). The phosphorylation of cortactin by Src occurs on 
tyrosine residues 421, 470, and 486 (Huang et al., 1998; Huang et al., 1997a). 
Phosphorylation of cortactin at these sites is important in many systems. Specific to my 
work, the level of tyrosine phosphorylation of cortactin is positively associated with 
Figure 3  Domain structure of cortactin and illustration of interacting partners. The N-
terminal acidic domain (NTA) contains a conserved DDW motif that binds and 
activates Arp2/3, followed by the repeat region (R) that interacts with F-actin. Src 
family tyrosine kinases and MAPK serine kinases phosphorylate cortactin in the 
proline-rich region (PRR). The SH3 domain of cortactin is necessary for binding to 
several proline-rich proteins that regulate a wide array of cellular processes.  
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increased cell motility and invasion in vitro and tumor cell metastasis in vivo 
(Bourguignon et al., 2001; Huang et al., 1998; Huang et al., 2003; Li et al., 2001; Liu et 
al., 1999). Conversely, non-functional mutants of these sites inhibit these processes. 
Tyrosine phosphorylated cortactin is enriched in lamellipodia (Head et al., 2003), 
invadopodia (Study 2) and dorsal waves (Boyle et al., 2007). Cortactin is also 
selectively targeted by calpain in the regulation of cell movement (Huang et al., 1997b; 
Perrin et al., 2006). In addition to Src, several other non-receptor tyrosine kinases and 
serine/threonine kinases have been shown to target cortactin. These include multiple 
Src family tyrosine kinases (Fyn, Fer, Syk, Abl, and Arg), extra-cellular signal-related 
kinase (Erk), and p21-activated kinase (PAK) (Boyle et al., 2007; Campbell et al., 1999; 
Craig et al., 2001; Gallet et al., 1999; Huang et al., 2003; Vidal et al., 2002; Webb et al., 
2006). Erk phosphorylates cortactin on S405 and S418 downstream of epidermal 
growth factor (EGF) stimulation, and results in a molecular weight shift from 80 to 
85kDa on SDS-PAGE (Campbell et al., 1999; Martinez-Quiles et al., 2004; Stuible et al., 
2008). How tyrosine and serine phosphorylation impacts cortactin localization has been 
an open question in the field for many years, yet remains poorly understood. 
 Phosphorylation of cortactin regulates the interaction of cortactin with other 
proteins through the creation of docking sites. This occurs either as a direct result of 
phosphorylation (pY/SH2 interactions) or by binding of the SH3 domain to the PRR of 
binding partners. The cortactin SH3 domain binds several regulators of the actin 
cytoskeleton, including MLCK, N-WASp, WIP (WASp-interacting protein), Dynamin-2, 
and CD2AP (CD2-associated protein) (Dudek et al., 2002; Kinley et al., 2003; Lynch et 
al., 2003; Martinez-Quiles et al., 2004; Zhu et al., 2007). It was initially reported that 
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tyrosine phosphorylation of cortactin does not affect its ability to activate the Arp2/3 
complex, since cortactin lacking the C-terminal region activated Arp2/3 similarly to the 
full-length protein (Weaver et al., 2001). However, it is now clear that phosphorylation of 
cortactin increases Arp2/3 activation indirectly through the recruitment of a trimeric 
phophocortactin/Nck1/N-Wasp or /WIP complex (Tehrani et al., 2007). 
 Recently, the ability of cortactin to bind and regulate N-WASp activity led to a 
proposed regulatory mechanism termed the “Serine-Tyrosine (SY) switch”. In this 
model, inactive cortactin is proposed to exist in an auto-inhibited form by intramolecular 
binding through the SH3 and PRR regions (Martinez-Quiles et al., 2004). This inhibition 
is released via ERK phosphorylation on serine residues 405 and 418, allowing the 
cortactin SH3 domain to bind and activate N-WASP. The result is synergistic activation 
of Arp2/3 by cortactin (via the NTA domain) and N-WASP by the SH3 domain to 
promote actin polymerization and stabilization required for cellular motility. Src 
phosphorylation of cortactin downregulates the binding of the cortactin SH3 domain to 
N-WASp and therefore inhibits N-WASp activity. This “on-off” view of cortactin 
regulation by Erk and Src phosphorylation is limited by the fact that it is solely based on 
data in relation to cortactin’s interaction with one SH3-binding partner (N-WASp) and is 
derived in vitro using purified proteins. In addition, data from our laboratory demonstrate 
that the ability of cortactin to be phosphorylated on tyrosine 421 is not dependent on 
serine phosphorylation status (Study 3). This suggests that phosphorylation of S405 
and S418 are not necessary to relieve the putative SH3-PRR intermolecular interactions 
that would subsequently expose the Src-targeted tyrosine 421 residue. While it is clear 
that Src and Erk phosphorylation serve to regulate cortactin function, the precise 
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mechanisms, as well as the degree of interplay between these two kinases in governing 
cortactin function remains largely unknown. 
 Cortactin overexpression is observed in several human cancers and tumor-
derived cell lines, including carcinomas of the head and neck, lung, esophagus, lung, 
bladder and breast (Chuma et al., 2004; Luo et al., 2006; Schuuring et al., 1993; 
Schuuring et al., 1992; Yuan et al., 2003). The cortactin gene (CTTN) maps to 
chromosome 11q13.3.  This region is amplified in 33% of HNSCC and 13% of breast 
carcinomas, resulting in cortactin overexpression in these tissues. Amplification of 
11q13 in HNSCC is associated with tumor aggressiveness, increased metastasis, and 
poor prognosis (Meredith et al., 1995; Takes et al., 1998; Williams et al., 1993). 
Cortactin is overexpressed in 50% of cell lines derived from HNSCC’s, and increased 
mRNA levels in patient tumor samples have been found to be an independent predictor 
of death (Patel et al., 1996; Rodrigo et al., 2000).  
 HNSCC is a highly aggressive and invasive disease largely driven by 
overexpression of EGFR (Kalyankrishna and Grandis, 2006). Recently, our laboratory 
found a link between CTTN copy number and enhanced tumor cell invasion and motility 
downstream of EGFR through comparison of HNSCC cells with and without 11q13 
amplification (Rothschild et al., 2006). The increase in cell motility demonstrated by cells 
that overexpress cortactin is associated with increased Arp2/3 binding/activation and 
tyrosine phosphorylation of cortactin. Pretreatment of cells with the EGFR inhibitor, 
gefitinib, blocked cortactin tyrosine phosphorylation and cell motility. While these 
experiments indicate that cortactin overexpression directly drives HNSCC motility and 
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invasion, validation of the role of cortactin in tumor progression can only be 
accomplished by the use of an in vivo cancer model.  
 Cortactin is a core invadopodia component and its abundance at invadopodia 
sites has made it the most recognized invadopodia marker. Early studies identified 
cortactin in a complex with PKCµ and paxillin in these structures whereby the level of 
tyrosine phosphorylation in invadopodia correlates with their ability to degrade the 
extracellular matrix (Bowden et al., 1999). Cortactin is necessary for invadopodia 
formation in several invadopodia-forming cell systems including transformed fibroblasts 
(Webb et al., 2007) and metastatic cell lines derived from multiple cancer types (Artym 
et al., 2006; Ayala et al., 2008; Clark et al., 2007; Oser et al., 2009).  A stepwise model 
of invadopodia formation has been proposed in which cortactin is recruited to sites of 
actin assembly and matrix adhesion resulting in pre-invadopodia complexes (Artym et 
al., 2006). The membrane-bound matrix metalloproteinase MT1-MMP is subsequently 
recruited to these sites, allowing for matrix degradation and invadopodia maturation.  
 Three separate reports have investigated the functional domains of cortactin 
necessary for invadopodia formation. The first, which used constitutively active cSrc to 
drive invadopodia formation in fibroblasts, concluded that the actin-binding repeat (ABR) 
alone is required for functional invadopodia (Webb et al., 2007). In addition, full-length 
cortactin with tyrosine to phenylalanine mutations at 421, 466, 482 was not able to 
rescue invadopodia formation, indicating that cortactin tyrosine phosphorylation is also a 
requirement for invadopodia formation. The second report, determined the DDW motif, 
SH3 domain, and the phosphorylation sites targeted by Src (tyrosine 421, 466, and 
470), ERK (serine 405 and 418), and PAK (serine 113) are all needed for efficient ECM 
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degradation in melanoma cells (Ayala et al., 2008). The most recent report (Oser et al., 
2009) evaluated invadopodia in MtLn3 breast cancer cells concluding that the DDW 
motif and SH3 domain are necessary for invadopodia formation. However for efficient 
degradation at invadopodia sites, tyrosines 421, 466, and 470 are needed. Taken 
together, these data suggest a model in which cortactin acts as a scaffold during 
invadopodia formation where it may link Arp2/3 activation, actin stabilization, and 
recruitment of SH3 binding partners such as N-WASp.  However, during invadopodia 
maturation cortactin is regulated by phosphorylation to direct ECM degradation.  
 Oser et al. (Oser et al., 2009) recently proposed a three step phosphorylation 
model whereby dephosphorylated cortactin is targeted to invadopodia and recruits N-
WASp, Arp2/3, and cofilin. Cortactin is then tyrosine phosphorylated to release cofilin to 
drive actin polymerization through barbed end production, and creates phosphotyrosine 
docking sites for the adapter protein Nck1 (Tehrani et al., 2007). Finally, cortactin is 
dephosphorylated to sequester cofilin, release Nck1 and stabilize invadopodia. This 
study identifies cortactin as a critical molecular “hub” that regulates the stages of actin 
assembly and stabilization. However, it still remains how cortactin is spatially and 
temporally regulated through upstream kinase-based signaling to drive invadopodia 
maturation.  
 While the above studies identify cortactin as a critical regulator at the level of the 
invadopodia actin cytoskeleton, other reports point to cortactin playing a major role in 
the secretion of MMPs (Clark and Weaver, 2008; Clark et al., 2007). Varying cortactin 
protein levels (through overexpression or RNAi) in HSNCC cells results in dramatic 
changes in matrix degradation that cannot be attributed to increased invadopodia 
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numbers. In addition, RNAi knockdown of cortactin results in decreased secretion of 
MMP-2, MMP-9 and surface expression of MT1-MMP.  While cortactin overexpression 
resulted in increased secretion/expression of these MMPs, altering cortactin levels also 
affected the secretion of Apo-1, a protein not linked to invadopodia or proteases, 
suggesting that cortactin has a general role in regulating secretory cell pathways rather 
than invadopodia-specific MMP targeting and secretion.  
  
Src tyrosine kinase: Master regulator of the invasive phenotype 
 Src tyrosine kinase is the first discovered proto-oncogene and is one of the most 
well-studied proteins to date. Since it was first described in the1980s as the cellular 
homologue (cSrc) of the viral Src gene (vSrc) encoded by the Rous Sarcoma virus, Src 
has been identified in regulating a host of cellular functions/processes important in 
cancer cell biology including proliferation and survival, cytoskeletal dynamics, cell 
shape, cell-cell contacts, epithelial to mesenchymal transition (EMT), adhesion, motility 
and invasion. Even though substantial progress has been made in identifying Src as a 
master regulator of the tumor cell phenotype, its role in cancer is not completely 
understood.  
 Src is the archetypical member of the membrane-bound non-receptor tyrosine 
kinase family which includes Fyn, Yes, Blk, Yrk, Fgr, Lck, and Lyn (Parsons and 
Parsons, 2004). Three of these kinases, Src, Yes and Fyn are ubiquitously expressed. 
The members of this family share a conserved domain structure which contains a N-
terminal myristoylated acid moiety necessary for insertion into the cytoplasmic face of 
the cell membrane, a Src homology 3 (SH3) domain able to bind proline-rich 
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sequences, a Src homomogy 2 (SH2) domain which interacts with phosphorylated 
tyrosines, a flexible linker domain, a tyrosine kinase domain, and a short C-terminal tail 
(Brown and Cooper, 1996)(Figure 4). Src kinase activity is regulated by conformational 
changes that govern whether the kinase domain is accessible to interact with substrates 
(including autophosphorylation of Src itself) (Yamaguchi and Hendrickson, 1996). In its 
inactive form, Src is phosphorylated on Tyr527 (530 in humans) and is held in a “closed” 
conformation through intermolecular binding of Tyr527 to the SH2 domain, and 
additional SH3 domain interactions with the linker region.  Src is activated when Tyr527 
is dephosphorylated, as the molecule adopts an “open” conformation allowing for 
autophosphorylation of Tyr416, phosphorylation of Src substrates and potential 
interaction with binding partners through SH2 domain-mediated interactions. 
Phosphorylation and dephosphorylation of Src at Tyr527 is facilitated by c-terminal Src 
kinase (Csk) (Cooper et al., 1986) and the protein tyrosine phosphatase PTP1B (Bjorge 
et al., 2000), respectively. Independent of phosphorylation on Tyr527, Src can be 
activated through SH2- and SH3-mediated binding to focal adhesion kinase (FAK), 
CRK-associated substrate (CAS), and a multitude of receptor tyrosine kinases (RTKs).  
These interactions “force” Src to adopt the open conformation, leading to kinase 
activation. Src is also regulated through subcellular localization.  Inactive Src resides in 
the perinuclear region associated with the microtubule organizing center, colocalizing 
with endosomal markers (Kaplan et al., 1992). Once activated, Src translocates to the 
cell periphery in an endosomal- and actin-dependent fashion (Fincham et al., 1996; 
Sandilands et al., 2004). The location in the cell where Src is targeted is contingent on 
the activation of specific Rho GTPases (Timpson et al., 2001), whereby activation of 
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Rac1 targets Src to lamellipodia, CDC42 targets it to filopodia, and RhoA targets it to 
focal adhesions.  
 
 
 Much of the seminal work on Src activity was facilitated through the use of 
temperature sensitive mutants of vSrc (Yeatman, 2004). In 1970 it was discovered that 
vSrc alone was the necessary and sufficient transforming agent responsible for Rous 
sarcoma virus (RSV) in chickens (Martin, 1970). The vSrc transformed cell phenotype 
includes a marked reorganization of the actin cytoskeleton, with disruption of cell-matrix 
(focal adhesion) and cell-cell adhesions, leading to rounded cell morphology.  Unlike its 
regulated cellular counterpart (cSrc), vSrc has a C-terminal truncation that removes the 
critical Tyr527 residue, rendering the kinase constitutively active and oncogenic (Takeya 
Figure 4  Structure and activation of Src tyrosine kinase. (Left) The molecular structures of cSrc 
and vSrc. Src tyrosine kinases contain the following domains: a N-terminal myristylation domain 
that allows for interaction with the plasma membrane; a unique or SH4 domain; a Src homology 3 
(SH3) and 2 (SH2) domain facilitating binding with interaction partners; a kinase domain with an 
autophosphorylation site at tyrosine 416 (Y416); a C-terminal regulatory region containing the auto-
inhibitory tyrosine 527. (Right) In the inactive conformation the SH2 domain binds the 
phosphorylated C-terminal Y527, and the SH3 domain interacts with the kinase domain promoting 
a “closed” conformation in which limits the interaction of the kinase domain with potential 
substrates. When Src is activated, Y527 is dephosphorylated and the inhibition of the kinase 
domain is released. Src is in an “open” conformation leading to autophosphorylation on Y416. vSrc 
has multiple point mutation throughout the molecule and lacks the C-terminal auto-inhibitory Y527 




et al., 1982; Takeya and Hanafusa, 1982). Additionally, vSrc contains several mutations 
throughout its domain structure, but how these differences may cooperate in enabling 
transforming ability is unknown (Jove and Hanafusa, 1987; Parsons and Weber, 1989).    
 Unlike vSrc, cSrc is poorly transforming and lacks oncogenicity even when 
expressed at high levels. While activating cSrc mutations have been identified in a 
subset of human cancers, these cases are extremely rare (Daigo et al., 1999; Irby et al., 
1999; Nilbert and Fernebro, 2000; Sugimura et al., 2000). Src is overexpressed or 
hyperactivated in a myriad of carcinomas and sarcomas (Guarino, 2010; Irby and 
Yeatman, 2000; Summy and Gallick, 2003; Yeatman, 2004), and Src has been shown 
to have a distinct, predictive oncogenic signature of pathway deregulation in cancer cell 
lines (Bild et al., 2006), supporting a substantial role for Src activity in tumor 
progression. Increased Src activity in tumors most likely occurs as a result of 
hyperactivated upstream signaling of RTKs and integrins (Abram and Courtneidge, 
2000; Summy and Gallick, 2003). In this way, Src is a necessary and potent mediator of 
the metastatic cascade regulating anoikis (Windham et al., 2002), EMT, cell migration 
and invasion and metastasis (Guarino, 2010). In addition, Src activity is not required for 
cancer cell proliferation in vitro or for tumor growth in vivo (Brunton et al., 2005).  
Therefore, it is highly likely that cSrc is not an initiator of cell transformation in human 
cancers, but instead is a powerful driver of tumor progression. 
 Invadopodia were initially identified in vSrc transformed cells (Chen, 1989), and 
exogenous expression of constitutively active Src remains the best known “trigger” to 
produce invadopodia in invadopodia-null lines. cSrc activity is also important in cells that 
form spontaneous invadopodia, since Src inhibitors ablate invadopodia formation and 
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activity (Ammer et al., 2009; Ayala et al., 2008; Pichot et al., 2009). In fact, Src activity 
levels seem to be intimately related to the formation and the degradative capacity of 
invadopodia forming cells, since cells expressing increasingly active Src constructs 
exhibit a dosage effect (Artym et al., 2006). Cells overexpressing WT Src have 
increased invadopodia number and ECM degradation over control cells, and addition of 
constitutively active Src enhances this result.  Conversely, expression of a kinase dead 
Src mutant inhibits invadopodia formation and ECM degradation to well below control 
cell levels. However, extremely high Src activity (via the expression of vSrc) in breast 
cancer cell lines has been reported to lead to a increased number of invadopodia/cell at 
the expense of a decrease in invadopodia lifetime, which results in a net decrease in 
degradation area per invadopodia (Oser et al., 2009).  
 It is not completely known how Src regulates invadopodia in cancer cell lines. It is 
clear that Src has an important role in the initiation of actin-based invadopodia 
assembly, since Src activity is tightly linked to the invadopodia formation. It is easily 
assumed that Src phosphorylation acts as the initial catalyst that recruits invadopodia-
associated proteins through a series of phosphorylation events. Invadopodia are 
enriched with phosho-tyrosine containing proteins (Bowden et al., 2006), and numerous 
Src substrates localize to invadopodia including cortactin (Bowden et al., 1999), N-
WASp (Yamaguchi et al., 2005a), dynamin2 (Baldassarre et al., 2003), AMAP1 
(Onodera et al., 2005), paxillin (Bowden et al., 1999), p130Cas (Brabek et al., 2004), 
Tsk5 (Seals et al., 2005), p190RhoGAP (Nakahara et al., 1998), AFAP110 (Gatesman 
et al., 2004), caveolin (Yamaguchi et al., 2009), and MT1-MMP (Nyalendo et al., 2008; 
Nyalendo et al., 2007). Several groups have reported that dynamic phosphorylation 
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events are necessary to regulate signaling pathways during invadopodia stability and 
maturation (Oser et al., 2009; Stylli et al., 2009). It is known that these events are 
dependent on upstream Src activity as the initial activator; however it is unclear what 
role Src plays after it acts as the initial trigger. It is possible that Src itself regulates 
additional downstream phosphorylation events during invadopodia maturation. 
However, it is also likely that Src activates or localizes additional kinases to invadopodia 
important in initiating and maintaining matrix degradation.  
 FAK has been shown to act upstream of Src as a negative regulator of 
invadopodia (Chan et al., 2009). FAK depletion from breast cancer cells increases the 
number of invadopodia formed and switches the distribution of phosphotyrosine-
containing proteins from focal adhesion complexes to invadopodia. It is clear that FAK, 
a prominent focal adhesion protein, is absent from invadopodia structures. However, 
Src is known to complex with FAK to regulate focal adhesion dynamics, suggesting that 
Src may be critical in regulation cross-talk between these two structures. Even though 
decreasing FAK levels increase invadopodia formation, invasion through matrigel is 
inhibited. These data suggest that FAK-dependant spatial and temporal Src regulation 
is needed to regulate efficient cell invasion.  Calpain 2 is another known upstream 
regulator of Src in invadopodia formation. In a model proposed by the Huttenlocher lab, 
calpain-2 cleaves PTP1B, which results in the de-phosphorylation of Src at Tyr527, 
leading to increased Src activity initiating cortactin-dependant invadopodia assembly 
(Cortesio et al., 2008). However, calpain-2 also functions downstream of Src to regulate 
invadopodia disassembly through proteolysis of cortactin. It has since been discovered 
that cortactin is also a substrate of PTP1B (Stuible et al., 2008), making it likely that 
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PTP1B knockdown in this study was additionally affecting invadopodia assembly 
through direct regulation of cortactin phosphorylation. These two recent papers from the 
Huttenlocker laboratory have confirmed the role of Src as the essential kinase mediating 
invadopodia assembly through regulated targeting of actin-associated substrates to 
invadopodia sites.  Future studies are necessary to define the role of Src in the later 
stages of invadopodia lifetimes. Src is known to promote the expression of several 
MMPs that localize to invadopodia, including MMP-2, MMP-9 (Artym et al., 2006; Hsia 
et al., 2003; Van Slambrouck et al., 2009) and MT1-MMP (Artym et al., 2006; Wu et al., 
2005). In addition, Src is known to regulate activity of MT1-MMP to promote invasion 
(Sabbota et al., 2010; Wu et al., 2005). These data strongly suggest that Src may play 
an important role in delivery and/or activation of MMPs necessary for efficient focal 
ECM degradation at invadopodia sites.  
 Because Src has been identified as an important mediator of tumor malignancy, 
it is a prime target for the development of anti-invasive therapies in multiple cancer 
types, including HNSCC (Egloff and Grandis, 2008).  Src is overexpressed in HNSCC 
(van Oijen et al., 1998) and is activated downstream of EGFR (Xi et al., 2003) to 
promote tumor cell proliferation and invasion (Zhang et al., 2004). In addition, several 
Src substrates important in tumor cell motility and invasion are overexpressed in 
HNSCC (including cortactin-mentioned previously), that may serve to amplify the effects 
of Src hyperactivation resulting in increased metastatic potential (Kelley et al., 2008).   
Dasatinib and saracatinib are ATP-binding site small molecule Src inhibitors that are 
currently in phase II clinical trials (NIH, 2010a; NIH, 2010b). Src inhibitors are being 
tested on patients with metastatic solid tumors refractory to standard therapies. Data 
30 
 
thus far demonstrate that Src inhibitors may be promising for treatment alone, however 
substantial evidence suggest that these compounds would be more effective in 
combination with EGFR inhibitors or conventional chemotherapy regimens (Egloff and 
Grandis, 2008; Pichot et al., 2009).   
 It is clear that Src and the Src substrate cortactin have substantial roles in tumor 
progression. However, the precise roles in which these molecules play in advancing 
tumor cell invasion and metastasis is incomplete. The following studies demonstrate 
advances in understanding the molecular mechanisms that promote invasion in 
HNSCC, with Src and cortactin being central to this process.  In Study 1 we reveal an 
important and previously unappreciated function of the Src inhibitor saracatinib to impair 
invadopodia formation and associated matrix degradation activity in HNSCC cells, 
resulting in decreased invasiveness. Ablation of invadopodia formation in response to 
saracatinib is associated with a decrease in tyrosine phosphorylation of several 
invadopodia-associated Src substrates, including cortactin. Study 2 further defines the 
role of WT Src in invadopodia formation and function in HNSCC. We confirm that 
activated Src is responsible for the initiation of invadopodia formation, and demonstrate 
the novel finding that regulated Src activity has an important role in invadopodia 
maturation. We also identify regulated cortactin tyrosine phosphorylation downstream of 
Src as central to this process.  The regulation and interplay of cortactin by Src-mediated 
tyrosine phosphorylation and Erk-mediated serine phosphorylation downstream of 
EGFR is evaluated in Study 3. We reveal that both pathways are important to promote 
cell motility in cancer cell lines. Finally, Study 4 illustrates a transgenic model of HNSCC 
where mice were designed to overexpress cortactin specifically in the oral cavity of 
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tumorgenic mice to provide an in vivo model evaluating the role of cortactin in promoting 
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Elevated Src kinase activity is linked to the progression of solid tumors, including head and 
neck squamous cell carcinoma (HNSCC).  Src regulates HNSCC proliferation and tumor 
invasion, with the Src-targeted small molecule inhibitor saracatinib displaying potent anti-
invasive effects in preclinical studies.  However, the pro-invasive cellular mechanism(s) 
perturbed by saracatinib are unclear.  The anti-proliferative and anti-invasive effects of 
saracatinib on HNSCC cell lines were therefore investigated in preclinical cell and mouse 
model systems. Saracatinib treatment inhibited growth, cell cycle progression and transwell 
Matrigel invasion in HNSCC cell lines. Dose-dependent decreases in Src activation and 
phosphorylation of the invasion-associated substrates focal adhesion kinase, p130 CAS and 
cortactin were also observed.  While saracatinib did not significantly impact HNSCC tumor 
growth in a mouse orthotopic model of tongue squamous cell carcinoma, impaired perineural 
invasion and cervical lymph node metastasis was observed.  Accordingly, saracatinib 
treatment displayed a dose-dependent inhibitory effect on invadopodia formation, extracellular 
matrix degradation and matrix metalloprotease 9 activation.  These results suggest that 
inhibition of Src kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting 
Src substrate phosphorylation important for invadopodia formation and associated matrix 












CAS- Crk-associated substrate 
c-Src- cellular Src kinase 
ECM- extracellular matrix 
FACS- fluorescence-activated cell sorting 
FAK- focal adhesion kinase 
FITC- fluorescein isothiocyanate 
HNSCC- head and neck squamous cell carcinoma 
IHC- immunohistochemistry 




Tumor cell invasion and metastasis is a compounding problem in cancer management, 
with therapeutic intervention of tumor invasion becoming recognized as an increasingly 
relevant clinical factor (Dolgin, 2009).  Increased activation of the proto-oncogene c-Src 
(Src) has been established in enhancing tumor progression in human cancer and 
corresponds with poor clinical outcome (Irby & Yeatman, 2000; Yeatman, 2004). Src is 
responsible for governing signaling pathways that regulate proliferation, angiogenesis, 
resistance to apoptosis, adhesion, motility and invasion (Summy & Gallick, 2006). High 
Src expression and/or activity is observed in metastases, supporting a role for Src in 
tumor progression by enhancing tumor invasion and metastatic potential (Summy & 
Gallick, 2003; Yeatman, 2004).  Small molecules targeting Src kinase activity suppress 
proliferation, invasion and metastasis in preclinical settings (Summy & Gallick, 2006), 
and are currently being evaluated in clinical trials (Kopetz et al., 2007).  
 
Head and neck squamous cell carcinoma (HSNCC) is highly invasive, frequently 
metastasizing to cervical lymph nodes and corresponds with poor prognosis (Kramer et 
al., 2005).  Src overexpression is common in HNSCC (van Oijen et al., 1998) and is 
activated following engagement of the epidermal growth factor receptor (EGFR), where 
it modulates HNSCC growth and invasion through several signaling pathways (Zhang et 
al., 2004).  The small molecule Src kinase inhibitor dasatinib suppresses motility and 
invasion of HNSCC cells in vitro and in mouse xenografts models, corresponding with 
decreased Src activation and invasion-associated substrate phosphorylation (Johnson 
et al., 2005; Sen et al., 2009). Amplification and/or overexpression of Src substrates in 
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HNSCC correlates with poor clinical outcome, potentially serving to magnify Src 
pathway effects on HNSCC invasion and metastasis (Kelley et al., 2008). 
 
HNSCC invasion and metastatic spread is mediated in part by the action of matrix 
metalloproteases (MMPs), with MMP1, MMP2, MMP9 and MT1-MMP activity 
associated with poor outcome (Rosenthal & Matrisian, 2006).  MT1-MMP, MMP2 and 
MMP9 localize to invadopodia, actin-based ventral protrusions in invasive tumor cells 
that mediate focalized proteolysis of the extracellular matrix (ECM) (Linder, 2007; 
Weaver, 2006).  Invadopodia formation is dependent on Src activity, which enhances 
MMP2 and MMP9 secretion (Hsia et al., 2003; Mueller et al., 1992), and matrix 
degradation in HNSCC cells (Clark et al., 2007).  The collective localization and action 
of MMPs at invadopodia allows matrix remodeling to accommodate primary tumor 
growth and to allow dissemination of encapsulated tumor cells to local and distant sites 
(Gimona et al., 2008). 
 
Saracatinib (AZD0530) is a recently developed anilinoquinazoline inhibitor designed to 
disrupt Src kinase activity (Hennequin et al., 2006; Summy & Gallick, 2006).  
Saracatinib exhibits inhibitory effects on tumor growth in some model systems (Herynk 
et al., 2006), but several preclinical reports suggest that the primary anticancer effects 
of saracatinib are impaired tumor cell migration and invasion in HNSCC and other 
cancer types (Green et al., 2009; Koppikar et al., 2008; Nozawa et al., 2008).  The anti-
invasive effects of saracatinib are consistent with the effects of Src kinase inhibition in 
HNSCC by dasatinib, another Src-targeted inhibitor (Johnson et al., 2005).  Saracatinib 
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is currently being evaluated in phase I/II clinical trials for efficacy against advanced 
stage HNSCC and other tumor types (Kopetz et al., 2007). 
 
Although saracatinib and other Src inhibitors are effective anti-invasive compounds, a 
complete understanding of the how therapeutic Src inhibition perturbs tumor invasion at 
the cellular level is lacking.  We show that saracatinib inhibited Src activation and 
phosphorylation of the invadopodia regulatory proteins focal adhesion kinase (FAK), 
p130 Crk-associated substrate (CAS) and cortactin in HNSCC cells.  Saracatinib 
suppressed HNSCC growth and cell cycle progression in a subset of HNSCC cell lines.  
Administration of saracatinib to nude mice containing orthotopic HNSCC tongue tumors 
inhibited Src activity, cortactin phosphorylation, perineural invasion and lymph node 
metastasis. We also demonstrated that saracatinib prevented invadopodia formation 
and ECM degradation in invasive HNSCC cells, as well as secretion and activation of 
MMP9.  Collectively these results suggest that saracatinib exhibits anti-tumor effects in 
HNSCC by inhibiting invasion through the prevention of invadopodia formation.  The 
ability of saracatinib to prevent invadopodia-mediated ECM proteolysis reveals a cellular 
process perturbed by Src inhibitors that is likely utilized in the progression of HNSCC 
and other invasive carcinomas containing high Src activity. 
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Materials and Methods 
 
Cell lines, antibodies and Western blotting 
HNSCC cell lines 1483, HN31, UMSCC 1, UMSCC19 and MSK 921 were maintained as 
described (Rothschild et al., 2006).  Western blotting of cell lysates was conducted 
essentially as before (Rothschild et al., 2006).  Western blotting of secreted MMP2 and 
9 was conducted on conditioned media, with volumes adjusted to compensate for 
variations in cell numbers using dimethyl sulfoxide (DMSO)-treated cell numbers as 
controls. 
Antibodies for immunoblotting included anti-Src (1:1000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), anti-pY418 Src (1:1000; Invitrogen, Carlsbad, CA, USA), anti-
p130CAS (1:1000; BD Biosciences, San Jose, CA, USA), anti-pY410 p130CAS 
(1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-FAK (1:1000; BD 
Biosciences), anti-pY861 FAK (1:1000; Invitrogen) and anti-cortactin (1µg/ml; 4F11 
(Rothschild et al., 2006)).  For detection of human pY421 cortactin, a custom antibody 
was developed by 21st Century Biochemicals (Marlboro, MA, USA).  Briefly, a synthetic 
cortactin peptide encompassing the sequence around tyrosine 421 (NH2-
VpYEDAASFKL-COOH) was synthesized, phosphorylated and injected into rabbits.  
Immune serum was passed through a column containing agarose beads coupled to the 
equivalent non-phosphorylated peptide, and then passed over a second agarose 
column containing a partially overlapping phosphorylated peptide (NH2-
LPSSPVpYEDAA-COOH).  Bound antibodies were eluted, concentrated and screened 
for specificity by Western blotting against recombinant cortactin mutant proteins 
harboring phenylalanine-tyrosine point mutations at tyrosine 421 (Fig. 1, Supplemental 
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Material).  Anti-ERK1/2 (Cell Signaling) and anti-pT202/pY204 ERK1/2 (Cell Signaling) 
were used at 1:1000.  Anti-MMP2 (1:500; Millipore, Billerica, MA, USA) was used to 
detect cellular MMP2 levels.  Secreted MMP2 was detected with antibody CA-4001 
(1:100; Millipore).  Cellular and secreted MMP9 was detected with monoclonal antibody 
9D4.2 (1:100; Millipore).  All Western blots were quantified by densitometry and ImageJ 
analysis, and band intensities determined relative to non-treated controls.  
 
Cell proliferation and cell cycle progression assays 
For cell proliferation assays, 4,000 cells were seeded overnight and treated with 0-10 
mM saracatinib (AstraZeneca, Cheshire, UK) for 5d.  100 µg of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich, St. Louis, MO, USA) was added to 
each saracatinib treatment condition for 4h, cells were washed and the reduced dye 
extracted with a 75% isopropanol/2% HCl/23% H2O mixture.  Dye absorbance was read 
at 490 nm with an automated plate reader. 
Cell cycle distribution was determined by fluorescence activated cell sorting (FACS) as 
previously described (Frederick et al., 2007). 
 
Invasion assays 
BioCoat Matrigel invasion chambers (BD Biosciences) were rehydrated with serum-free 
DMEM media for 2 h. 1 X 105 cells suspended in serum-free media were plated in the 
chamber insert and incubated for 2 h to allow attachment. The media in the upper and 
lower chambers was replaced, with serum-free DMEM added to the upper chamber and 
DMEM containing 5% FBS added to the lower chamber to generate a chemotactic 
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gradient.  Increasing doses of saracatinib (0-1 µM) of saracatinib as indicated (Fig. 1D) 
to the upper and lower chambers.  Cells were allowed to invade for 12-24 h (depending 
on cell line), fixed with 10% buffered formalin phosphate (Fisher Scientific, Hanover 
Park, IL, USA) and rinsed with PBS. Non-invasive cells were removed from the interior 
of the chamber insert with a swab and the remaining cells were stained with 0.4% 
Crystal Violet solution (Fisher) for 15 min. Invasion was assessed by counting cells in 
four random 20X microscopic fields. 
 
Orthotopic xenograft assay of HNSCC invasion 
An in vivo mouse model of oral tongue squamous cell carcinoma was established as 
described (Myers et al., 2002) with minor modification using female athymic Foxn1nu/nu 
mice 4-5 weeks of age (Harlan Laboratories, Indianapolis, IN, USA). All animal 
procedures were conducted according to an approved protocol by the West Virginia 
University Animal Care and Use Committee.  Anesthetized mice were injected with 2.5 x 
104 UMSCC1 cells suspended in DMEM into the anterior ~1/3 of the tongue.  After 10 d, 
treatment was initiated by daily oral gavage of 25mg/kg saracatinib suspended in a 
sterile solution of 0.5% methyl cellulose/0.1% polysorbate 80 (Tween 80, Sigma-
Aldrich).  Control animals were gavaged with the methylcellulose/Tween 80 vehicle.  No 
overt difficulties were encountered when gavaging mice over time as the tumor size 
increased.  Six mice were used for each treatment group.  After 30 d of treatment, mice 
were euthanized by carbon dioxide inhalation and tumor volumes determined as 
described (Huang et al., 2002).  Tongues, sublingual tissue containing the superficial 
cervical lymph nodes and the tracheoesophageal region, deep cervical and mediastinial 
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lymph nodes, liver and lung were removed from each animal, rinsed, fixed and paraffin 
embedded for routine histological evaluation. 
 
Immunohistochemistry 
Human HNSCC cases were obtained from the West Virginia Tissue Bank and used 
under the approval of West Virginia University Institutional Review Board.  Five-
micrometer sections from human HNSCC and mouse tissue blocks were processed and 
immunolabeled or hematoxylin and eosin (H&E) stained using a Discovery XT 
automated staining system (Ventana Medical Systems, Tucson, AZ, USA).  For 
immunohistochemistry, primary antibody conditions were: anti-total Src (Cell Signaling) 
1:600 in Dako diluent (Dako, Carpinteria, CA, USA) for 1 h, anti-pY416 Src family 
kinase (SFK) (Cell Signaling) 1:25 in phosphate saline solution (PSS) (Ventana) for 12 
h, anti-total cortactin (Novus Biologicals, Littleton, CO, USA) 1:700 in PSS for 1 h, anti-
pY421 cortactin 1:50 in Tris-buffered saline containing 4% BSA for 1 h, and prediluted 
anti-cytokeratin 14 (Abcam, Cambridge, MA, USA) for 20 min.  Primary antibodies were 
detected using the Omnimap antibody horseradish peroxidase kit (Ventana) and slides 
were counterstained with hematoxylin.  Images were acquired as described (Rothschild 
et al., 2006).  For quantifying pY416 Src and pY421 cortactin staining intensities, 
brightfield images from at least 5 randomly selected images were captured on an 
Olympus ZX70 Provis microscope (Olympus, Center Valley, PA, USA) with a 20x/0.70 
UPlanApo objective and an Optronics MicroFire 1600x1200 color CCD camera 
(Optronics Inc, Goleta, CA, USA) using the StereoInvestigator imaging package (MBF 
Bioscience, Williston, VT) with the same camera settings and brightfield correction 
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enabled to ensure even illumination across the image.  Brown 3,3'-diaminobenzidine 
(DAB) staining was separated from blue hematoxylin staining using the color 
deconvolution plug-in function of ImageJ (NIH) as described (Park et al., 2008).  The 
vector values for the DAB staining were determined from ROIs with brown staining 
(R=0.425, G=0.600 and B=0.677 for pY421 cortactin; R=0.475, G= 0.653 and B=0.686 
for pY416 Src).  Brown images were inverted and intensities were measured inside the 
tumor tissue.  The mean DAB intensities were averaged within the group to calculate 
ratios of phosphorylation-specific staining in treated vs. control tissues. 
 
Immunofluorescence labeling, confocal microscopy and image analysis 
UMSCC1 cells were plated on fluorescein isothiocyanate (FITC)-gelatin (Sigma) coated 
coverslips as described (Artym et al., 2006) for 2 h.  Cells were left untreated or treated 
with saracatinib for 6 h, rinsed and fixed with 4% formaldehyde.  Cells were 
permeabilized with 0.4% Triton-X/PBS for 4 minutes, then blocked in 5% BSA/PBS for 1 
h.  To identify invadopodia, cells were incubated with rhodamine-conjugated phalloidin 
(1:1000; Invitrogen), anti-cortactin monoclonal antibody 4F11 (1 µg/ml) and polyclonal 
pTyr-100 (1:200; BD Biosciences) in 5% BSA/PBS for 1 h.  After washing, cells were 
incubated in 5% BSA/PBS containing AlexaFluor 405 goat anti-rabbit and AlexaFluor 
647 goat anti-mouse secondary antibodies (Invitrogen) at 1:1000.  Cells were rinsed 
and mounted in Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).  
For quantifying saracatinib effects on invadopodia incidence and matrix degradation, 
eight-bit 1024x1024 pixel confocal images were acquired with a Zeiss LSM510 confocal 
microscope using AIM software (Carl Zeiss MicroImaging, Thronwood, NY, USA).  
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Images were scanned with a 63x/1.4 NA Oil Plan-Apochromat objective at 1.3x zoom, 
yielding a resolution of 10.14 pixels/µm.  All images of the FITC-gelatin were taken with 
the same parameters (pinhole size, laser intensity and gain) so image intensity would 
be comparable between samples.  For invadopodia formation, a minimum of six 
independent fields comprising > 50 cells were analyzed for cells containing invadopodia 
compared to total cell number.  For matrix degradation, cells were analyzed using 
ImageJ software.  Actin images were adjusted to threshold values to include all cellular 
regions, and the resulting images were used to calculate total cell areas in µm2.  For 
quantifying matrix degradation, FITC-gelatin images were inverted so that regions with 
increased degradation would yield higher intensity values, ensuring selection of all 
areas of matrix degradation.  The integrated density was reported as the amount of 




UMSCC1 and 1483 cells were plated overnight at 5 X 106 in complete media and were 
treated with saracatinib at increasing dosage for 24 h, rinsed and incubated for 24 h in 
serum-free media containing the equivalent saracatinib dose.  Cells were counted, and 
conditioned media collected and concentrated by ultrafiltration using Amicon Ultra-4 
centrifugal filter devices with a 10kDa molecular weight cutoff (Millipore).  Zymography 
was conducted as described (Clark et al., 2007) with minor modification.  Conditioned 
media (35 µl) was diluted in 2X non-reducing SDS-PAGE sample buffer and resolved on 
8% SDS-PAGE gels containing 1 mg/ml bovine gelatin (Sigma).  Aliquots of serum-free 
DMEM and DMEM containing 10% FBS were used as negative and positive controls, 
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respectively.  MMP activity was renatured by washing gels in 2.5% Triton X-100 for 30 
min, followed by washing gels in Developing Buffer (50 mM Tris, 0.2M NaCl, 5mM 
CaCl2, 0.02% Brij 35) for 30 min at room temperature.  Gels were then incubated in 
renewed Developing buffer for 24h at 37° C to allow MMP activity to proceed.  Gels 
were stained with Coomassie Brilliant Blue R-250 (0.5% w/v) for 30 min, followed by 
destaining in water.  Resulting gels were scanned using a FotoAnalyst Investigator 
(Fotodyne Inc, Hartland, WI, USA) and areas of gelatinase activity quantified using 
ImageJ.  Results were adjusted relative to control DMSO treatment for gelatinase 




Differences in mean values between saracatinib treatment groups for invasion, 
invadopodia and gelatinase assays were evaluated using one-way ANOVA, followed by 
Student-Newman-Keuls post hoc testing.  Differences were considered significant at 





Saracatinib effects on HNSCC proliferation and invasion  
As a first step in our work, we characterized several HNSCC cell lines previously 
determined to have varying degrees of invasive and metastatic potential (Rothschild et 
al., 2006; Sano & Myers, 2007; Yang et al., 2004) for their response to saracatinib. To 
determine the effect of saracatinib treatment on proliferation in these lines, growth 
inhibition was assessed by 5d 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays for cells treated with increasing doses of saracatinib (Fig. 1A).  
The HN31 and UMSCC1 lines were sensitive to growth inhibition by saracatinib, as 
indicated by sub-micromolar IC50 values (Fig. 1A).  In contrast, the 1483 line 
demonstrated a marked resistance to saracatinib, with an IC50 = 7.60µM.  
Corresponding effects on cell cycle progression are also observed, with increasing 
saracatinib concentrations resulting in enhanced G1 checkpoint arrest in HN31 and 
UMSCC1 lines determined by FACS analysis (Fig. 1B).  Saracatinib treatment did not 
alter the percentage of cells undergoing G2-M transition for either line.  Arrest of G1 was 
not evident in 1483 cells treated with saracatinib concentrations up to 1µM, in 
agreement with resistance of this line in proliferation analysis (Fig. 1A).   Erk1/2 
activation, a potent driver of mitogenesis, was impaired in HN31 and UMSCC1 cells at 
concentrations above 0.5 µM as determined by Western blotting (Fig. 1C). Similar 
results were obtained for the invasive HNSCC lines MSK921 and UMSCC19 (data not 
shown).  Erk1/2 activation was elevated in 1483 cells at doses up to 1µM (Fig. 1C), in 
agreement with the high IC50 value for this line (Fig. 1A).  These data indicate that the 
HNSCC lines used in this study vary in their proliferative response to saracatinib 
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treatment, and can be segregated into sensitive (HN31 and UMSCC1) and resistant 
(1483) populations. 
Next we evaluated the effect of saracatinib on HNSCC invasion in vitro using modified 
Boyden chamber transwell assays.  In the absence of saracatinib, UMSCC1 and HN31 
cells displayed an invasive response to serum, averaging 4150 cells/aggregate field and 
1719 cells/aggregate field, respectively (Fig. 1D).  1483 cells were weakly invasive, with 
an average of 243 cells/aggregate field (Fig. 1D).  Increased concentrations of 
saracatinib resulted in dose-dependent inhibition of HNSCC invasion for all tested lines, 
with reduced invasion compared to control levels of 88% in UMSCC1, 70% in HN31, 
and 78% in 1483 cells at the highest evaluated dose (1.0 µM) (Fig. 1D).  These results 
indicate that saracatinib directly impacts the ability of HNSCC cell lines to invade in an 
in vitro setting. 
 
Saracatinib inhibits Src activation and substrate phosphorylation in HNSCC cells 
To determine the impact of saracatinib on Src activity and phosphorylation of 
invadopodia-related Src substrates, dose-dependence experiments were performed on 
HN31, UMSCC1 and 1483 cells (Fig. 2).  Cell lines were treated with increasing doses 
of saracatinib for 24 hours, lysed and assessed for phosphorylation by immunoblotting 
using anti-phosphorylation site-specific antibodies to detect Src activation (pY418) and 
specific Src phosphorylation sites in downstream substrates (pY410 p130 CAS, pY421 
cortactin and pY861 FAK).  The phosphorylation of Src at Y418 was inhibited by 
saracatinib in all tested lines at concentrations between 0.5 and 1.0 µM (Fig. 2).  
Phosphorylation of cortactin at tyrosine 421 and FAK at tyrosine 861 was also reduced 
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within the same range of saracatinib concentrations (FAK phosphorylation in 1483 cells 
could not be evaluated due to the absence of detectable FAK expression in this line).  
While phosphorylation of tyrosine 410 in p130 CAS was inhibited within this same dose 
range in UMSCC1 cells, we observed that p130 CAS phosphorylation was consistently 
inhibited at lower dose ranges (0.01-0.05 µM) in HN31 and 1483 cells (Fig. 2).  
Immunoblotting with antibodies against total p130 CAS, cortactin and FAK indicate that 
the expression levels of these proteins are somewhat reduced at high dose levels of 
saracatinib treatment (0.5-1µM), but not at levels accountable for the resultant decrease 
of tyrosine phosphorylation at the assayed sites (0.1-0.5µM).   
 
Saracatinib inhibits Src activation, invasion and cervical lymph node metastasis 
in an orthotopic mouse model of oral squamous cell carcinoma 
A mouse orthotopic model of tongue squamous cell carcinoma (Myers et al., 2002) that 
phenotypically mimics human HNSCC (Fig. 3) was utilized to evaluate the effects of 
saracatinib on HNSCC progression and invasion in an in vivo setting.  Athymic mice 
with UMSCC1 tongue tumors were randomized and treated with either vehicle or daily 
with 25mg/kg saracatinib.  At the end of treatment (40d), mice from both groups had 
similar weight (24g) and mean tumor volumes (54.1mm3+ 2.3mm for controls; 
43.7mm3+ 4.6mm with saracatinib treatment).  The modest impact of saracatinib on 
UMSCC1 tumor growth was not statistically significant.  To determine the impact of 
saracatinib on Src activity, primary tumors were evaluated for Src and cortactin 
phosphorylation by immunohistochemistry.  Active Src (determined by pY416 SFK 
staining) and pY421 cortactin labeling in UMSCC1 tumors displayed similar patterns 
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compared to human HNSCC (Fig. 3A).  Saracatinib treatment reduced the ratios of 
pY416 SFK and pY421 cortactin compared to control-treated mice (Figure 3A).  
Human HNSCC often displays perineural invasion with regional lymph node 
involvement.  Given the invasive nature of UMSCC1 cells (Fig. 1D), we evaluated the 
impact of saracatinib treatment on loco-regional tissue invasion and cervical lymph node 
metastasis in treated mice.  Soft tissues from the submental space through the 
tracheoesophageal region were evaluated for perineural invasion and cervical lymph 
node metastasis by immunostaining for the epithelial marker cytokeratin 14.  Similar to 
human tumors, extensive perineural invasion and metastasis to the superficial cervical 
lymph nodes was evident in 5/6 control treated mice (Fig. 3B).  Invasion and lymph 
node metastasis was found in 1/6 saracatinib-treated mice, and the remaining mice 
displayed a complete absence of cytokeratin-positive cells associated with nerves, 
sublingual glands, connective tissue or cervical lymph nodes (Fig. 3B).  These data 
demonstrate that the in vivo ability of saracatinib to down-regulate Src activity and 
cortactin phosphorylation correlates with decreased invasion and local lymph node 
metastasis. 
 
Saracatinib inhibits invadopodia formation and matrix degradation in UMSCC1 
cells 
 
UMSCC1 cells plated on fluorescently-labeled gelatin formed centrally localized ventral 
puncta enriched with cortactin, filamentous (F)-actin and phosphotyrosine (Fig. 4A, 
DMSO), three markers that define invadopodia (Bowden et al., 2006).  Spontaneous 
invadopodia formation was observed in 51% of UMSCC1 cells by confocal microscopy 
at a given time, corresponding with focalized areas of matrix clearing (FITC-gelatin) 
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(Fig. 4B, 0µM dosage point).  The gelatin matrix underneath UMSCC1 cells typically 
displayed degradation encompassing ~53% of the overlying cell area, reflecting the 
action of invadopodia-associated MMP activity (Fig. 4C).   
UMSCC1 cells plated on FITC-coated gelatin were treated with increasing 
concentrations of saracatinib, and invadopodia formation and matrix degradation was 
evaluated by confocal microscopy (Fig. 4).  The number of cells containing invadopodia 
was significantly decreased with increasing saracatinib dosage, with < 2% of cells 
having formed invadopodia at concentrations at or above 0.5 µM (Fig. 4B).  Effects on 
matrix degradation were more pronounced, where increased saracatinib dosage 
resulted in similar incremental decreases in degradation (Fig. 4C).  UMSCC1 cells 
treated with 1.0 µM saracatinib did not contain invadopodia and were incapable of 
degrading matrix (Fig. 4A).  These cells also lacked focal cortactin localization, had 
diminished phosphotyrosine levels at focal adhesions and contained disorganized F-
actin puncta on the ventral membrane surface where invadopodia typically form (Fig. 
4A, arrowheads). 
 
Saracatinib inhibits MMP9 secretion from HNSCC cells 
In addition to MT1-MMP, secretion and activation of MMP2 and MMP9 at invadopodia 
has been reported to be partially responsible for the observed effects on matrix 
degradation (Linder, 2007).  Src activity regulates MMP2 and MMP9 secretion in 
fibroblasts (Hsia et al., 2003).  We therefore determined the effect of saracatinib on 
MMP secretion.  Confocal immunofluorescence microscopy indicated that UMSCC1 
cells have MMP9-containing vesicles localized to invadopodia at sites that correspond 
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with gelatin degradation (Fig. 5A), indicating that MMP9 is concentrated in UMSCC1 
invadopodia.  To evaluate the impact of saracatinib on MMP2 and MMP9 secretion and 
activity in HNSCC cells, total cell lysates and conditioned media from saracatinib-
treated 1483 and UMSCC1 cells were analyzed for the presence of cellular and 
secreted MMP2 and MMP9 by Western blotting (Fig. 5B).  Saracatinib treatment 
resulted in modest decreases (up to 24%) in cellular MMP2 levels at concentrations to 1 
µM, while cellular MMP9 levels demonstrated up to a two-fold increase under the same 
concentration range.  Although secreted MMP2 was not detected in the media of either 
cell line, both lines secreted detectible amounts of MMP9 (Fig. 5B).  Treatment of either 
line with saracatinib inhibited MMP9 secretion, and each line displayed differential drug 
sensitivity.  Detectible MMP9 secretion from 1483 cells was largely absent at the lowest 
evaluated concentration (0.01 µM) whereas secretion from the more invasive UMSCC1 
line was inhibited at concentrations of 0.5 µM and above (Fig. 5B).  The secreted MMP9 
from both lines displayed proteolytic activity when assayed by gelatin zymography (Fig. 
5C).  Saracatinib concentrations up to 0.1µM did not significantly affect MMP9 activity 
as determined by ANOVA analysis for both lines, although mean values for 1483 cells 
treated with these lower doses were consistently below control levels (Fig. 5C).  Higher 
saracatinib concentrations (0.5 µM and 1.0 µM) reduced MMP9 activity to respective 
mean values of 39% and 25% for control levels in 1483 cells, and 22% and 12% in 
UMSCC1 cells (Fig. 5B,C).  These data indicate that saracatinib treatment of HNSCC 
cells leads to selective inhibition of MMP9 secretion in 1483 and UMSCC1 cells, 





The present study demonstrates that inhibition of HNSCC invasion in preclinical in vitro 
and in vivo settings by saracatinib directly corresponds to disruption of HNSCC 
invadopodia formation and function, identifying invadopodia as a potential downstream 
target of therapeutic Src kinase inhibition in HNSCC and other invasive human cancers.   
Invasive HNSCC presents a difficult problem in patient care, given the proximity of most 
tumors to multiple vital organ sites in the head and neck region.  Disregulation of 
signaling pathways that promote and sustain invasion impinge on adhesion- and 
cytoskeletal-associated proteins.  These proteins function in concert with MMPs to 
enable tumor cells to degrade and protrude through an encapsulating ECM, allowing 
movement into neighboring tissues.  The ability of saracatinib to ablate invadopodia and 
the associated invasive behavior of HNSCC cells in mice provides further evidence for a 
direct link between invadopodia activity and tumor invasion, shedding light on the 
specific invasion-promoting cellular processes perturbed by Src kinase inhibition.  
 
The HNSCC lines used in this study displayed differential responses to saracatinib in 
terms of anti-proliferate effects, with some lines (HN31 and UMSCC1) having 
submicromolar sensitivity, cell cycle inhibition and decreased ERK1/2 activity and others 
(1483) demonstrating resistance to the drug at concentrations up to 1 µM (Fig. 1A-C).  
While a recent study reported IC50 saracatinib values near 1 µM for five different 
HNSCC lines (Koppikar et al., 2008), our findings are in line with the wider range of IC50 
values reported for different HNSCC lines treated with the non-related Src kinase 
inhibitor dasatinib (Johnson et al., 2005) as well as in other tumor cell types (Boyer et 
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al., 2002; Johnson et al., 2005; Jones et al., 2002).  These reports taken together with 
our data suggest that the HNSCC lines utilized in this study fall within the typical in vitro 
proliferative response profile to therapeutic Src inhibition.  While the underlying 
compensatory mechanism for saracatinib resistance in 1483 cells is unknown, future 
expression profiling of resistant and sensitive lines may provide insight into the 
molecular nature of saracatinib resistance, as has been recently conducted for the 
EGFR inhibitor gefitinib in a variety of HNSCC lines (Frederick et al., 2007). 
 
Saracatinib treatment resulted in in vitro anti-invasive activity, impaired Src activation 
and tyrosine phosphorylation of FAK and p130 CAS in all analyzed HNSCC lines (Fig. 
1D; Fig. 2).  This is in accord with other studies on other HNSCC lines utilizing 
saracatinib or dasatinib as single agents (Johnson et al., 2005; Koppikar et al., 2008; 
Nozawa et al., 2008). Tyrosine phosphorylation of FAK and p130 CAS have been 
commonly utilized as downstream indicators for preclinical therapeutic anti-Src efficacy, 
since Src-mediated phosphorylation of these proteins are critical events in enabling 
tumor invasiveness (Brabek et al., 2005; Zhao & Guan, 2009).  In addition, we show 
that cortactin tyrosine phosphorylation was also reduced following saracatinib treatment 
(Fig. 2).  Cortactin is a Src substrate commonly overexpressed in invasive HNSCC and 
regulates invadopodia formation (Rodrigo et al., 2000; Rothschild et al., 2006; Weaver, 
2008). Cortactin phosphorylation is important for tumor cell motility and matrix 
degradation at invadopodia (Ayala et al., 2008; Oser et al., 2009; Rothschild et al., 
2006).  These results suggest that cortactin tyrosine phosphorylation status can serve 
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as an additional downstream monitor of Src activity and invasive potential in HNSCC 
cells where Src kinase function is impaired. 
 
While saracatinib was able to modestly decrease the size of in vivo UMSCC1 tongue 
tumors, the reduction in tumor size was not significant compared to untreated controls.  
UMSCC1 cell growth is inhibited by saracatinib in vitro (Fig. 1A), implying that 
microenvironmental factors such as inflammatory cytokines, growth factors, 
neoangiogenic and hypoxic aspects responsible for promoting and maintaining HNSCC 
growth (Pries & Wollenberg, 2006; Timar et al., 2005) may partially circumvent the 
growth-inhibitory effects of saracatinib in UMSCC1 xenografts.  On the other hand, 
saracatinib displays in vivo anti-invasive properties by potently inhibiting perineural 
invasion and cervical lymph node metastasis.  Suppressed Src activation and cortactin 
tyrosine phosphorylation in primary tumors (Fig. 4A) supports this conclusion, as 
signaling through these proteins promotes invasion and metastatic spread (Weaver, 
2008; Yeatman, 2004).  Recent findings in a comparable xenograft system utilizing mice 
treated with dasatinib demonstrated reduced Src and FAK activity (Sen et al., 2009).  
EGFR overexpression is common in HNSCC, resulting in enhanced Src activity, 
cortactin phosphorylation and tumor invasiveness (Koppikar et al., 2008; Rothschild et 
al., 2006).  Clinical EGFR inhibitors also display anti-invasive activity and impair 
invadopodia formation in preclinical settings (Huang et al., 2002; Yamaguchi et al., 
2005; Yang et al., 2004), suggesting in light of our findings that inhibiting EGFR activity 
in HNSCC impairs Src activation and substrate phosphorylation required for invasion.  
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This is supported by emerging rationale for dual targeting of EGFR and Src in treating 
advanced HNSCC (Egloff & Grandis, 2008). 
 
Elevated Src activity is necessary and essential for invadopodia formation (Chen et al., 
1985; Chen et al., 1984).  The ability of saracatinib to ablate invadopodia and 
associated matrix degradation demonstrates that a clinically utilized Src inhibitor 
disrupts a vital subcellular structure required for tumor invasion.  Src-induced 
invadopodia formation in carcinoma cells first targets cortactin and F-actin formation at 
matrix adhesion sites, forming a core preinvadopodia complex.  Recruitment of MT1-
MMP to preinvadopodia initiates matrix degradation and invadopodia maturation, with 
further maturation involving dissolution of the cortactin-F-actin complex, focal retention 
of MT1-MMP and continued proteolytic activity (Artym et al., 2006).  While rudimentary 
invadopodia-like F-actin structures formed in UMSCC1 cells treated with inhibitory 
concentrations of saracatinib, they do not contain cortactin (Fig. 4A), which is essential 
for invadopodia formation (Artym et al., 2006), indicating that Src kinase activity is 
required for cortactin localization to invadopodia.  Similar results have been shown 
through the use of kinase-inactive Src constructs (Bowden et al., 2006).  Tyrosine 
phosphorylation of invadopodia proteins is strongly linked with the ability to degrade 
extracellular matrix (Bowden et al., 2006), with Src phosphorylation of cortactin (Ayala 
et al., 2008), paxillin (Badowski et al., 2008), and ASAP1 (Bharti et al., 2007) requisite 
for invadopodia formation and/or proteolytic activity.  Src kinase inhibition therefore 
displays at least a two-fold effect on substrates in invadopodia by impairing proper 
preinvadopodia targeting and perturbing phosphotyrosine-based signaling dynamics 
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involved in regulating invadopodia maturation and function.  Tyrosine phosphorylation in 
peripheral focal adhesions was observed in UMSCC1 cells, indicating saracatinib may 
also perturb focal adhesion formation and/or function given the critical role for Src and 
related kinases in these structures (Frame, 2004). 
MMP activity is essential for HNSCC invadopodia formation and function (Clark et al., 
2007).  The impairment of MMP9 secretion and activation from HNSCC cells treated 
with saracatinib indicates that Src kinase activity is required for targeting and secretion 
of MMP9-containing vesicles at invadopodia.  This is in agreement with observed 
effects of Src kinase inhibition on MMP9 secretion in other tumor types (Cortes-
Reynosa et al., 2008; Lee et al., 2005).  The lack of apparent MMP2 secretion in the 
HNSCC lines used in our studies precluded evaluation of this metalloproteinase, and is 
likely characteristic to these lines since other HNSCC cells secrete MMP2 (Clark et al., 
2007).  Localization of transmembrane and secreted MMPs to invadopodia involves 
directed trafficking of vesicles emanating from the trans-Golgi network, where a 
dynamin-2-N-WASp-Arp2/3-cortactin complex has been implicated in coupling cortical 
actin regulation with invadopodia membrane dynamics (Buccione et al., 2004).  
Cortactin has been implicated as a key regulator of MT1-MMP surface expression and 
MMP2 and MMP9 secretion in HNSCC (Clark & Weaver, 2008; Clark et al., 2007).  
While it is currently unknown how cortactin regulates the targeting of MMP-containing 
vesicles, Src-mediated phosphorylation may play a vital role since tyrosine 
phosphorylation of cortactin increases its binding to vesicle-associated proteins (Ammer 
& Weed, 2008) and is required for efficient invadopodia-mediated ECM degradation 
(Ayala et al., 2008; Webb et al., 2007).   
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Our results indicate that disruption of Src activity by saracatinib impairs HNSCC cell 
invasion and lymph node metastasis by preventing invadopodia formation and function, 
identifying a cellular mechanism that may be universally impacted by Src inhibition in 
invasive carcinoma cells.  In addition to Src and related kinases, saracatinib also inhibits 
Abl kinase, an activity that has been exploited to evaluate imatinib-resistant chronic 
myelogenous leukemia (CML) cases expressing the constitutively active BCR-Abl 
Philadelphia chromosome gene product (Gwanmesia et al., 2009).  Along with the 
tumor-promoting activities in CML, elevated Abl kinase activity has been shown to be 
important in breast (Srinivasan & Plattner, 2006) and non small cell lung cancer (Lin et 
al., 2007), indicating Abl kinase activity has a functional role in solid tumor progression 
(Lin & Arlinghaus, 2008).  Abl expression has been evaluated in oral squamous cell 
carcinoma and correlates with tumor stage (Yanagawa et al., 2000), suggesting that 
elevated Abl expression may contribute to HNSCC progression.  While a mechanism 
pertaining to Abl function in solid tumor invasion or invadopodia function has not been 
reported, Abl does bind and phosphorylate cortactin, (Boyle et al., 2007), raising the 
potential for Abl kinase to play a role in cortactin-based invadopodia function in HNSCC 
and other invasive Abl-expressing solid tumors.  Such a role for Abl in regulating tumor 
invasion would also likely be impaired by saracatinib and other dual Src/Abl inhibitory 
compounds.  
In addition to carcinoma invadopodia, Src-mediated processes in non-cancerous cell 
types involved in promoting invasion may also be impacted by Src family kinase 
inhibition. The motility and protease remodeling ability of tumor stromal fibroblasts 
involved in enabling collective HNSCC invasion could be affected by impairing Src 
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family kinases in vivo (Gaggioli et al., 2007), as well as the proinvasive properties of 
tumor-associated macrophages (Condeelis & Pollard, 2006).  The ability of saracatinib 
and other Src inhibitors to impair functions of different cellular types that propagate 
tumor invasion provides the opportunity for the future discovery of additional Src-based 
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Figure 1.  Effects of saracatinib on HNSCC proliferation, cell cycle progression, Erk1/2 
activation and in vitro invasion.  A. IC50 values for cell growth determined by 5 day MTT 
assays for the indicated HNSCC lines treated with 0-10 mM saracatinib.  Mean values 
are shown for each line from three independent assays.  B. Impact of saracatinib on 
HNSCC cell cycle progression.  HNSCC cell lines were treated with the indicated 
amounts of saracatinib for 24 hours, fixed labeled with propidium iodide to assess DNA 
content, and analyzed for cell cycle status by fluorescence-activated cell sorting.  
Results show the average percentage of cells in each cell cycle phase as indicated on 
the left. Bars, SD of two independent experiments.  C. Effects of saracatinib on Erk1/2 
activity.  HNSCC cells were treated with saracatinib for 24 hours at the indicated doses, 
lysed and analyzed by Western blotting with phosphorylation-specific (pErk1/2) and total 
Erk1/2 antibodies.  Blots shown are representative of three different experiments, with 
indicated band intensities shown relative to no treatment (0 mM) for each cell line.  D.  
Saracatinib inhibits in vitro HNSCC invasion.  HNSCC cells (1x105) were plated in 
Matrigel-coated transwells alone or with increasing concentrations of saracatinib.  After 
2 h, invasion was stimulated with 5% FBS and cells were allowed to invade for 12 h 
(UMSCC1) or 24 h (HN31 and 1483).  Invaded cells were quantified by brightfield 






Figure 2.  Saracatinib inhibits Src activity and downstream Src substrate 
phosphorylation in HNSCC cell lines.  HN31, UMSCC1 and 1483 cells were treated with 
DMSO vehicle or saracatinib (0.01-1 µM) for 24 h.  Cells were lysed and total protein 
amounts were analyzed by Western blotting with total or phosphorylation site-specific 
antibodies for Src and the indicated substrates.  Blots shown are representative of at 
least four independent experiments, with band intensities for each substrate quantified 
relative to the untreated (0 mM) condition for each cell line.  
 
Figure 3.  Saracatinib inhibits Src activity, perineural invasion and cervical lymph node 
metastasis in orthotopic UMSCC1 tongue tumors.  A.  UMSCC1 tongue tumors from 
representative control-treated or saracatinib-treated mice were sectioned and stained 
with hematoxylin and eosin (H&E) or by IHC with the indicated antibodies (left).  A case 
of human HNSCC was evaluated in parallel as a positive control.   The pY416 SFK and 
pY421 cortactin ratios from saracatinib treated to control levels are indicated.  Bars, 100 
µm.  B.  Locoregional invasion and lymph node metastasis is inhibited by saracatinib.  
Submental and associated tracheoesophageal tissue from control treated and 
saracatinib treated mice was immunostained for cytokeratin 14 to detect cells of 
epithelial origin.  Magnified regions containing a single sublingual nerve and superficial 
cervical lymph node are shown for clarity.  Inset shows a magnified cortical region of 
superficial cervical lymph nodes from control and saracatinib treated mice.  Arrowheads 
denote metastasized UMSCC1 cells. N; sublingual nerve, ED; excretory duct.  Bars 100 
µm; inset, 50 µm.  
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Figure 4.  Saracatinib inhibits invadopodia formation and ECM degradation.  A. 
Representative images of UMSCC1 cells treated with different saracatinib 
concentrations.  UMSCC1 cells plated on FITC-gelatin coated coverslips 
(pseudocolored white) for 2 h were treated with saracatinib as indicated (left) for 6 h.  
Cells were labeled to visualize F-actin (red), cortactin (green) and phosphotyrosine 
(blue).  Arrows denote invadopodia and corresponding colocalized areas of focal matrix 
degradation with invadopodia components. Treatment with 1.0 µM saracatinib resulted 
in F-actin aggregates lacking cortactin but accumulated at cytoplasmic sites where 
invadopodia typically occur (arrowheads). Bar, 10 µm.  B.  UMSCC1 cells treated with 
increasing concentrations of saracatinib were stained as in A and quantified to 
determine the percentage of cells that produced functional invadopodia, presented as 
the mean ± SEM.  All treatment groups were significantly different from each another 
based on a one-way ANOVA (p<0.05) except 0 and 0.01 µM, and 0.5 and 1.0 µM pairs.  
C.  Saracatinib decreases the ability of UNSCC1 cells to degrade ECM.  The 
percentage of gelatin degradation per cell area for the cell population analyzed in B is 
shown with the mean ± SEM.  
 
Figure 5: MMP9 secretion and ECM degradation activity in HNSCC cells is blocked by 
saracatinib.  A. Localization of MMP9-containing vesicles in UMSCC1 invadopodia.  
Top:  UMSCC1 cells plated on FITC-coated gelatin coverslips for 2 h were fixed and 
labeled with antibodies against cortactin and MMP9.  The merged image indicates 
areas of cortactin and MMP9 co-localization (yellow; white arrows) that correspond with 
sites of focal gelatin degradation (black arrows).  Bar; 10 mM, Asterisk; regions of global 
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matrix degradation due to secreted protease activity.  Bottom:  Magnified view of 
indicated Top region.  B.  Inhibition of MMP9 secretion by saracatinib.  Total cell lysates 
(cell) and aliquots of normalized conditioned media containing secreted MMPs (sec) 
from 1483 and UMSCC1 cells treated with increasing doses of saracatinib (bottom) 
were assayed for the presence of MMP2 and MMP9 by immunoblotting.  Band 
intensities relative to control (0 mM) are shown for each treatment condition; secreted 
MMP2 was not detected and therefore not quantified.  C. Gelatin zymography of MMP9 
activity.  Representative zymograms from conditioned media of 1483 or UMSCC1 cells 
cultured with the indicated saracatinib concentrations (bottom).  DMEM was used as a 
negative control (M), DMEM containing 10% FBS (FBS) was used as a positive control 
for zymography.  Graphs, densitometric analysis of MMP9 zymography.  Percentage of 
































































Supplementary Figure 1:  Specificity of human anti-pY421 cortactin antibody.  SYF 
fibroblasts lacking Src, Yes and Fyn were cotransfected with the temperature-sensitive 
Src allele La29 along with expression vectors encoding recombinant wild-type human 
cortactin (WT) or cortactin mutants containing tyrosine-phenylalanine substitutions at 
the indicated Src-targeted amino acids and held at the non-permissive temperature 
(41°C) or switched to the activating permissive temperature (35°C).  TYM; triple 
tyrosine-phenylalanine cortactin mutant lacking all three Src-targeted sites.  Cells were 
lysed and analyzed by Western blot analysis with anti-pY421 cortactin (left).  The blot 
was stripped and reprobed with anti-cortactin monoclonal antibody 4F11 (right).  The 
position of molecular weight markers is noted on the left in kilodaltons. 
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Study 2: Oncogenic Src requires a wild-type counterpart to regulate  
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Summary  
 The proto-oncogene Src tyrosine kinase (Src) is overexpressed in human 
cancers and is a current target of anti-invasive therapies.  Src activation is an essential 
catalyst of invadopodia production.  Invadopodia are cellular structures that mediate 
extracellular matrix (ECM) proteolysis, allowing invasive cell types to breach confining 
tissue barriers.  Invadopodia assembly and maturation is a multistep process, first 
requiring the targeting of actin-associated proteins to form pre-invadopodia.  Pre-
invadopodia subsequently mature by recruitment and activation of matrix 
metalloproteases (MMPs) that facilitate ECM degradation.  We demonstrate that active, 
oncogenic Src alleles require the presence of a wild-type counterpart to induce ECM 
degradation at invadopodia sites.  In addition, we identify the phosphorylation of the 
invadopodia regulatory protein cortactin as an important mediator of invadopodia 
maturation downstream of WT Src.  Distinct phosphotyrosine-based protein binding 
profiles in cells forming pre- and mature invadopodia were identified by SH2-domain 
array analysis.  These results indicate that while elevated Src kinase activity is required 
to target actin-associated proteins to pre-invadopodia, regulated Src activity is required 
for invadopodia maturation and matrix degradation activity.  Our findings describe a 
previously unappreciated role for proto-oncogenic Src in enabling the invasive activity of 






 Src is the first described proto-oncogene and a current target for anti-invasive 
compounds in clinical trials (Brunton and Frame, 2008; Yeatman, 2004).  Src 
participates in a vast array of cellular functions that include the regulation of cell 
proliferation, adhesion, migration, and invasion (Guarino, 2010; Thomas and Brugge, 
1997).  In normal cells, Src activity is tightly controlled through intramolecular regulation, 
subcellular localization and protein expression levels.  Elevated or aberrant Src activity 
is a potent mediator of cell transformation and tumor progression, and is associated with 
the majority of human cancers including head and neck squamous cell carcinoma 
(HNSCC) (Summy and Gallick, 2003).   
 One of the most evident phenotypes of Src transformed cells is the formation of 
actin rich ventral membrane protrusive structures that actively degrade ECM (Chen, 
1989).  These structures, termed invadopodia, are made by metastatic cancer cells and 
Src-transformed fibroblasts (Linder, 2009).  Invadopodia spontaneously form in tumor 
cells directly cultured from patient samples and are hypothesized to facilitate breaching 
of basement membranes during metastasis (Clark et al., 2007; Yamaguchi and 
Condeelis, 2007).  Src activity is absolutely necessary for invadopodia formation and 
function, with the level of tyrosine phosphorylation at invadopodia positively correlating 
with the degree of ECM degradation (Bowden et al., 2006; Spinardi et al., 2004).  The 
molecular components that make up invadopodia include proteins that facilitate actin-
assembly, membrane trafficking, and focal degradation.  Src substrates participate in all 
of these functions and include the proteins cortactin (Bowden et al., 1999), N-WASp 
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(Yamaguchi et al., 2005), dynamin2 (Baldassarre et al., 2003), AMAP1 (Onodera et al., 
2005), paxillin (Bowden et al., 1999), p130Cas (Brabek et al., 2004), Tsk5 (Seals et al., 
2005), p190RhoGAP (Nakahara et al., 1998), AFAP110 (Gatesman et al., 2004), and 
caveolin (Yamaguchi et al., 2009).  Several studies have evaluated Src activity in 
invadopodia formation through the ectopic expression of constitutively active Src alleles 
(Artym et al., 2006; Oser et al., 2009; Stylli et al., 2009).  However, these activating Src 
mutants are rarely found in human tumors, which instead typically contain increased 
levels of wild-type (WT) Src expression and/or aberrant WT Src activity due to 
hyperactivation of upstream pathways (Yeatman, 2004).  The role of WT Src in 
invadopodia formation and function is unknown.  
 Invadopodia assembly has been proposed to involve several stages that regulate 
the progression from pre-invadopodia (non-degradative) complexes to functional, 
mature invadopodia containing active MMPs that degrade ECM (Artym et al., 2006; 
Oser et al., 2009).  In current models of invadopodia formation, filamentous (F)-actin 
and the actin-associated protein cortactin are recruited to sites of matrix adhesion, 
resulting in pre-invadopodia complexes (Artym et al., 2006).  The membrane-bound 
matrix metalloproteinase MT1-MMP (MMP 14) is subsequently recruited to these sites, 
allowing for matrix degradation and invadopodia maturation.  Cortactin is an actin-
binding protein phosphorylated by Src kinase (Head et al., 2003), and is a core 
invadopodia component.  Knockdown of cortactin expression results in decreased 
invadopodia formation (Artym et al., 2006; Webb et al., 2007) and MMP secretion (Clark 
and Weaver, 2008; Clark et al., 2007), whereas phosphorylation of cortactin is important 
in regulating matrix degradation at invadopodia (Ayala et al., 2008).   
 91 
 Recent work on discerning the molecular mechanism regulating actin 
polymerization prior to MMP recruitment has identified dynamic regulation of cortactin 
phosphorylation/dephophorylation downstream of Src as central to this process (Oser et 
al., 2009).  In this model, cortactin sequesters the actin-severing protein cofilin within 
pre-invadopodia.  Tyrosine phosphorylation of cortactin releases cofilin, which in turn 
accelerates actin polymerization through the severing of existing invadopodial actin 
filaments.  In addition, tyrosine phosphorylation of cortactin creates docking sites for the 
adaptor protein Nck1, which binds and activates the Arp2/3 activator N-WASp.  The 
combined effect of cofilin activation and N-WASp-mediated Arp2/3 activity serves to 
increase actin polymerization as pre-invadopodia mature and obtain the ability to 
degrade ECM.  Dephosphorylation of cortactin is proposed to stabilize maturing 
invadopodia by downregulating actin polymerization through liberation of the Nck1/N-
WASp complex, coupled with rebinding of inactive cofilin.  While these data implicate 
cycles of cortactin phosphorylation/dephosphorylation as critical in invadopodia 
maturation, how the phosphorylation of cortactin and other invadopodia maturation-
associated proteins is spatially and temporally orchestrated through upstream kinase-
based signaling to drive invadopodia maturation is unknown.  In this study we have 
determined that the presence of endogenous, regulated WT cSrc is required for pre-
invadopodia complexes induced by oncogenic Src activity to mature into degradative 
invadopodia.  In addition, we distinguish cortactin phosphorylation downstream of WT 
cSrc as an important mediator of the maturation process.  
Results  
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 Elevated Src activity regulates invadopodia formation in HNSCC cell lines.  
The introduction of constitutively-active viral Src (vSrc) or cellular Src (Src527F) has 
been examined in invadopodia formation in cancer cell lines (Artym et al., 2006; 
Buschman et al., 2009; Oikawa et al., 2008; Stylli et al., 2009), but the role of 
endogenous cSrc in invadopodia function is unclear.  We analyzed a panel of HNSCC 
lines for endogenous cSrc activity and total cSrc protein levels (Fig. 1A), as well as the 
ability of these lines to form spontaneous invadopodia on FITC-gelatin matrix (Fig. 1B, 
supplementary material Fig. S1A).  Two (UMSCC1 and OSC19) out of the six tested 
lines generate invadopodia that can be identified by the colocalization of actin and 
cortactin-rich yellow aggregates in merged images (Fig. 1B, white arrows) coinciding 
with areas of focal gelatin degradation (black arrows).  UMSCC1 and OSC19 cells have 
substantially elevated cSrc expression and cSrc activity compared to the UMSCC2, 
1483, and MSK921 invadopodia-null lines (Fig. 1A).  The FADU cells have elevated 
cSrc activity but fail to generate spontaneous invadopodia, suggesting that elevated Src 
expression alone is not sufficient to drive invadopodia biogenesis in this line.  
However, invadopodia are formed and matrix degradation occurs in all the HNSCC cell 
lines that do not form spontaneous invadopodia (UMSCC2, 1483, FADU, and MSK921) 
following exogenous Src527F expression (Fig. 1B, supplementary material Fig 1B).  
These data suggest a cell line-specific threshold of Src activity (highest in FADU cells) 
that must be reached to support invadopodia formation and matrix degradation.  These 
results are consistent with elevated Src activity driving invadopodia biogenesis, and are 
in agreement with previous work with small molecule Src inhibitors in HNSCC cell lines 
decreasing invadopodia formation and matrix degradation in a dose dependent manner 
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(Ammer et al., 2009).  Similar results were also found in breast cancer cells (Pichot et 
al., 2009). 
 Endogenous Src expression is required for efficient invadopodia-based 
matrix degradation in HNSCC cells expressing constitutively-active Src.  To test 
the effect of depleting endogenous cSrc on HNSCC invadopodia formation and function, 
cSrc expression was knocked down in UMSCC1 cells by RNA interference (SrcSi) (Fig. 
2A) and assayed for invadopodia formation and gelatin degradation (Fig. 2B).  
Endogenous cSrc was depleted by 58% two days, and 70% three days post-
transfection.  SrcSi cells had no statistically significant difference in the number of cells 
with invadopodia or the number of invadopodia per cell (Fig.2C, top and middle panels).  
However Src knockdown cells exhibited a 2.3-fold decrease in gelatin degradation 
compared to control cells (Ctl) (Fig. 2C, lower panel).  Rescue of WT Src expression in 
SrcSi cells (SrcSi+WT) restored matrix degradation to above control cell levels (1.7-
Fold) (Fig. 2C).  Increases above control are presumably attributed to the additive effect 
of remaining endogenous Src from incomplete knockdown coupled with the modest 
overexpression of the SrcWT construct (Fig. 2B).  
  We also examined the effect of silencing endogenous cSrc in the presence of 
constitutively active Src (Fig. 2B, C).  Consistent with previous reports (Artym et al., 
2006; Oser et al., 2009), expression of Src527F in control cells (Ctl+527) or SrcSi cells 
(SrcSi+527F) resulted in increases in cells with invadopodia (~30%) and the number 
invadopodia per cell (~36%).  Surprisingly, cSrc knockdown markedly blunted the 
increased degradation due to Src527F expression, a 2.5-fold (SrcSi+Src527F cells) 
increase compared to a 4.8-fold (Ctl+527F) increase over control cells (Fig. 2C).  These 
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results demonstrate that constitutively active Src cannot completely rescue endogenous 
cSrc function in regulating matrix degradation. Collectively these data indicate that while 
increased Src activity enhances invadopodia formation as previously reported, the 
presence of endogenous cSrc is required for optimal matrix degradation.  Similar results 
were found in OSC19 cells (supplementary material Fig. S2).   
 Constitutively active Src is sufficient to promote invadopodia formation but 
not ECM degradation in Src-null cells.  Complete cSrc knockdown in our HNSCC 
lines is technically problematic, and additional Src family kinases (Yes and Fyn), with 
unknown functions in invadopodia biology, are present and maintained in OSC19 and 
UMSCC1 cell lines treated with Src RNAi (Fig. 3A).  We therefore utilized Src/Yes/Fyn-
deficient (SYF) fibroblasts to further evaluate the role of WT Src in invadopodia function.  
A GFP-tagged temperature-sensitive mutant of vSrc (tsLa29-GFP) was generated and 
expressed in SYF cells to dynamically regulate Src activity and invadopodia formation.  
Src kinase activation occurs within 15 min when cells are switched from the non-
permissive temperature (41ºC) to the permissive temperature (35ºC) (Fig. 3B). vSrc 
inactivation occurs within 30 min when cells are shifted back to 41ºC. Activation of vSrc 
leads to the phosphorylation of cortactin on tyrosine 421, indicating that tsLa29-GFP 
regulates phosphorylation of a known downstream Src target critical for invadopodia 
assembly.  In agreement with previous reports (Walker et al., 2007), invadopodia 
formation is induced when cells expressing tsLa29-GFP are switched to the permissive 
temperature (Fig. 3C).  These invadopodia are enriched with active vSrc and 
phosphorylated cortactin (Fig. 3C, supplementary material Fig. S3A).  As reported in 
other invadopodia forming cell systems (Artym et al., 2006; Ayala et al., 2008; Clark et 
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al., 2007; Webb et al., 2006), inhibition of cortactin expression by siRNA diminishes the 
ability of tsLA29-GFP to induce invadopodia formation at the permissive temperature 
(supplementary  material Fig. S3B, C).  
 To evaluate the functionality of invadopodia in this system, we plated SYF cells 
on FITC-gelatin coated coverslips to assay ECM degradation.  Invadopodia induced by 
tsLa29-GFP in the Src-null fibroblasts fail to degrade the ECM at periods up to and >48 
h, indicating they remain in a pre-invadopodia state (Fig. 3D).  Experiments with an 
untagged vSrc produced a similar result, ruling out improper activation or localization 
related to the addition of GFP.  We also attempted to rescue invadopodia maturation in 
the SYF cells with tsla29-vSrc.  Manipulating tsla29-vSrc activity over the 24 h 
incubation period by switching cells from permissive to the non-permissive temperatures 
did not result in invadopodia maturation (data not shown).  These results demonstrate 
that constitutively active vSrc activity is responsible for the induction of the initial 
phosphorylation cascade that drives recruitment of invadopodia components to form 
pre-invadopodia complexes, but these vSrc induced complexes are insufficient to direct 
matrix degradation in SYF cells.    
 Wild-type Src kinase is necessary for invadopodia maturation.  Based on 
our findings we hypothesized that either: 1) Another ubiquitously expressed Src family 
kinase (Yes and/or Fyn) absent from SYF cells is required for invadopodia maturation in 
addition to active Src, or 2) WT Src or “regulated” Src must also be present with active 
Src for degradation of ECM to occur.  To test these hypotheses, we utilized a SYF cell 
line with two copies of WT Src genetically reintroduced to restore normal WT Src 
expression (SYF+/+; Fig. 3A, 4A).  The percentages of cells forming invadopodia and the 
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percentage of invadopodia-forming cells degrading matrix were assessed following 
introduction of vSrc or Src527F.  Transfection with activated Src constructs in the form 
of tsLa29 or Src527F induces mature matrix-degrading invadopodia in SYF+/+ cells, in 
contrast to pre-invadopodia formation in SYF cells (Fig. 4B).  Approximately 55% of 
SYF+/+ cells forming invadopodia contain invadopodia that actively degrade matrix, 
compared to 2% of SYF cells (Fig. 4C).  There is no difference in the percentage of cells 
forming invadopodia (pre and mature) in SYF or SYF+/+ cells expressing Src527F (Fig. 
4C), similar to results in UMSCC1 cells (Fig. 2C).  Also, the level of general 
phosphotyrosine-containing proteins localized to invadopodia is unchanged in SYF527F 
or SYF527F+/+ (Fig. 4B).  Taken together, these results support that catalytically active 
Src alone promotes the assembly of pre-invadopodia complexes and targets tyrosine 
phosphorylation of proteins within these structures, but WT Src is necessary for pre-
invadopodia maturation required to induce ECM degradation. 
 To further confirm these findings, WT Src expression was transiently restored in 
SYF cells and assayed for ECM degradation.  Monitoring co-expression of Src527F and 
SrcWT was achieved by creating carboxyl-terminal linker fusions with mCherry 
(Src527F-mCh) and cerulean (Src-Cer) fluorescent proteins (see supplementary 
material Fig. S4).  Transfection efficiency of the co-transfected Src constructs is 
consistently greater than 90% and imaging reveals that nearly all SYF cells express 
both Src alleles (supplementary material Fig. S5A).  In SYF cells expressing SrcWT 
alone, Src has a perinuclear localization consistent with previous reports (Sandilands et 
al., 2004) (supplementary material Fig. 4B, C).  Co-expression of Src527F with SrcWT 
results in recruitment of SrcWT to invadopodia where it colocolizes with Src 527F (Fig. 
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5A).  In addition, cells co-expressing these constructs regain the ability to degrade ECM 
(Fig. 5B, C).  To further verify the functional requirement for WT Src in invadopodia 
maturation, we conducted Src WT-specific staining of SYF cells containing Src527F. 
Src-WT colocalizes with cortactin to areas of ECM degradation, further demonstrating 
that Src-WT localizes to mature invadopodia (Fig. 5D, upper panels).  In addition, direct 
visualization of WT Src-Cer and Src527F-mCh in SYF cells demonstrates a 
concentration of Src-Cer at areas of ECM degradation, with Src527F-mCh localized to 
the same vicinity (Fig. 5D, lower panels). 
 Since the localization of endogenous Src to invadopodia is required for 
invadopodia maturation, we determined if catalytically-inactive Src could substitute for 
WT Src and rescue ECM degradation in SYF cells.  This result would suggest that two 
separate and distinct pools of Src (constitutively-active and kinase-inactive) were 
necessary and sufficient for maturation.  To test this hypothesis, constitutively-active 
Src527F-mCh was coexpressed with a cerulean-tagged kinase-inactive Src (Src295M-
Cer) in SYF cells. Like SrcWT, Src295M is largely perinuclear when expressed alone in 
SYF cells (supplementary Fig. 4B, C), but is recruited to invadopodia when co-
expressed with Src527F (Fig. 5A).  However, Src295M fails to rescue invadopodia 
maturation (Fig. 5B, C), indicating that catalytically inactive (Src295M) Src does not 
substitute for WT Src function. Since constitutively active and kinase dead Src alleles 
cannot support invadopodia maturation, this suggests that WT Src kinase activity is 
dynamically regulated to promote invadopodia maturation.  Along these lines, cell 
staining for active Src (pY418) localizes to pre-invadopodia in SYF cells and mature 
invadopodia in SYF+/+ cells (Fig. 5E), ruling out the possibility that catalytically-active 
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Src drives invadopodia assembly, is inactivated, and remains inactive during 
maturation.  Taken together, these results demonstrate that regulated WT Src kinase 
activation/inactivation within pre-invadopodia complexes is necessary to govern the 
downstream signaling events required for invadopodia maturation and ECM 
degradation.   
 Regulated Src activity directs cortactin phosphorylation dynamics to 
control invadopodia maturation. In proposed models of invadopodia maturation, 
dynamic cortactin tyrosine phosphorylation is required for pre-invadopodia maturation 
(Oser et al., 2009).  In order to identify a potential mechanism of invadopodia maturation 
affected by Src activation/inactivation, we assessed the role of Src kinase activity on 
cortactin phosphorylation. In the SYF/SYF+/+ system, cortactin phosphorylated on 
tyrosine 421 localizes to pre- and mature invadopodia (Fig. 6A) suggesting that cortactin 
phosphorylation is important in pre-invadopodia assembly and invadopodia maturation.  
This is consistent with a well-described role for cortactin in invadopodia maturation in 
other systems (Artym et al., 2006; Clark et al., 2007; Oser et al., 2009).  Stable cell lines 
were generated expressing endogenous levels of wild-type cortactin (SYF+/+ CortWT) or 
a cortactin mutant in which the three Src-targeted tyrosine residues (421, 470, 486) are 
mutated to phenylalanine (SYF+/+CortTYM) (Fig. 6B). Endogenous murine cortactin was 
silenced with siRNA (CortSi, knockdown >90%), resulting in the exclusive expression of 
WT or TYM human cortactin (Fig. 6C). SYF+/+ CortWT and SYF+/+ CortTYM cell lines 
treated with cortactin siRNA were transfected with Src527F to promote invadopodia 
formation. WT human cortactin expression rescued the inhibitory effects of cortactin 
knockdown on invadopodia formation, resulting in the formation of mature invadopodia 
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(~60% of total cells with invadopodia, Fig. 6D, E).  However, only ~10% of SYF+/+ 
CortTYM cells produce degrading invadopodia.  Consistent with previous reports (Oser 
et al., 2009), there were no differences observed in the percentage of cells forming 
actin/cortactin aggregates in SYF+/+ CortWT and SYF+/+ CortTYM cells, demonstrating 
that cortactin is targeted to pre-invadopodia independent of tyrosine phosphorylation.  
However, expression of CortTYM in SYF+/+ cells completely blocks the upstream 
function of WT Src, rendering the SYF+/+ Src527F cells with a degradation profile similar 
to that seen in cells lacking WT Src (SYF Src527F, Fig. 4B, C).  These results indicate 
that there is differential phosphotyrosine signaling in SYF cells with WT Src that 
supports invadopodia maturation downstream of constitutively-active Src.  
 Cells forming pre- and mature invadopodia have distinct phosphotyrosine 
signatures. To examine if distinct tyrosine phosphorylation signatures occur in cells 
that form pre- and mature invadopodia, we conducted a non-biased, comprehensive 
and quantitative SH2-domain screen (Machida et al., 2007) to identify differences in 
potential phosphotyrosine binding proteins under conditions of pre- and mature 
invadopodia formation  (Fig 7, supplementary  material Fig. S6).  Non-transfected SYF 
and SYF+/+ cells had minimal differences in SH2 domain binding profiles.  Expression of 
Src527F in either cell type enhanced overall SH2 domain signal binding intensity, 
indicating a broad increase in phosphotyrosine signaling and creation of new SH2 
domain docking sites. This result is anticipated with expression of constitutively-active 
Src.  However, cells that form pre-invadopodia (SYF Src527F) have distinct differences 
in their SH2 binding intensity from cells that form functional mature invadopodia (SYF+/+ 
Src527F) (bottom row, difference).  The variations in binding intensity that arise in SYF 
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and SYF+/+ cells expressing Src527F indicate a fundamental mechanistic difference in 
the concentration of phosphotyrosine binding sites for several SH2 domain containing 
proteins likely playing key roles in invadopodia maturation.  Interestingly, tyrosine 
phosphorylated cortactin is known to interact with several high intensity “hits”, including 
Arg, Abl (Boyle et al., 2007), Fer (El Sayegh et al., 2005), Crk (Bougneres et al., 2004), 
and Nck (Tehrani et al., 2007), consistent with its role in invadopodia maturation.  
Experiments to elucidate additional proteins involved in these signaling complexes are 
currently underway.  
Discussion 
 In this study we investigated the role of endogenous or WT cSrc, and the 
interplay between constitutively-active Src and cellular Src in invadopodia formation.  
Previous studies on Src in invadopodia formation have exclusively manipulated Src 
activity in cells containing WT cSrc.  Tumor cells that form spontaneous invadopodia 
presumably have upstream oncogenic signals such as over-activation/expression of 
epidermal growth factor receptor (EGFR) that drives cSrc activation (Xue et al., 2006).  
Accordingly, increased Src kinase activity (through overexpression of constitutively 
active Src, or overexpression of WT Src) in tumor cells that form spontaneous 
invadopodia is associated with increased invadopodia formation and matrix degradation 
(Artym et al., 2006; Oser et al., 2009).  Unlike previous reports (Oser et al., 2009), we 
did not observe that tumor cells overexpressing constitutively active Src have less 
degradation per invadopodia than spontaneous invadopodia formed in control cells (Fig. 
2, supplementary  material Fig 2). However, these differences may be attributed to a 
much larger capacity for invadopodia formation in UMSCC1/OSC19 cells compared to 
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MtLn3 cells (~25 vs. ~two invadopodia formed in control cells, respectively).  In HNSCC 
cells and Src-null fibroblasts, we propose that constitutively-active Src acts as an 
oncogenic “trigger” that promotes pre-invadopodia formation, whereas WT Src acts 
downstream to direct invadopodia stability and maturation.  Though models of 
spontaneous invadopodia formation are invaluable to the field, our novel finding that Src 
cycling is critical for invadopodia maturation could only be completely uncovered 
through the use of the SYF/SYF+/+ system.  
 In this study, we show that WT Src is indispensible for invadopodia maturation 
driven by elevated Src activity. We hypothesize that distinct, temporally and spatially 
regulated Src function is necessary to regulate the phosphorylation of cortactin.  It is 
likely that Src regulates other scaffolding proteins important in invadopodia stability and 
maturation, such as dynamin (Caldieri et al., 2008), Tks5 (Seals et al., 2005), 
IQGAP1(Sakurai-Yageta et al., 2008), and paxillin (Bowden et al., 1999).  It is possible 
that Src is activated prior to its localization with downstream actin-associated substrates 
in pre-invadopodia. Once pre-invadopodia assembly is complete, Src is inactivated 
(presumably by COOH-terminal Src kinase (Csk) acting on pY527 (Okada et al., 1991)) 
and released to regulate additional proteins involved in actin dynamics and MMP 
delivery to invadopodia.  In this way, Src may act as a regulator of several sequentially 
coordinated protein interaction events that directs the diverse array of cellular processes 
at invadopodia, including actin assembly, membrane trafficking, and ECM degradation.  
 It is known that invadopodia produced by cancer cells and transformed 
fibroblasts use similar signaling pathways and contain many of the same proteins as 
podosomes produced by osteoclasts, dendritic cells and macrophages (Linder, 2009).  
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Src-null osteoclasts have been used to study the role of Src in podosome assembly and 
dynamics (Destaing et al., 2008). WT Src and Src527F were both able to restore normal 
podosome organization, whereas Src 295M did not.  These data in podosomes support 
our findings in invadopodia, but since this report did not address the functionality of 
these cells to degrade ECM, it is not known if WT Src is needed for maturation in this 
system.  These results are particularly interesting since Src has been suggested to act 
as a “molecular switch” to regulate dynamin-Cbl signaling complexes (Bruzzaniti et al., 
2005) and as having an important adapter (kinase-independent) function (Bruzzaniti et 
al., 2009) in osteoclast podosomes.  Manipulation of Src activity in WT osteoclasts also 
suggest a dual function for Src in regulating actin dynamics through cortactin 
phosphorylation in podosome assembly and subsequent maturation into higher 
organized structures known as sealing zones (Luxenburg et al., 2006).   
 We identify cortactin as a key regulator of invadopodia maturation downstream of 
WT Src activity.  We show that constituitively-active Src is sufficient to target cortactin to 
pre-invadopodia (Fig. 3C, 4B), but cortactin is targeted independent of its tyrosine 
phosphorylation (Fig. 6D, E).  This is in agreement with previous reports demonstrating 
that dephophorylated cortactin acts as a scaffold to recruit Arp2/3, N-WASp, and cofilin 
(Oser et al., 2009). Interestingly, cortactin phosphorylated at tyrosine 421 is enriched in 
pre-invadopodia (SYF Src527F) and in matrix degrading mature invadopodia (SYF+/+ 
Src527F) (Fig. 6A, supplementary  material Fig. S3A).  In addition, tyrosine 
phosphorylation of cortactin is required for invadopodia maturation and ECM 
degradation (Fig. 6 D, E; (Ayala et al., 2008; Desmarais et al., 2009; Webb et al., 
2007)).  These data are consistent with phosphorylation of cortactin occurring before 
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ECM degradation.  However, in our SYF/SYF+/+ model this initial cortactin 
phosphorylation is not sufficient to drive maturation in the absence of WT Src, 
suggesting that cortactin must be dephosphorylated before maturation can occur.  Our 
proposed mechanism of dynamic Src activity on cortactin phosphorylation in 
invadopodia maturation is consistent with the model of cyclical cortactin phosphorylation 
regulating actin polymerization and invadopodia stabilization recently proposed by the 
Condeelis laboratory (Oser et al., 2009).  
 Here we show that Src activation and inactivation regulates cortactin 
phosphorylation during invadopodia maturation. Future studies will be required to 
determine if Src kinase is directly responsible for initially phosphorylating cortactin to 
promote invadopodia assembly, or in subsequent step(s) to regulate maturation (Huang 
et al., 1998). Fer (El Sayegh et al., 2005) and Abl family kinases (Boyle et al., 2007) are 
also present in SYF cells and may act downstream of Src to regulate one or more of 
these steps. It also follows that tyrosine phosphatases are critically important in the 
regulation of invadopodia maturation, since cortactin and other possible targets 
downstream of Src kinase activity in our system require dynamic cycles of 
phosphorylation and dephosphorylation to drive ECM degradation.  Protein tyrosine 
phosphatase 1B is a good candidate for this process since it is known to regulate Src in 
invadopodia dynamics (Cortesio et al., 2008) and has subsequently been shown to 
regulate cortactin dephosphorylation (Stuible et al., 2008).  Nonetheless, we show that 
WT Src kinase is the critical upstream regulator of other downstream 
kinases/phosphatases important to these processes.  
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 Invadopodia maturation is associated with the delivery of MMPs to invadopodia 
sites (Artym et al., 2006; Clark et al., 2007).  MT1-MMP is cited as the key MMP 
regulating ECM degradation at invadopodia (Poincloux et al., 2009), and Src kinase 
activity is known to regulate phosphorylation of MT1-MMP and proteins associated with 
its trafficking to the cell membrane (Nyalendo et al., 2008; Nyalendo et al., 2007).  
Future studies should address whether WT Src is necessary to control trafficking to, or 
activation of, MT1-MMP at invadopodia.  These studies are further warranted since it 
has been proposed that a major role of cortactin in invadopodia function involves the 
targeting and delivery of MMPs to invadopodia enhancing ECM degradation (Clark and 
Weaver, 2008; Clark et al., 2007). 
 This report identifies a dominant oncogene that requires the proto-oncogenic 
complement to reach its full spectrum of transforming functionality.  Unlike tumor 
suppressor proteins that often require loss of non-mutated alleles, little is known about 
the potential effect of the presence or absence of proto-oncogenes on their oncogenic 
counterparts during tumorigenesis.  A function in Ras-induced tumorigenesis has been 
described for Ras proto-oncogenes (Singh et al., 2005), where WT Ras has been 
reported to regulate the functioning of oncogenic Ras with regards to cell proliferation.  
Our results are consistent with the majority of solid human tumors that contain elevated 
cSrc expression or specific activity due to hyperactivation of upstream regulatory 
pathways rather than activating point mutations (Yeatman, 2004).  To our knowledge 
this is the first description of such a finding. Similar mechanisms may be required for 
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Materials and Methods 
Cell culture 
HNSCC cell lines UMSCC1, FADU and OSC19 were obtained from Jeffery Myers (MD 
Anderson Cancer Center).  These lines along with UMSCC2 (Tom Carey, University of 
Michigan), 1483 (David Raben, University of Colorado), and MSK921 (Peter Sacks, 
New York University) were cultured as previously described (Rothschild et al., 2006).  
SYF (Src-/-Yes-/-Fyn-/-) and SYF+/+ (Src+/+Yes-/-Fyn-/-) cells were obtained from the 
American Type Culture Collection.  Control non-silencing and human Src targeted 
siRNA (5’-AAACTCCCCTTGCTCATGTACTT-3’) were from Dharmacon.  OSC19 cells 
stably expressing vector control or Src targeted shRNA were created by infection with 
control or human Src specific lentivirus (Santa Cruz) and cultured according to 
manufacturer’s instructions. SYF or SYF+/+ cells stably expressing GFP-tagged human 
cortactin (wild-type [WT] or Y421F, Y466F, Y482F [triple point mutant (TPM)]) were 
created using the Flp In™ system (Invitrogen). These lines were transfected with siRNA 
targeting murine cortactin (5’-GCTTCGAGAGAATGTCTTC-3’) (siCTTN, Dharmacon). 
For transient transfections, 3 x 106 cells were incubated with 2µg plasmid construct or 
siRNA.  Fibroblast lines were transfected with the Nucleofector I device (Amaxa 
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Biosystems), and HNSCC lines were transfected with TurboFectTM transfection reagent 
(Fermentas).  
Immunofluorescence labeling and confocal microscopy 
Cells were plated on FITC-gelatin (Sigma) coated coverslips as described (Artym et al., 
2006) for 12-24 hours.  Cells were fixed with fresh 4% formaldehyde and permeabilized 
with 0.4% Triton-X/PBS. Primary antibodies were diluted in 5% BSA/PBS. Antibodies 
used were: cortactin 4F11, cortactin EP1922Y (Novus Biologicals), human cort-
pY421(Ammer et al., 2009), Src-pY418 (Biosource), Src GD11 (Upstate), GFP/Cerulean 
3E6 (Invitrogen), pTyr-100 (BD Biosciences), Alexa Fluor 405 goat anti-rabbit and Alexa 
Fluor 647 goat anti-mouse (Molecular Probes). F-actin was labeled with rhodamine-
conjugated phalloidin (Molecular Probes).  Cells were mounted in Fluoromount-G 
(Southern Biotech) and imaged with a Zeiss LSM510 confocal microscope using AIM 
software (Carl Zeiss MicroImaging).  A Nikon Swept-Field using Nikon Elements 
software (Nikon Instruments Inc.) was used for imaging of Src-Cer.  
Invadopodia and matrix degradation assays 
Cells with invadopodia were identified by the presence of at least one actin/cortactin 
aggregate within the cell (N≥300).  The number of invadopodia per cell was calculated 
by counting the number of actin/cortactin aggregates within invadopodia forming cells 
(N≥150).  Degradation per cell area was analyzed using ImageJ as described previously 
(Clark et al., 2007).  Cells with invadopodia degrading matrix were identified by at least 
one actin/cortactin aggregate colocalizing with a “dark hole” corresponding to degraded 
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FITC-matrix (N≥50).  Data were pooled from multiple independent experiments; N 
represents the number of cells analyzed within each experimental group.  
Antibodies and Western blotting 
Western blotting of cell lysates was conducted as described (Rothschild et al., 2006).  
The following antibodies were used: 4F11, Src clone GD11 (Upstate); β-actin 
(Calbiochem); Living Colors GFP clone JL-8 (BD); Cort-pY421, Src-pY418 (Biosource); 
avian Src clone EC10 (Millipore), and Yes, Fyn (Cell Signaling).  
Plasmids  
The Src-GFP linker constructs (WT, 527F, and 295M) were a gift from Margaret Frame 
(The Beatson Institute for Cancer Research, Glasgow, United Kingdom).  Substitution of 
green fluorescent protein (GFP) with cerulean or mCherry fluorescent protein was 
accomplished through digestion of Src-pEGFP-N1, pmCherry-C1, and mCerulean-C1 
fluorescent vectors with AgeI and BrsGI.  The resulting mCherry and mCerulean 
fragments (~700 bps) were ligated into the GFP-digested Src-containing pEGFP-N1 
vector (BD).  Temperature-sensitive vSrc (tsLA29) was subcloned from pCMV-tsLA29 
vector into EGFP-N1 using unique EcoRI and BamHI restriction sites.  
Human cortactin constructs.  
A single-stranded primed cDNA library (Invitrogen) was used for cloning the human 
cortactin (CTTN) cDNA.  The cDNA was PCR amplified to produce a 965bp KpnI-HincII 
fragment and a 688bp HincII-EcoRI fragment.  Fragments were ligated into KpnI/EcoRI 
digested pcDNA3FLAG2AB to generate the 1653bp full-length CTTN cDNA.    The 
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CTTN triple tyrosine mutant (TYM) was generated using the QickChange kit with 
primers designed to alter codons 421, 470 and 486 from tyrosine to phenylalanine and 
confirmed by DNA sequencing. WT and TYM CTTN cDNAs were subsequently 
amplified as EcoRI/KpnI fragments and subcloned into pEGFP-N1 (WT) or pAcGFP-N1 
(TYM).  GFP-CTTN WT and TYM fragments were PCR amplified and subcloned into 
pEF5/FRT/V5-D-TOPO (Invitrogen) and stable SYF and SYF+/+ cell lines generated 
using the Flp-In system according to manufacturer’s instructions. 
Immunoprecipitations   
Cells were lysed in NP40 Buffer (20 mM Hepes-KOH, pH 7.8, 50 mM KCl, 1 mM EDTA, 
and 1% NP40). Anti-cortactin (4F11, 5ug) was incubated with 0.5 mg of clarified lysates 
for 2 h at 4°C, then incubated with 40 µl of Protein A/G Beads (Thermo Scientific) for 1 h 
at 4°C.  Immune complexes were collected by centrifugation, washed twice with NP40 
Buffer, separated by SDS-PAGE, and Western blotted with antibodies as described.  
SH2/PTB binding assay  
SH2/PTB domain binding assay was performed as described (Dierck et al., 2009; 
Machida et al., 2007). Briefly, SYF cell lysates were spotted in duplicate on a 
nitrocellulose membrane in register with the wells of a 96-well chamber plate. Each well 
was separately incubated with purified GST-SH2 or -PTB domains (~100 nM) for 2 h.  
Probe binding was detected by enhanced chemiluminescence (ECL) (PerkinElmer) and 
digitally captured (Kodak Image Station). Two independent experiments were performed 
in duplicate, providing four quantifiable data points for each probe.  The array images 
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were background-subtracted and the integrated density of each spot was measured 
using ImageJ (v1.40).  
Statistical analysis  
Differences in mean values between groups were evaluated using a student’s T-test (2 
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Fig 1. Src activity regulates invadopodia formation in HNSCC lines. (A) Protein levels of 
active cSrc (Src-pY418), total cSrc (Src), and β-actin (loading control) in HNSCC lines. 
For quantification of active Src and total Src, expression levels were normalized to 
MSK921 cells, a line with low Src activity that does not form invadopodia. Multiple 
bands in the Src-pY418 panel presumably represent additional Src Family kinases; see 
Fig. 3A. (B) HNSCC cell lines with or without Src-527F were incubated on FITC-gelatin 
(pseudocolored white) coverslips for 12 hrs and labeled with TRITC-phalloidin (red) and 
anti-cortactin (green).  Invadopodia are identified by the yellow aggregates in the 
merged images of actin and cortactin (white arrows) that localize with the dark holes in 
the FITC-gelatin (black arrows). Bars, 10µm.  
Fig 2. Inhibition of endogenous Src expression decreases matrix degradation 
independent of changes in invadopodia number or increased Src activity. (A) UMSCC1 
cells transfected with Src SiRNA (SrcSi) or a non-targeting SiRNA (Ctl) were evaluated 
for Src knockdown two and three days post-transfection by anti-Src Western blotting. β-
actin blotting was used as a loading control. (B) Cell lysates from UMSCC1 cells 
transfected with non-targeting SiRNA (Ctl) or Src SiRNA (Si) alone, or in combination 
with cerulean-tagged SrcWT (WT) or Src-527F (527) were evaluated by 
immunoblotting. Lysates were probed with anti-Src and β-actin antibodies. Filled 
arrowheads point to exogenously expressed Src (WT or 527F), open arrowheads 
denote endogenous Src (C) Representative confocal images of UMSCC1 cells 
transfected with non-targeting SiRNA (Ctl) or Src SiRNA (Si) alone, or in combination 
with cerulean-tagged SrcWT (WT) or Src-527F (527). Cells were plated on FITC-gelatin 
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coated (pseudocolored white) cover slips for 10 hrs and immunolabeled with TRITC-
phalloidin (red) and cortactin (green). Bars, 10µm. (D) Quantification of the percent of 
cells displaying invadopodia (top), the number of invadopodia per cell (middle), and the 
amount of matrix degradation per cell (bottom) were examined for each line evaluated in 
(B). Data are represented as mean ± s.e.m., # statistically different from ctl, * groups 
under the bar are statically different (p≤0.01).   
Fig 3. Invadopodia produced by constitutively active Src in Src/Yes/Fyn-null fibroblasts 
fail to degrade ECM. (A) Src family kinase expression in HNSCC and fibroblast cell 
lines. Clarified cell lysates from SYF, SYF+/+, UMSCC1 (treated with control and 
SrcSiRNA), and OSC19 (expressing control vector and SrcShRNA) cells were resolved 
by SDS-PAGE and immunoblotted with anti-Src, anti-Yes, anti-Fyn, and anti-β-actin 
antibodies. (B) Time course of tsLa29 vSrc activation and resulting cortactin 
phosphorylation.  Cells transfected with tsLa29 were incubated at 35ºC (permissive 
temperature) for the indicated times and were lysed or returned to 41ºC (non-permissive 
temperature) for 15 or 30 minutes and analyzed for Src-pY418, GFP, cortactin, and 
cortactin-pY421. (C) Invadopodia formation in vSrc expression cells. SYF cells were 
transfected with tsLa29-GFP (pseudocolored light blue) and incubated at 41°C or 35°C 
and labeled with TRITC-phalloidin (red) and cortactin (green). Cells were visualized by 
confocal microscopy and Z-stack sectioning. Invadopodia are visible in Z-stack images 
as actin/cortactin rich puncta that are several microns in length (white arrows). Bars, 
10µm; 5µm (z-stacks). (D) Defective ECM degradation in vSrc expressing SYF cells. 
SYF cells transfected with tsLa29-vSrc and non-transfected UMSCC1 cells (positive 
control) were plated directly onto FITC-gelatin coverslips. After 24 hrs cells were labeled 
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with TRITC-phalloidin and anti-cortactin antibodies. Bars, 10µm; white arrows point to 
invadopodia and black arrows point to areas of degraded matrix (C and D).  
 
Fig 4. WT Src rescues invadopodia maturation in cells expressing constitutively active 
Src. (A) SYF, SYF+/+, and UMSCC1 cells were non-transfected (NT), transfected with 
Src-527F or tsvSrc were lysed, resolved by SDS-PAGE and immunoblotted with anti-
Src-pY418, anti-Src clone EC10 (only recognizes avian Src), anti-cortactin-pY421,anti-
cortactin (4F11), and anti-β-actin antibodies.  (B) SYF, SYF+/+, and UMSCC1 cells that 
were non-transfected (NT), transfected with SRC-527F, or tsLa29-vSrc were plated onto 
FITC-conjugated gelatin coverslips and evaluated by confocal microscopy. Cells were 
labeled with TRITC-phalloidin (red), cortactin (green), and anti-phosphotyrosine (light 
blue) antibodies.  Invadopodia are identified by the yellow aggregates in the merged 
image of actin and cortactin in cells containing phosphotyrosine. In addition, degrading 
(mature) invadopodia localize with the dark holes (arrows) in the FITC-gelatin (white). 
(C) Quantification of the percentage of cells forming invadopodia structures 
(actin/cortactin aggregates, left), and the percentage of invadopodia forming cells that 
contain matrix degradation (mature invadopodia, right). Data are represented as mean ± 
s.d., * groups are statically different (p≤0.05).   
 
Fig 5. Expression of regulated Src is necessary for ECM degradation at invadopodia. 
(A) Confocal imaging of SYF cells co-expressing Src-cerulean and Src527F-mCherry, 
or Src-295M-cerulean and Src527F-mCherry. Cells were immunolabeled with anti-
cortactin and AlexaFlour 647- phalloidin. Dashed boxes represent enlarged image 
 117 
regions shown below. Arrows denote invadopodia. (B) Representative fields of SYF and 
SYF+/+ cells expressing Src527F-mCherry, SYF cells co-expressing Src527F-mCherry 
and Src-cerulean, or SYF cells co-expressing Src527F-mCherry and Src-295M-
cerulean. Cells were plated on FITC-gelatin coated cover slips for 24 hours and 
immunolabeled with anti-cortactin. Areas of gelatin degradation and clearing appear 
black against the pseudocolored white background. (C) Assessment of the % cells with 
forming invadopodia (actin/cortactin aggregates, left), and % of invadopodia forming 
cells with degraded matrix (mature invadopodia, right) from the experimental conditions 
shown in (B). Data are represented as mean ± s.d., * groups that are statistically 
different from groups without asterisks (p≤0.05). (D) Confocal imaging (upper panel) or 
swept field imaging (lower panel) of SYF cells co-expressing cSrc527F and Src-
cerulean. Cells were plated on FITC-gelatin coated cover slips and immunolabeled with 
anti-cerulean (dark blue) and anti-cortactin (yellow) (colocalization appears white in 
merged image; upper panel) or directly imaged for Src527F-mCherry (red) and Src-
cerulean (dark blue) (lower panels). Arrow indicates co-localization of Src 527F-
mCherry and WT Src-cerulean at sites of gelatin degradation.  (E) Confocal imaging of 
Src activity in SYF and SYF+/+ cells expressing Src527F. Cells were incubated on FITC-
gelatin coated coverslips for 24 hrs, fixed and immunolabeled with TRITC-phalloidin 
(red), anti-pY418 Src (light blue), and anti-Src (green) antibodies. White arrows denote 
invadopodia; black arrows matrix degradation. Bars, 20 µm (A); 10 µm (A, D, E). 
Fig 6. WT Src regulates cortactin phosphorylation during invadopodia maturation. (A) 
SYF and SYF+/+ cells expressing Src527F were incubated on FITC-gelatin coated 
coverslips for 24 hrs, fixed and immunolabeled with TRITC-phalloidin (red), human anti-
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pY421 cortactin (light blue), and anti-cortactin (green) antibodies.  Note that cortactin is 
phosphorylated in pre-invadopodia and in mature invadopodia as defined by the 
absence or presence of matrix degradation.  (B) Validation of GFP-tagged cortactin 
expression in stable cell lines. Cellular extracts from SYF or SYF++ cells stably 
expressing GFP-CortWT, or GFP-CortTYM were resolved by SDS-PAGE and 
immunoblotted with an anti-cortactin (4F11) antibody. * endogenous cortactin, ** GFP-
tagged cortactin (the slight mobility disparity is due to the size difference in AcGFP and 
EGFP tags); ratios of exogenous (WT and TYM) to endogenous cortactin is depicted 
under the blot. (C) Clarified lysates from SYF+/+ GFP-CortWT and SYF+/+ GFP-CortTYM 
cells were transfected with Cort-SiRNA alone or in combination with Src527F. Cortactin 
was immunoprecipitated with the anti-cortactin (4F11) antibody, immune complexes 
resolved by SDS-PAGE and immunoblotted with human anti-pY421 cortactin and anti-
cortactin (4F11) antibodies. Total cell lysates were immunoblotted with anti-β-actin for a 
loading control. (D) SYF+/+ cells stably expressing human GFP-CortWT or GFP-Cort 
TYM were transfected with murine cortactin-targeted siRNA to eliminate endogenous 
cortactin expression. Two days later cells were transfected with Src527F and plated on 
FITC-gelatin coated coverslips for 24 hrs to promote gelatin degradation. Cells were 
assessed for the percent of cells forming invadopodia (actin/cortactin aggregates) and 
the percent of invadopodia forming cells with matrix degradation. Data are represented 
as mean ± s.d., * groups under the bar are statically different (p≤0.05). Bars, 10 µm (A); 
20 µm (B).  
Fig 7. Enhanced binding of SH2 domains binding in SYF+/+ cells expressing Src527F. 
In-vitro SH2/PTB domain binding profiles for SYF, SYF+/+, and SYF and SYF+/+ 
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expressing Src527F. Binding of SH2/PTB domains to cell lysates are shown as a heat 
map where intensity of red indicates strength of binding. Domain names are on the top 
row, with a rank order of binding to SYF+/+ Src527F to denote potential importance in 
invadopodia maturation. Sample labels are on the left side. Difference = Signal[SYF+/+ 
Src527F] - Signal[SYF Src527F].   
Supplemental Figure legends 
 
Fig. S1. Confocal imaging of additional HNSCC cell lines assayed for Src activity and 
invadopodia forming capability in Fig 1A. (A) The FADU and MSK921 HNSCC cell lines 
were incubated on FITC-coated gelatin (white) coverslips for 12 hrs, then fixed and 
labeled with TRITC-phalloidin (red), and cortactin (green) (top panels).   Both lines fail to 
make endogenous invadopodia or degrade matrix.  (B) FADU and MSK921 cells 
transfected with Src527F-mCh (red) were incubated on FITC-coated gelatin (white) 
coverslips for 12 hrs, then fixed and labeled with cortactin (green) (top panels). Src-
induced invadopodia are present and identified by the cortactin aggregates (white 
arrows) that localize with Src527F and the dark holes in the FITC-gelatin (black arrows). 
Bars, 10µm.  
 
Fig. S2. Src regulates invadopodia maturation in OSC19 cells. (A) Src protein levels in 
OSC19 cells treated with with Src ShRNA (SrcSh) or a ShRNA vector control (Ctl). 
Expression SrcWT (WT) or Src-527F (527) in Ctl and SrcSh cells evaluated by 
immunoblotting (B), and confocal microscopy (C). Cells were plated on FITC-gelatin 
coated (pseudocolored white) cover slips for 10 hrs and immunolabeled with TRITC-
phalloidin (red) Bars, 10µm. (D) The effect of Src expression on percent of cells 
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displaying invadopodia, the number of invadopodia per cell, and the amount of matrix 
degradation per cell were examined. Data are represented as mean ± SEM, groups are 
statically different (*p≤0.01, ** p≤0.05).   
 
Fig. S3. (A) Invadopodia are formed in cells expressing tsLa29-GFP at the permissive 
temperature. SYF cells transfected with empty GFP vector (EV) or with tsLa29 tagged 
with GFP on the carboxyl-terminus (tsLa29-GFP) were incubated at 41°C or 35°C. Cells 
were fixed, permeabalized, and dual-labeled with TRITC-phalloidin and a phospho-
specific antibody for cortactin tyrosine 421. Cells were visualized by confocal 
microscopy through 2-D and 3-D (z-stack) sectioning. (B) Silencing of cortactin with 
siRNA prevents invadopodia formation. SYF cells were transfected with cortactin-
targeted or control siRNA (Ctl) and incubated at 37°C for two days. Cells were then 
transfected with tsLa29-GFP and the experiment proceeded as described in (A).  Cells 
were fixed, permeablized, and immunolabeled with TRITC-phalloidin and an anti-
cortactin (4F11) antibody. Invadopodia fail to form in cells treated with cortactin siRNA.  
(C) Clarified cell lysates (30µg) from cells transfected with mock- or Cort-SiRNA alone 
or in combination with tsLa29-GFP were incubated at 41°C or 35°C, resolved by SDS-
PAGE and immunoblotted with anti-Src-pY418, anti-Src (EC10), anti-cortactin (4F11), 
anti-cortactin-pY421, anti-GFP (JL8) and anti-β-actin antibodies. (Bars = 10µm). 
 
Fig. S4. Characterization of fluorescent protein-tagged Src constructs. (A) 
Determination of relative Src kinase activity.  SYF cells expressing cSrc-GFP, cSrc- 
cerulean, cSrc527F-GFP, cSrc527F-mCherry, cSrc295M-GFP, or cSrc295M-cerulean 
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were lysed, resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-Src, 
and anti-β-actin antibodies. Quantification of the relative Src phospohorylation in 
transfected SYF cells was conducted using densitometry.  Src-pY18 protein expression 
was normalized to total Src protein levels.  (B) Swept field imaging of fluorescently 
labeled Src constructs. Fixed cells were imaged for expression and localization of GFP, 
mCherry, and cerulean-tagged Src fluorescent proteins by direct fluorescence. GFP, 
green fluorescent protein; CerFP, cerulean fluorescent protein; mChFP, mCherry 
fluorescent protein.  (C) Confocal imaging of GFP-tagged SrcWT, Src295M, and 
Src527F. Transfected cells expressing the indicated Src constructs were fixed, 
permeablized, and immunolabeled with TRITC-phalloidin and the anti-cortactin (4F11) 
antibody. Arrows point to invadopodia in cells expressing Src527F. (Bars = 10µm).  
Fig. S5. Co-transfection and localization of fluorescent protein tagged Src constructs. 
(A) Representative images of non-transfected SYF cells (left) and SYF cells co-
expressing WT Src tagged with Cerulean fluorescent protein (Src-Cer) and GFP-tagged 
Src527F (527F-GFP) (right). Cells were fixed, permeablized, and immunolabeled with 
TRITC-phalloidin and anti-cortactin (4F11) antibody. Arrows denote invadopodia in the 
527F-GFP transfected cells.   Bar, 20µm. (B) SYF and SYF+/+ cells expressing 
cSrc527F-mCherry alone or in combination with cSrc-cerulean or cSrc295M-cerulean, 
were lysed and resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-
Src, anti- GFP/cerulean (JL8, does not recognize mCherry), anti-actin, anti-cortactin-
pY421, and anti-cortactin (4F11) antibodies. 
Fig. S6. Comprehensive SH2/PTB binding assay. An in vitro binding assay was 
performed using 91 GST-SH2 domains and 3 GST-PTB domains representing nearly 
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the full complement of human phosphotyrosine binding domains. GST and mutated Abl 
SH2 domain (Abl R>K) were used as negative controls. SH2 binding to SYF cell lysate 
was determined by densitometric quantification of digitally captured chemiluminescence 
images. The mean raw binding intensities with SEM from two independent experiments 
are shown. Domains are ordered from left to right by their binding intensity to SYF+/+ 
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Tumor cell motility and invasion is governed by dynamic regulation of the cortical actin 
cytoskeleton.  The actin-binding protein cortactin is commonly upregulated in multiple 
cancer types and is associated with increased invasion and metastasis.  Cortactin 
regulates actin nucleation through the actin related protein (Arp)2/3 complex, stabilizing 
the cortical actin cytoskeleton.  Cortactin is regulated by multiple phosphorylation 
events, including phosphorylation of S405 and S418 by extracellular regulated kinase 
(ERK)1/2.  ERK1/2 phosphorylation of cortactin has emerged as an important positive 
regulatory event, enabling cortactin to bind and activate the Arp2/3 regulator neuronal 
Wiskott-Aldrich syndrome protein (N-WASp), promoting actin polymerization and 
enhancing cell migration and tumor cell invasiveness. 
Methodology/Principal Findings 
In this report we have developed phosphorylation-specific antibodies against cortactin 
phosphorylated at S405 and S418 to analyze the subcellular localization of this cortactin 
form in tumor cells and patient samples by microscopy.  We evaluated the interplay 
between cortactin S405 and S418 phosphorylation with cortactin tyrosine 
phosphorylation in regulating cortactin conformational forms by Western blotting.  
Cortactin is simultaneously phosphorylated at S405/418 and Y421 in tumor cells, and 
through the use of point mutant constructs we determined that serine and tyrosine 
phosphorylation events lack any co-dependency.  Expression of S405/418 
phosphorylation-null constructs impaired carcinoma motility and adhesion, and also 
inhibited lamellipodia persistence monitored by live cell imaging. 
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Conclusions/Significance 
Cortactin phosphorylated at S405/418 is localized to sites of dynamic actin assembly in 
tumor cells.  Concurrent phosphorylation of cortactin by ERK1/2 and tyrosine kinases 
enables cells with the ability to regulate actin dynamics through N-WASp and other 
effector proteins by synchronizing upstream regulatory pathways, confirming cortactin 
as an important node in actin-based signal transduction.  Reduced lamellipodia 
persistence in cells with S405/418A expression identifies an essential motility-based 
process reliant on ERK1/2 signaling, providing additional understanding as to how this 






Tumor cell motility and invasion is a central problem in cancer that is paramount in 
contributing to metastasis [1].  Tumor cells move through successive series of 
coordinated and integrated stages, with formation of protrusive membranous structures 
including filopodia, invadopodia and lamellipodia required for initiation and maintenance 
of invasion and migration [2,3,4,5].  Central to the movement of most carcinoma cell 
types undergoing single or collective migration is the production of lamellipodia at the 
leading edge of the cell.  Lamellipodia are planar protrusive extensions of the plasma 
membrane produced by motile cells in two- and three-dimensional settings [6].  
Lamellipodia extension drives cell migration through integrin-based adhesion with the 
underlying substratum, providing the necessary traction for contractile-based 
translocation of the cell body to generate productive movement [7]. It is generally 
accepted that dynamic regulation of the cortical actin cytoskeleton through cycles of 
actin polymerization and depolymerization are responsible for generating the propulsive 
force needed for lamellipodia extension [8].  
The actin cytoskeleton within lamellipodia is governed by the activity of numerous actin-
binding proteins.  One element central to the formation of lamellipodia actin networks is 
activation of the actin-related (Arp) 2/3 complex, which nucleates filamentous (F-) actin 
polymerization within lamellipodia [9].  Arp2/3 complex binds to the sides of pre-existing 
F-actin, where upon activation the Arp2 and Arp3 subunits mimic the fast growing 
(“barbed” or “+”) end of an actin filament, allowing for the rapid addition of actin 
monomers to the complex and subsequent filament extension [4]. The resulting Arp2/3-
F-actin networks comprise an organized branched array of F-actin filaments that 
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contribute to lamellipodia extension, with Arp2/3 localized at filament branch points 
[8,9].  Arp2/3 branch points are metastable, allowing for rapid breakdown of Arp2/3-F-
actin networks by filament debranching [10].  Debranched F-actin filaments are further 
disassembled through the severing activity of members of the actin depolymerizing 
factor/cofilin family, which ultimately dissolve F-actin filaments to promote 
depolymerization, recycling actin monomers for additional rounds of polymerization and 
lamellipodia extension [11]. 
Arp2/3 activation is controlled by the activity of several actin nucleation promoting 
factors (NPFs).  The best characterized NPFs to date are members of the Wiskott-
Aldrich syndrome protein (WASp) family, which include the WASp and WAVE protein 
subgroups [12,13].  In many cell types, regulation of Arp2/3 activity by the WASp 
proteins N-WASp and WAVE2 are largely responsible for generating the actin network 
used for creating and regulating lamellipodia, filopodia and invadopodia [4,12,14], 
making these NPFs critical mediators of cell motility and invasion.  
Another well-characterized NPF independent of the WASp protein family is the cortical 
actin-binding protein cortactin [15,16].  Cortactin directly binds Arp2/3 complex [17,18] 
and activates Arp2/3 complex nucleation activity in vitro, albeit at a lesser degree than 
WASp-family proteins [18,19].  In addition to actin nucleation, a unique function of 
cortactin is its ability to prevent spontaneous debranching of Arp2/3-F-actin networks by 
simultaneous binding to Arp2/3 and F-actin, prolonging the lifetime of branched 
filaments [19]. While the biochemical features of cortactin seem to point to a 
straightforward role in lamellipodia actin regulation, studies of cortactin function in 
lamellipodia have proven controversial, suggesting to a more complex role in cell 
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migration. For instance, RNA interference studies have yielded conflicting results in 
regards to lamellipodia dynamics, with cortactin knockdown resulting in decreased 
lamellipodia stability and reduced persistence [20,21,22], whereas similar studies in 
different cell types suggest cortactin downregulation increases the length of extending 
lamellipodia [23].  Furthermore, recent analysis of fibroblast lamellipodia dynamics in 
cortactin-/- cells indicates that cortactin does not play a role in directly regulating 
lamellipodia protrusion or Arp2/3-based actin dynamics, but rather is important in 
mediating upstream activation of the small GTPases Rac1 and Cdc42, which in turn 
regulate WAVE2 and N-WASp activity [24].  While these reported discrepancies 
regarding cortactin function in lamellipodia have yet to be fully reconciled, it is clear that 
cortactin is an important regulator for normal and tumor cell migration in many cell 
systems [25,26].  An unambiguous role for cortactin has been shown in invadopodia, 
where removal of cortactin by RNA interference ablates invadopodia formation in 
multiple invasive tumor cell types [27,28,29].      
Besides regulating Arp2/3-based cortical actin networks by direct interactions, cortactin 
also functions as a key mediator in several kinase-based signal transduction cascades 
that serve to indirectly govern Arp2/3 activity and subsequent cell movement.  Cortactin 
is a well-defined target for Src kinase [30], phosphorylating human cortactin on tyrosine 
residues Y421, Y470 and Y486 within the proline-rich (PR) carboxyl-terminal domain 
[31].  Several other tyrosine kinases target these residues [32,33,34,35], indicating that 
they collectively form a “hot spot” region as a point of convergence for multiple signaling 
pathways.  Cortactin phosphorylated at tyrosines 421, 470 and/or 486 creates Src 
homology (SH)2 docking sites for several phosphorylating kinases, as well as the 
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adaptor proteins Crk [36] and Nck1 [37].  In the case of Nck1, Nck1/cortactin complexes 
interact with N-WASp or WASp interacting protein through the Nck1 SH3 domain to 
stimulate Arp2/3-dependent actin nucleation [37], which in cooperation with Arg kinase 
has been recently demonstrated to be important for regulating lamellipodia protrusion 
and leading edge adhesion formation [38].  The cortactin/Nck1 complex is also required 
to stimulate actin polymerization essential for invadopodia function in invasive breast 
cancer cells [39].  These studies are in agreement with the localization of tyrosine 
phosphorylated cortactin within lamellipodia and invadopodia [40], lending mechanistic 
insight into the long recognized pro-migratory and pro-invasive properties associated 
with cortactin tyrosine phosphorylation [29,31,41,42]. 
In addition to tyrosine phosphorylation, cortactin is a target for multiple serine/threonine 
kinases [43].  Stimulation of tumor cells with epidermal growth factor (EGF) results in 
increased serine/threonine phosphorylation of serine residues 405 and 418 within the 
PR domain, coincident with a characteristic shift in cortactin electrophoretic mobility 
from 80 kDa to 85 kDa in SDS-PAGE [44,45].  The mobility shift and phosphorylation of 
S405/S418 are impaired by pharmacologic inhibition of mitogen activated 
protein/extracellular signal regulated kinase kinase (MEK)1/2, and direct biochemical 
evidence indicates that the MEK effector kinases ERK1/2 directly phosphorylate 
cortactin at these sites [45].  Phosphorylation of S405/S418 enhances binding of the 
cortactin carboxyl-terminal SH3 domain to N-WASp and activates N-WASp NPF activity, 
indicating a functional role in stimulating Arp2/3-mediated actin dynamics independent 
of tyrosine phosphorylation [46].  This is supported by studies expressing 
phosphorylation-null and phosphomimetic point mutant constructs in cells, suggesting 
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that S405/S418 phosphorylation plays a critical role in regulating cellular actin 
polymerization necessary to promote cell motility [47] and invadopodia function [29]. In 
addition, p21 activated kinase 1 (PAK1) phosphorylates cortactin at S405/S418, serving 
to stimulate N-WASp activity required for clathrin-independent endocytosis [48].  While 
studies to date implicate a positive regulatory function for cortactin S405/418 
phosphorylation in promoting N-WASp-mediated Arp2/3 actin structures, the subcellular 
localization of phosphorylated S405/418 cortactin, as well as the precise role S405/418 
phosphorylation plays in regulating lamellipodia dynamics have not been evaluated.  
In this study, we have generated site-specific antibodies against phosphorylated 
cortactin S405 and S418 to determine the spatial and temporal localization of cortactin 
in dynamic actin structures and human tumors, and to evaluate signaling interplay 
between cortactin tyrosine and serine phosphorylation events.  We also determined the 
effects of S405/418 cortactin phosphorylation on EGF-induced cell migration, adhesion 





DNA Constructs and siRNA 
For Myc-tagged human cortactin expression constructs, the wild-type human cortactin 
cDNA subcloned into pcDNA FLAG2AB [49] was used as a template for producing point 
mutants by site-directed mutagenesis (QuickChange; Stratagene, La Jolla, CA).  Codon 
alterations in human cortactin were: S405A, S418A, S405A/S418A, Y421F, Y470F, 
Y486F, Y421F/Y470F/Y486F and W492K. Cortactin cDNAs were amplified by PCR as 
BamHI-EcoRI fragments and subcloned into BamHI-EcoRI digested pRK5Myc [50].  
Murine GFP-tagged expression constructs were produced using pcDNA3FLAG2AB 
wild-type murine cortactin [17] as the template for mutagenesis, then subcloned as 
EcoRI-KpnI PCR fragments into pAcGFP-C1 (Clontech, Mountain View, CA).  The 
temperature-sensitive vSrc LA29 construct was previously described [51]. mCherry-b-
actin was obtained from D. Schafer (University of Virginia), with the parent construct 
produced by R. Tsien (University of California, San Diego).  Small interfering (si)RNA 
targeting rodent cortactin (5’-GCTTCGAGAGAATGTCTTC-3’) was purchased from 
Thermo Scientific (Waltham, MA) 
Cell lines and Transfection 
The HNSCC cell lines 1483 [52], UMSCC1 and UMSCC2 [53] were maintained as 
described [41].  SYF cells were obtained from the American Type Culture Collection 
(Manassas, VA) and maintained according to the supplied protocol.  The rat mammary 
adneocarcinoma line MTLn3 was maintained in aMEM supplemented with 10% fetal 
bovine serum, 1% L-glutamine and 1% penicillin-streptomycin.  Transient transfections 
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were conducted with 3 x 106 cells and 2mg of plasmid construct or siRNA using the 
Nucleofector I device (Amaxa Biosystems, Berlin, Germany). 
Antibodies 
Antibodies against phosphorylated serine 405 (pS405) and serine 418 (pS418) of 
human cortactin were produced by 21st Century Biochemicals (Marlboro, MA).  
Synthetic phosphorylated cortactin peptides containing the sequences NH2-
KTQTPPV[pS]PAPQPTC-COOH (cortactin pS405) and NH2-TEERLPS[pS]PV-COOH 
(cortactin pS418) were produced, conjugated to keyhole limpet cyanine and injected 
into rabbits.  Immune serum was screened by enzyme-linked immunosorbent assay 
against the appropriate phosphorylated cortactin peptide coupled to bovine serum 
albumin.  High-titer bleeds were identified for each peptide, and immune serum was 
passed two successive times through chromatography columns containing agarose 
beads coupled to the equivalent non-phosphorylated peptide.  The flow through material 
for each peptide was subsequently passed twice through chromatography columns 
containing beads conjugated to the matched phosphorylated cortactin peptide.  After 
extensive washing, bound antibodies for each phosphorylation site were eluted, 
concentrated and screened for specificity by Western blotting against recombinant 
cortactin mutant proteins harboring alanine-serine point mutations at serine 405 or 418, 
respectively (Fig. 1A).  The anti-pS405 and anti-pS418 cortactin antibodies are currently 
available through Protea Biosciences (Morgantown, WV).  Anti-cortactin (4F11) was 
used as described [41].  Anti-pY421 cortactin and anti-pY418 Src were from Invitrogen 
(Carlsbad, CA).  Anti-ERK1/2 and pERK1/2 were from Cell Signaling (Danvers, MA).  
Anti-Myc epitope tag (4A6) was from Millipore (Billerica, MA).  Anti-GFP (JL-8) was from 
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Clontech (Mountain View, CA) and anti-b-actin was from EMD4Biosciences (San Diego, 
CA).  
Western blotting and Immunoprecipitation 
Western blotting was conducted as described [41].  Primary antibody dilutions used 
were:  anti-pS405 cortactin (1:4000), anti-pS418 cortactin (1:500), anti-cortactin 
(1:1000), anti-pY-421 cortactin (1:2000), anti-ERK1/2 (1:2000), anti-pERK (1:2000), 
anti-pY418 Src, anti-GFP (1:1000) and anti-b-actin (1:5000).  Immunoprecipitations 
were performed as described [40] using 5mg of precipitating antibody captured with 
40ml of a 50% Protein A/G bead slurry (Thermo Fisher Scientific, Pittsburgh, PA).   In 
some cases cells were treated with selumetinib (AZD6244; ARRY-142886) or 
saracatinib (AZD0530) for 24h prior to immuoprecipitation and Western blotting 
analysis. 
Microscopy 
UMSCC2 cells were plated on fibronectin-coated coverslips (10mg/ml; Sigma, St Louis, 
MO) and allowed to attach before serum starvation for 16h.  Cells were stimulated with 
100ng/ml EGF (Millipore) for 1h before fixation.  UMSCC1 cells plated on FITC-gelatin 
(Sigma) for 8 h were processed for confocal microscopy using Zeiss LSM 510 Meta 
system (Thornwood, NY) as described [49]. Anti-pS418 cortactin was used at 1:1000, 
4F11 at 1:500 and rhodamine-conjugated phalloidin at 1:1000 (Invitrogen, Carlsbad, 
CA).  
For immunohistochemistry, HNSCC tissue blocks were obtained from the West Virginia 
University Tissue Bank and used under approval of the West Virginia University 
Institutional Review Board.  Five-micrometer sections from formalin-fixed, paraffin-
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embedded blocks were processed for immunostaining using the Discovery XT 
automated staining system (Ventana, Tucon AZ).  Briefly, after deparaffinization and 
antigen retrieval, sections were incubated with monoclonal rabbit anti-cortactin (Novus, 
Littleton, CO) at 1:2000, anti-pS418 cortactin at 1:25 and anti-pERK1/2 at 1:100 
dilutions.  All primary antibodies were incubated in Dako diluent (Dako, Carpinteria, CA) 
for 1 h.  Primary antibodies were detected with the Omnimap antibody horseradish 
peroxidase kit (Ventana).  Slides were counterstained with hematoxylin and post-
counterstained with bluing reagent (Ventana).  Images were visualized with an Olympus 
AX70 microscope and captured using the MicroBrightfield system (Williston, VT). 
Live cell imaging was conducted using MTLn3 cells starved for 3 h with serum-free 
media prior to stimulation with 100ng/ml EGF.  Cells were plated on delta-T glass 
bottom dishes (Fisher) coated with 10mg/ml fibronectin (Sigma). Immediately following 
EGF addition, cells were imaged by differential interference contrast using a Nikon 
TE2000 inverted microscope equipped with a Roper CoolSNAP HQ charge-coupled 
device camera (Photometrics, Tucson, AZ).  Images were captured every 5 s for 15 min 
(181 total frames).  A Nikon LiveScan SFC swept field microscope was used for imaging 
cells expressing mCherry-actin.  In all cases, GFP-cortactin expressing cells were 
identified by fluorescence microcopy prior to imaging.  Kymograms were produced by 
extracting 1 pixel-width strips from each movie frame at points of initial and maximal 
lamellipodia extension, and assembled using ImageJ (v1.40).  
Electric Cell Substrate Impedance Sensing  
To assay cell motility and adhesion, 5x 105 cells were plated into 8-well electric cell 
substrate impedance sensing dishes (ECIS; Applied Biophysics, Troy, NY).  For motility 
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measurements, cells were allowed to adhere overnight on 8W1E dishes to form a 
monolayer.  Adhesion was assayed immediately after plating cells onto 8W10E dishes. 
Measurements were conducted for 24 h at 45kHz, with reading taken at 1 min intervals.  
Cells treated with selumetinib were serum starved 24 h in the presence of drug prior to 
ECIS.  
Statistical Analysis 
Differences in mean groups for migration, adhesion and kymography between control 
and treated groups were evaluated using one way ANOVA, followed by Student-
Newman-Keuls post hoc testing.  All differences were considered significant at p<0.05.  




Localization of pS418 cortactin with dynamic cortical actin structures 
We developed antibodies specific to phosphoserine 405 (pS405) and phosphoserine 
418 (pS418) of human cortactin to facilitate analysis of these sites.  To validate antibody 
specificity, epitope (Myc)-tagged cortactin constructs containing wild-type (WT) 
cortactin, cortactin with individual serine to alanine mutations at serine 405 (S405A), 
418 (S418A) or with both mutated in tandem (S405,418A) were produced and 
transfected into 1483 cells.  Total cell lysates were blotted with anti-pS405 or anti-
pS418 antibodies (Figure 1A).  The anti-pS405 antibody recognized the WT and S418A 
cortactin variants, failing to blot constructs containing the S405A mutation. Conversely, 
anti-pS418 blotted WT and S405A, failing to recognize cortactin constructs with S418A 
mutations.  All cortactin variants were recognized by an anti-cortactin monoclonal 
antibody (Figure 1A), indicating equivalent expression of the assayed constructs.  
These results indicate that the anti-pS405 and anti-pS418 antibodies specifically 
recognize their cognate phosphorylated cortactin epitope, and that no interdependence 
exists between phosphorylation of cortactin S405 and S418. 
To determine the subcellular localization of serine phosphorylated cortactin, we 
conducted indirect immunofluoresence studies on cells producing lamellipodia and 
invadopodia, two actin-based structures that depend in part on N-WASp activity.  While 
the anti-pS405 antibody yielded non-specific staining in our hands (data not shown), 
anti-pS418 specifically labeled lamellipodia and cytoplasmic puncta (presumably 
vesicles) in UMSCC2 cells.  In cells with a motile phenotype, anti-pS418 localized with 
cortactin and F-actin in these regions (Figure 1B, top row).  Labeling of UMSCC1 cells 
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plated on FITC-coated gelatin matrix with anti-pS418 indicated specific localization to a 
subset of invadopodia that coincided with cortactin, F-actin and areas of gelatin clearing 
indicative of matrix metalloproteinase mediated invadopodia activity (Figure 1B, middle 
and bottom rows). 
In solid human tumors, cortactin and cortactin phosphorylated on tyrosine 421 (pY421) 
localizes to invasive tumor fronts and to cell-cell junctions [41,49].  To determine the 
location of pS418 cortactin in tumor tissue, head and neck squamous cell carcinoma 
(HNSCC) cases were sectioned and stained with anti-pS418 (Figure 1C).  Cortactin 
pS418 was abundant in HNSCC cell cytoplasm and was enriched in areas of cell-cell 
contact, displaying a pattern similar to sections labeled with a total cortactin antibody 
(Cort). These tumor regions also contained activated ERK1/2, as evidenced by 
pronounced cytoplasmic and nuclear staining of phosphorylated ERK1/2 in serial 
sections (Figure 1C).   
Growth factor mediated phosphorylation of cortactin S405/418 is MEK dependent 
Previous biochemical work has implicated chemical inhibition of MEK and subsequent 
blocking of ERK1/2 activation as a major pathway responsible for cortactin S405/418 
phosphorylation [45].  To further evaluate the role of the MEK-ERK1/2 pathway on 
cortactin phosphorylation, we utilized the anti-pS405 and pS418 cortactin antibodies to 
directly test the effects of MEK inhibition on cortactin pS405/418.  Western blot analysis 
of cell extracts from EGF- and serum-stimulated UMSCC1 cells with anti-pS405 and 
pS418 antibodies displayed similar phosphorylation kinetics of S405 and S418, with 
phosphorylation of both sites first evident 10 min after stimulation (Figure 2A) and 
remaining phosphorylated up to 2 h (data not shown).  Treatment of UMSCC1 or 1483 
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cells with the small molecule MEK inhibitor selumetinib [54] reduced EGF-stimulated 
cortactin S405/418 phosphorylation in a dose-dependent manner, where near 
elimination of phosphorylation at both serine residues occurred at doses > 1mM (Figure 
2B).  ERK1/2 activity was also reduced under similar dose conditions, although 
complete ablation of ERK1/2 phosphorylation was observed at doses > 5mM (Figure 
2B).  These data suggest that the MEK-ERK pathway is largely responsible for growth-
factor induced cortactin S405/418 phosphorylation in HNSCC cells, in agreement with 
previous findings in other cell types [45]. 
 
The 80kDa to 85kDa cortactin conformational shift is associated with serine and 
tyrosine phosphorylation  
Based on sequence analysis, the largest and most prominent cortactin isoform 
(cortactin “A” or “SV1”) encodes a 61.5kDa protein [55,56].  This cortactin form 
frequently migrates as an 80/85kDa doublet in SDS-PAGE [30,57] that has been 
attributed to conformational alterations within the polypeptide chain [15,45].  Shifting 
from the 80kDa to 85kDa form is seen in response to EGF, with the resulting 85kDa 
band associated with S405/418 phosphorylation [44,45].  To directly assess the 
presence of pS405/418 in the two cortactin conformational isomers, serum-starved 
UMSCC2 (Figure 3A) and 1483 (Figure 3B) cells were stimulated with EGF and the 
cortactin forms in cell lysates were analyzed at successive time points with anti-pS405 
and anti-pS418 antibodies.  S405/418 phosphorylation was maintained in the 85kDa 
cortactin form in both cell lines following serum starvation, despite of the lack of ERK1/2 
activity (0 min, Figure 3A and Figure 3B).  EGF stimulation resulted in complete 
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conversion of the 80kDa to the 85kDa cortactin form by 1 h after EGF treatment in both 
cell lines (Figure 3A and Figure 3B). Cortactin pS405 and pS418 was observed 
primarily in the 85kDa form and increased at both sites during the entire time course, 
whereas ERK1/2 activity peaked at 15 min and rapidly declined afterwards (Figure 3A 
and Figure 3B). Interestingly, the phosphorylation of S405 was also associated with an 
increase appearance of cortactin degradation in UMSCC2 cells (Figure 3A). It is 
uncertain whether these products represent increased overall cortactin degradation, or if 
the net cortactin degradation is constant but is selectively identified by the pS405 
antibody in response to EGF treatment and phosphorylation.  EGF-induced Src 
activation and cortactin pY421 phosphorylation was sustained throughout the entire 
time course in UMSCC2 cells (Figure 3A), indicating that cortactin can be 
simultaneously phosphorylated by ERK1/2 and Src or potentially other EGF-stimulated 
cortactin tyrosine kinases. Pretreatment of UMSCC2 cells with the Src family kinase 
inhibitor saracatinib at 10mM or selumetinib at 1mM completely impaired the cortactin 
shift from 80kDa to 85kDa (Figure 3C).  The exclusive presence of pS405 and pS418 in 
the EGF-induced 85kDa cortactin form, as well as the ability of MEK inhibition to impair 
the cortactin shift is consistent with results obtained from previous work [45].  Our 
results also identified EGF-induced Src-mediated phosphorylation of cortactin at 
tyrosine 421 as a necessary mediator of the cortactin shift. 
 
Cortactin serine phosphorylation in vivo is independent from tyrosine 
phosphorylation  
EGF treatment of UMSCC2 cells resulted in phosphorylation of cortactin S405/418 and 
cortactin pY421 (Figure 3A).  A previous in vitro study evaluating the impact of cortactin 
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phosphorylation on N-WASp activation determined that S405/418 phosphorylation by 
ERK1/2 enables the cortactin SH3 domain to stimulate N-WASp Arp2/3 activation, while 
Src phosphorylation downregulates N-WASp activity and counteracts the effects of 
S405/418 phosphorylation [46].  This proposed “on-off switch” postulates that cortactin 
serine and tyrosine phosphorylation are mutually exclusive events governing the ability 
of cortactin to regulate N-WASp activity and downstream actin reorganization [58].  
Using the available antibodies reactive against cortactin pS405 and pY421, we sought 
to determine if these two different classes of phosphorylation events are interdependent 
in any manner. Cortactin depleted SYF fibroblasts (null for the Src, Yes and Fyn 
kinases) were co-transfected with the temperature-sensitive vSrc construct tsLa29-GFP 
[51] to activate the Src and ERK1/2 signaling pathways, along with constructs encoding 
wild-type cortactin or the following Myc-tagged cortactin mutants: Y421F, Y470F, 
Y486F, Y421/Y470/Y486F (TPM), S405A, S418A, S405/418A (Figure 4A).  A W492K 
cortactin mutant was also included, as this mutant abolishes the ability of the cortactin 
SH3 domain to interact with corresponding SH3 binding proteins [59].  After shifting to 
35ºC for 2 h to activate tsLa29-GFP, the serine and tyrosine cortactin mutants were 
analyzed for phosphorylation at Y421 and S405 by SDS-PAGE and Western blotting 
(Figure 4B).  Mutations to S405 and S418 alone and in combination did not impact the 
ability of these constructs to be phosphorylated on Y421, as indicated by their 
recognition with the anti-pY421 antibody (Figure 4B). Similarly, mutations to Y421, 
Y470, and Y486, alone and in combination (TYM) did not affect the ability of these 
constructs to be phosphorylated on S405. These data indicate that cortactin is 
simultaneously phosphorylated at S405 and Y421 downstream of vSrc activation, 
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suggesting in this system that phospho-regulation of cortactin SH3 domain function is 
not governed in vivo by the serine-tyrosine “on-off switch” mechanism proposed from 
previous in vitro experimentation [46,58].  
S405/418 phosphorylation is required for efficient tumor cell motility and 
adhesion 
To evaluate the role of cortactin S405/418 phosphorylation on carcinoma cell migration, 
1483 and UMSCC1 cells were treated with selumetinib and assayed for effects on 
motility by ECIS (Figure 5).  Selumetinib treatment impaired the motility of both cell 
types in a dose-dependent manner, corresponding to the observed decreases in 
S405/418 phosphorylation (Figure 2B).  Since MEK inhibition likely impaired the 
phosphorylation of other proteins involved in motility in addition to cortactin, we directly 
assessed the impact of cortactin S405/418 phosphorylation on cell migration using 
phosphorylation-null cortactin expression constructs.  MTLn3 rat mammary 
adneocarcinoma cells were initially transfected with a siRNA targeted against rodent 
cortactin, followed by transfection with GFP-tagged human wild-type (WT), S405A, 
S418A and S405/418A cortactin constructs.  Cortactin siRNA reduced endogenous 
cortactin levels to > 90%, having no impact on expression of the human GFP-labeled 
variants (Figure 6A).  MTLn3 cells with cortactin knockdown (si) displayed a 29% 
reduction in motility compared to control (Ctl) (Figure 6B).  Expression of wild-type 
human GFP-cortactin (WT) led to a 2-fold increase in motility, presumably due to 
increased expression of this variant over endogenous (Ctl) levels (Figure 6A).  
Expression of S405A, S418A or S405,418A cortactin resulted in an 49% average 
decrease in cell migration for each cortactin mutant, indicating that phosphorylation of 
 155 
S405 and S418 are both vital in maintaining optimal carcinoma cell motility (Figure 6B).  
Since lamellipodia formation is required for detached cells to adhere to the ECM, we 
conducted ECIS assays to determine the effects of cortactin S405/418 phosphorylation 
on cell adhesion.  MTLn3 cells lacking cortactin expression (si) exhibited a 50% 
decrease in cell adhesion compared to control (Ctl) cells.  Expression of wild type (WT) 
GFP-cortactin restored adhesion to levels similar to Ctl, whereas expression of S405A, 
S418A or S405/418A cortactin mutants all reduced adhesion to levels 42-58% of Ctl, 
failing to restore adhesion to levels above cortactin si cells (Figure 6C).  These results 
suggest that S405/418 phosphorylation is critical for carcinoma cell motility and 
adhesion, representing an important pro-migratory substrate targeted by the MEK-
ERK1/2 pathway. 
 
Cortactin S405/418 phosphorylation is required for carcinoma cell lamellipodia 
persistence      
Given the localization of pS418 cortactin within lamellipodia (Figure 1B) and the effects 
of cortactin S405/418A expression on cell motility, we evaluated the impact of cortactin 
S405/418 phosphorylation on lamellipodia dynamics using live-cell imaging and 
kymographic analysis.  Serum-starved MTLn3 cells expressing mCherry-b-actin and 
containing endogenous cortactin knockdown alone (si), rescued with human GFP- wild 
type cortactin (si+WT) or with GFP-cortactin S405/418A (si+S405,418) were stimulated 
with EGF for 15 min.  Lamellipodia dynamics were monitored by time lapse video 
microscopy (Figures S1-S4) and assayed by kymography (Figure 7A).  EGF-stimulated 
MTLn3 cells produced an initial dominant lamellipodia that reached maximal extension 
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between 1.5 and 3 min, and retracted to the point of origin between 5-7 min [60,61].  
Control MTLn3 cells containing mCherry-b-actin displayed similar extension-retraction 
kinetics when assayed by kymography (Figure 7B and Figure S1).  While no differences 
were observed in lamellipodia protrusion rates in any of the assayed cellular conditions 
(Figure 7A), cortactin knockdown (si) increased lamellipodia extension by an average of 
5.8mm over the maximum extension length observed in control cells (Figure 7A and B).  
Lamellipodia formed in cortactin si cells failed to effectively retract lamellipodia, 
demonstrating a ~2-fold increase in average lamellipodia persistence over control levels 
(Figure 7A and Figure S2).  These results are consistent with the observed increase in 
lamellipodia extension and persistence observed when MTLn3 cells contact EGF-
coated bead matrices [23].  These effects are fully rescued to control levels upon 
expression of WT GFP-cortactin (si+WT; Figure 7A and B).  Although expression of 
GFP-cortactin S405/418A in cortactin si cells did not impact EGF-induced lamellipodia 
extension, average lamellipodia persistence was reduced by 46%, from 195 sec in 
si+WT cells to 106 sec in si+405,418 cells (Figure 7A).  The lamellipodia in si+405,418 
cells displayed series of multiple short extensions and retractions, had enhanced ruffling 
and appeared more labile than control or si+WT cells (Figure 7B: Figures S1 and S2 
compared to Figure S4). These results suggest that S405/418 phosphorylation is vital in 




While the effects of cortactin phosphorylation at S405 and S418 by ERK1/2 have been 
studied at the biochemical and functional level in several systems [29,45,46,47], the 
spatial and temporal evaluation of S405 and S418 phosphorylation have been 
hampered due to the lack of suitable reagents to directly study these sites in cellular 
and tissue contexts.  Our development of anti-pS405 and anti-p418 cortactin antibodies 
has allowed us to examine the localization and signaling pathways regulating these 
cortactin phosphorylation events.  These antibodies, coupled with the use of 
phosphorylation-null mutant constructs, allowed us to validate and extend previous 
findings implicating these sites in the regulation of carcinoma cell motility and 
associated lamellipodia dynamics.   
The localization of pS418 cortactin in carcinoma lamellipodia and invadopodia is 
consistent with the defined and emerging roles cortactin plays in regulating actin 
dynamics within these structures [26,62].  To date, all studies designed to evaluate the 
cellular effects of pS405/418 phosphorylation have relied on the use of phosphorylation 
null or phosphomimetic (S405/418D) constructs.  In pancreatic tumor cells, S405/418A 
and S405/418D both promote lamellipodia protrusion over control levels, whereas 
S405/418A inhibits and S405/418D promotes cell motility [47].  While the ability of 
S405/418A to promote lamellipodia protrusion in these studies is unclear, the remaining 
results are consistent with an activating role for S405/418 phosphorylation in 
lamellipodia dynamics and motility.  Similar results were obtained in the analysis of 
S405/418 on invadopodia function, with S405/418A expression impairing and 
S405/418D promoting ECM degradation activity [29].  Phosphorylation of cortactin S418 
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within lamellipodia and invadopodia (Figure 1B) supports these results.  Precisely where 
cortactin is phosphorylated on S405/418 in carcinoma cells remains to be determined, 
although the phosphorylating kinases ERK1/2 and PAK1 have been localized within 
lamellipodia [63,64] and invadopodia [65].  This could suggest that cortactin is initially 
localized to lamellipodia or invadopodia, where it is subsequently phosphorylated on 
S405/418 when associated with the cortical actin networks within these structures.  An 
analogous mechanism is employed for cortactin tyrosine phosphorylation within 
lamellipodia [40].  
In HNSCC and several other tumor types, cortactin is present in the cytoplasm and is 
enriched at cell-cell junctions [41,66,67]. The localization of pS418 cortactin at regions 
of HNSCC cellular contact within tumors resembles the localization pattern of pY421 
cortactin in this tumor type [68].  The staining pattern of cortactin and its tyrosine 
phosphorylated form is reminiscent of that found in two-dimensional epithelial 
monolayers, where cortactin has been shown to be essential for Arp2/3-mediated actin 
remodeling resultant from E-cadherin homoligation and subsequent Src activity [69,70].  
While the presence of pS418 cortactin at these sites suggests additional functional roles 
for cortactin in E-cadherin-mediated actin regulation within tumors, whether or not 
cortactin S405/418 phosphorylation impacts elements of E-cadherin-based regulation of 
solid tumor behavior (such as tumor cell cohesion, motility or dissemination) remains to 
be examined.  
Selumetinib inhibition of cortactin S405/S418 phosphorylation is consistent with results 
obtained with non-clinical MEK inhibitors [29,45], reinforcing the MEK-ERK1/2 pathway 
as the main signaling route responsible for phosphorylating these cortactin sites in 
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tumor cells.  This is supported by direct phosphorylation of cortactin by ERK1/2 in vitro 
[45] along with our data demonstrating concomitant downregulation of active ERK1/2 
resultant of selumetinib treatment. In addition to MEK, PAK1 has recently been shown 
to phosphorylate cortactin at S405/418, regulating N-WASp actin dynamics responsible 
for clathrin- and caveolin-independent endocytosis [48]. PAK1 is activated primarily by 
binding to active Cdc42 or Rac1 [71], although alternative modes of activation have also 
been described [72]. Activated PAK1 also binds and activates MEK, stimulating ERK1/2 
activation [73]. Since MEK inhibition largely ablates S405/418 phosphorylation in most 
cell types, the impact of PAK1 activity on S405/418 phosphorylation may be context 
dependent, with direct PAK1 phosphorylation of cortactin S405/418 regulating actin 
polymerization required for endosomal trafficking, while MEK-mediated phosphorylation 
(activated by Raf or other MEK activators) may be primarily responsible for governing 
motility-based actin dynamics.  In addition, the related kinase PAK3 phosphorylates 
cortactin at S113, an event that downregulates the ability of cortactin to bind F-actin and 
is important in modulating invadopodia function [29,74].  While our understanding 
regarding the interrelationship and regulation between PAK and MEK in governing 
cortactin S405/418 phosphorylation is currently incomplete, it is clear that the PAK-
MEK-ERK1/2 signaling nexus impinges at multiple levels on cortactin to regulate actin 
dynamics involved in several membrane-based cellular processes.  
Consistent with other reports [44,45], we observed the MEK-dependent EGF-induced 
shifting of cortactin from the 80kDa to 85kDa form by Western blotting.  Direct analysis 
with anti-pS405 and anti-pS418 antibodies indicates that the 85kDa form is almost 
exclusively phosphorylated on these residues, as was determined by 32P labeling and 
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tryptic peptide analysis [44,45].  The shift in cortactin Mr is not attributable to bulk 
addition of phosphate, since phosphatase treatment of cortactin immunoprecipitates 
from EGF-treated cells failed to reconvert the 85kDa form to 80kDa (data not shown).    
While the distinct 80kDa and 85kDa bands represent different post-translationally 
modified cortactin forms associated with pS405/418 phosphorylation, mutations at these 
sites have no effect on 80/85kDa cortactin ratios, with the S405/418A mutant displaying 
a similar cortactin electrophoretic pattern to wild type cortactin (Figure 4). This suggests 
that S405/418 cortactin phosphorylation, while associated with the shift from 80 to 
85kDa, is not necessary for generation of the 85kDa cortactin form.  This is supported 
by the presence of 80kDa and 85kDa cortactin forms produced in kinase-free systems 
[30,75] and by the existence of a single 85kDa form when analyzed by urea denaturing 
SDS-PAGE [75]. 
The lack of detailed structural data for cortactin derived by nuclear magnetic resonance 
spectroscopy or X-ray crystallography has hindered the field in understanding 
conformational changes cortactin undertakes in response to post-translational modifying 
events.  The existence of cortactin in a “closed” versus “open” form regulated by 
S405/418 phosphorylation has been proposed to explain the observed 80 to 85kDa shift 
[45].  Support for this is derived from biochemical studies on N-WASp activation by the 
cortactin SH3 domain, where S405/418 phosphorylation enhances N-WASp activation 
and Arp2/3 actin nucleation activity [46].   These studies propose that the “closed” 
cortactin form undergoes an autoinhibitory conformational state where the carboxyl 
terminal helical proline-rich (HP) domain containing S405 and S418 is altered to render 
the SH3 domain inaccessible to binding N-WASp or other proteins.  Phosphorylation of 
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S405/418 results in liberating the SH3 domain, where it in turn is capable of binding and 
stimulating N-WASp activation. Expression of cortactin S405/418D phosphomimetic 
forms in cells increases branched actin networks in actin tails associated with 
cytoplasmic vesicles, providing support for this model in promoting cellular actin 
polymerization [47].  Initial assessments of cortactin structure by rotary shadow electron 
microscopy revealed cortactin to exist as a rod shaped monomer 220Å in length[76]. 
However, a recent biophysical analysis utilizing chemical crosslinking and small angle x-
ray scattering suggests that cortactin exists in a more globular form, with the carboxyl 
terminal HP and SH3 domains folding back onto the amino terminal actin binding region 
[77]. Such a structure would support a “closed” conformation, although “open” structures 
were not observed, nor were the effects of ERK1/2 phosphorylation evaluated.  
Additional evidence for an inhibitory function of the amino terminus can be inferred from 
the ability of the cortactin carboxyl terminal domain to promote N-WASP-dependent cell 
motility as effectively as wild type cortactin [78], as well as the prevalence of the 85kDa 
form in invasive colorectal cancer [66].     
In the ERK-Src “switch” model proposed for cortactin regulation, cortactin 
phosphorylation by Src at Y421, 470 and 486 serves to downregulate N-WASp activity 
promoted by S405/418 phosphorylation [46].  This model therefore suggests that serine 
and tyrosine phosphorylation of cortactin function in a reciprocal manner to govern N-
WASp activation [58].  Our data with site-specific phosphorylation antibodies on lysates 
from EGF-stimulated cells indicates that S405/418 and Y421 are co-phosphorylated, 
and analysis of point mutant cortactin constructs does not indicate a reciprocal influence 
between cortactin serine and tyrosine phosphorylation events.  These data suggest that 
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cortactin function is not exclusively regulated by a serine-tyrosine “switch” mechanism.  
This view is additionally reinforced by the presence of pS418 and pY421 cortactin within 
lamellipodia and invadopodia.  While our data do not rule out scenarios where such a 
mechanism may be employed at the cellular level, they are consistent with biochemical 
and cellular evidence indicating that tyrosine phosphorylation promotes N-WASp activity 
through binding of the adaptor Nck1 [37,39], a component that was not present in the 
original assays where the “switch” mechanism was defined.  The ability of cortactin to 
be simultaneously phosphorylated at S405/418 and Y421/470/486 may therefore 
provide cells with the ability to fine-tune the level of N-WASp activation and subsequent 
actin remodeling in response to diverse upstream stimulatory input that triggers motility 
and invasion. 
Consistent with the mechanistic descriptions above, inhibition of carcinoma cell motility 
by MEK inhibition and S405/418A expression indicates that S405/418 cortactin 
phosphorylation is important in promoting and maintaining cell migration.  While similar 
results were observed in wound healing assays with pancreatic cancer cells [47], our 
work extends these findings by evaluating the effects of pS405/418 on lamellipodia 
dynamics.  The inability of MTLn3 cells expressing S405/418A cortactin to maintain 
EGF-stimulated dominant lamellipodia persistence implies that the actin networks within 
these cells fail to maintain proper Arp2/3 nucleation, or are more labile following 
lamellipodia extension.  While N-WASp activation and Arp2/3-mediated actin 
polymerization resultant of cortactin SH3 domain binding has been shown to be 
important in governing motility in multiple cell types [47,78], a detailed study of EGF-
induced lamellipodia protrusion in this cell type has recently shown that WAVE2 and 
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formin proteins, not N-WASp, are responsible for lamellipodia protrusion [14].  These 
results would therefore rule out a role for direct N-WASp activation by pS405/418 
cortactin in MTLn3 lamellipodia extension.  In addition to N-WASp, the cortactin SH3 
domain interacts with several other proteins that have the potential to directly or 
indirectly regulate lamellipodia actin dynamics (reviewed in [62]).  In particular, cortactin 
binds and activates the Dbl family guanine nucleotide exchange factor faciogenital 
dysplasia protein 1 (FGD1) [79,80], a potent activator of Cdc42 [50].  Cdc42 activity is 
required for localization of WAVE2 and its activator IRSp53 to the cell membrane, 
where it mediates lamellipodia extension [81]. FGD1 also activates the MEK-ERK1/2 
pathway [50], allowing the potential of a positive feedback loop in stimulating cortactin 
S405/418 phosphorylation through continuous cortactin SH3-mediated FGD1 activity.  
FGD1 binding represents just one possible cortactin SH3 domain ligand with the 
capability to influence WAVE2 localization and lamellipodia dynamics.  Whether such an 
FGD1-based regulatory circuit or other modes of potential pS405/418 cortactin 
regulation of WAVE2 activity exist in MTLn3 cells remains to be confirmed. 
Previous studies on lamellipodia dynamics in other cells types indicate that cortactin 
removal decreases lamellipodia persistence, which can be rescued by re-expression of 
a cortactin amino terminal fragment lacking the carboxyl terminal region [20], eliminating 
contributions from pS405/418 in this system.  These results differ from our work in 
MTLn3 cells, where cortactin removal results in enhanced persistence that can be 
rescued by re-expression of wild type cortactin.  It is likely that these observed 
differences are due to a combination of different cell types, chemotactic cues, and 
analysis of dominant, initial lamellipodia versus steady-state lamellipodia dynamics [62].  
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Interestingly, inhibition of ERK1/2 signaling during macrophage lamellipodia extension 
results in decreased lamellipodia stability, with similar kymograph profiles to EGF-
stimulated MTLn3 cells with S405/418A expression [64].  These studies provide 
supporting evidence for our observations.  
Through the use of phosphorylation-specific antibodies, we have analyzed the 
localization of cortactin pS405 and pS418 in tumor cells and tissue, as well as the 
signaling pathways regulating pS405/418 phosphorylation.  Through the use of these 
reagents, we have been able to validate and further clarify the role of pS405/418 in 
cortactin-based signaling.  Our functional studies of carcinoma motility and lamellipodia 
dynamics with phosphorylation-null constructs have shed additional light on the role 
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Figure 1. Specificity and validation of pS405 and pS418 phospho-specific 
cortactin antibodies. (A) Phospho-specific recognition of anti-cortactin pS405 and 
pS418 antibodies.  Clarified lysates (50µg) from 1483 cells transfected with Myc-tagged 
wild-type cortactin (WT), Myc-cortactin S405A, Myc-cortactin S418A or Myc-cortactin 
S405A,S418A point mutants were immunoblotted with affinity purified anti-Cort-pS418 
(left) and anti-Cort-pS405 (right) antibodies.  (B) Localization of pS418 cortactin in areas 
of motile and invasive actin dynamics. UMSCC2 cells (top row) were serum starved for 
16h prior to stimulation with 100ng/µl EGF for 1 h to induce lamellipodia formation, while 
UMSCC1 cells (middle row) were plated on FITC-conjugated gelatin coated coverslips 
(pseudocolored white) for 6 h to promote invadopodia formation.  Cells were fixed, 
permeablized, and labeled with TRITC-phalloidin (Actin), anti-cortactin (Cort) and anti-
cortactin-pS418 antibodies.  Arrows denote localization of pS418 cortactin with total 
cortactin and F-actin in lamellipodia (top) and to invadopodia (middle) coinciding with 
areas of active matrix degradation.  Bottom panels are magnified views of the indicated 
cellular region.  Bars, 10µM.  (C) Localization of pS418 cortactin in HNSCC tumor 
tissue.  Serial sections from a patient with invasive HNSCC were processed for 
immunohistochemistry with control IgG (Ctl), pS418 cortactin (pS418), total cortactin 
(Cort) and phospho-ERK1/2 (pERK) antibodies.  Sections were counterstained with 
hematoxylin.  Arrowheads indicate areas of peripheral pS418 cortactin and total 
cortactin enrichment.  Bar, 100µM.    
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Figure 2.  Growth factor-stimulated Erk 1/2 activation mediates phosphorylation 
of cortactin at serine 405 and 418. (A) Growth factor-induced phosphorylation of 
cortactin S405 and S418.  Serum starved UMSCC1 cells were stimulated with EGF 
(left) or FBS (right) for the indicated times. Cells were lysed and analyzed by Western 
blotting with anti-Cort-pS418 and anti-Cort-pS405 antibodies.  Blots were stripped and 
reprobed with a pan-cortactin antibody to confirm equal loading (bottom).  (B) 
Pharmacologic MEK inhibition inhibits cortactin S405 and S418 phosphorylation.  
UMSSC1 (left) and 1483 (right) cells were serum starved in the presence of the 
indicated selumetinib concentrations prior to stimulation with EGF for 20 min. Cortactin 
immunoprecipitated from cell extracts was assayed by Western blotting with anti-Cort-
pS418 and anti-Cort-pS405 antibodies.  Blots were stripped and reprobed with pan-
cortactin antibody as in (A) (bottom panels). Selumetinib efficacy was verified by the 
blotting of lyastes from selected timepoints with phospho-ERK1/2 (pERK1/2) and pan 
ERK1/2 antibodies (bottom).  All blots are representative images from 3-4 independent 
experiments. 
Figure 3. EGF-induced conversion of cortactin from 80kDa to 85kDa is impaired 
by Src and MEK1/2 inhibition.  EGF induces the p80kDa to p85kDa shift in HNSCC 
cells. Serum starved UMSCC2 (A) and 1483 (B) cells were treated with 100ng/ml EGF 
for the indicated times.  Clarified lysates were assayed by Western blotting with anti-
cortactin, anti-Cort-pS418, anti-cort-pS405, anti-Cort-pY421, anti-Src-pY418, anti-
pErk1/2 and total Erk1/2 antibodies as indicated. Red bars denote the position of the 85 
kDa cortactin form; black bars denote the 80 kDa form. (C) Inhibition of Src and MEK1/2 
kinase activity inhibits the cortactin “shift”. UMSCC2 cells were treated with vehicle 
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(DMSO), saracatinib, or selumetinib for 16 hrs in serum free media.  Cells were 
stimulated with 100ng/ml EGF for 1h, lysed and analyzed by Western blot analysis with 
an anti-cortactin antibody.  
Figure 4. Cortactin tyrosine and serine phosphorylation resultant of v-Src 
activation are not interdependent. (A) Schematic diagram of the cortactin point 
mutant constructs assayed for phosphorylation.  Mutated codons are denoted on the left 
and displayed with the corresponding mutant amino acid at the appropriate position 
within cortactin in red.  (B) Murine fibroblasts lacking endogenous Src, Yes and Fyn 
(SYF) were transfected with murine-specific cortactin siRNA and cultured for 48h to 
deplete endogenous cortactin.  Cells were subsequently co-transected with the 
temperature-sensitive v-Src construct La29 (tsLa29) and wild-type or the indicated myc-
tagged human cortactin point-mutant constructs at 41°C (non-permissive temperature). 
TPM; triple point mutant consisting of Y-F mutations at positions 421, 470 and 486.  
After transfection, cells were cultured at 41°C, then shifted to 35°C (permissive 
temperature) for 2 h to promote v-Src activation. Recombinant cortactin proteins were 
assayed by immunoblotting with anti-cortactin-pY421, anti-cortactin-pS405, anti-myc, 
anti-cortactin, and anti-β-actin antibodies. Note that the inability of cortactin to be 
phosphorylated on Y421 does not impact its ability to be phosphorylated on S405, nor 
does lack of S405 phosphorylation impact Y421 phosphorylation.  
Figure 5. Targeted inhibition of MEK1/2 inhibits HNSCC cell motility.  1483 and 
UMSCC1 cells (5x105) were starved for 24h in the presence of vehicle (DMSO) or 
increasing concentrations of selumetinib as indicated.  Cells were assayed for motility 
by electric substrate impedance sensing (ECIS) following stimulation with complete 
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media containing the matched selumetinib concentration for 24h. Data is displayed as 
slope values calculated from the linear part of ECIS tracings.  Bars represent mean ± 
SE.  *, p < 0.05 compared to DMSO treated control cells.  
Figure 6. Cortactin phosphorylation at serine 405 and 418 regulates carcinoma 
cell migration and adhesion. (A) Expression of GFP-cortactin constructs in MTLn3 
cells.  MtLn3 cells were transfected with murine-specific cortactin siRNA (Si) for 48h to 
silence endogenous cortactin expression.  Cells were subsequently transfected with the 
indicated human GFP-tagged cortactin wild-type and the various Erk1/2 
phosphorylation-null point mutant constructs.  Following transfection, cell lysates were 
immunoblotted with anti-cortactin, anti-GFP and anti-β-actin antibodies.  Solid 
arrowheads indicate the position of GFP-tagged cortactin variants; open arrowheads 
denote the position of endogenous cortactin.  (B)  Serine 405 and 418 phosphorylation 
is required for efficient carcinoma cell motility. MTLn3 cells transfected as in (A) were 
analyzed for cell migration by ECIS.  Cell impedance versus time plots for each 
transfected line are shown on the left; slope values calculated from the linear region of 
each plot are displayed on the right.  (C) Carcinoma cell spreading requires 
phosphorylation of cortactin S405 and S418.  Transfected MTLn3 cells were plated, with 
rates of spreading were monitored by ECIS tracings over time left.  Slope values from 
the linear regions are shown on the right. Bars represent mean ± SE for 3 independent 
experiments. *, P < 0.05 compared to control (ctl) cells. 
Figure 7.  Cortactin phosphorylation at serine 405 and 418 is required for 
lamellipodia persistence.  (A)  Kymographic analysis of MTLn3 lamellipodia.  Serum 
starved MTLn3 cells (Ctl) or cells transfected with the indicated cortactin siRNA and 
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cortactin constructs were monitored for dominant lamellipodia formation by live cell 
imaging following EGF stimulation.  Quantification of lamellipodia protrusion rates, 
length of extension, and time of lamellipodia persistence are shown for each 
experimental condition. >10 cells were analyzed for each group from > 3 independent 
experiments.  (B) Representative kymograms of each cell type.  Kymograms were 
constructed from 1-pixel wide lines drawn from the initial leading edge and in the 
direction of the dominant lamellipodia.  Cells were visualized by fluorescent microscopy 
using mCherry-b-actin as the lamellipodia marker.  Images were captured every 5 sec 
for a period of 15 min.  Black lines denote the baseline position of the leading edge prior 
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Study 4: Transgenic Model of Oral-esophageal Tumor Cell Invasion: 
Overexpression of Cortactin in Tumorigenic Mice 
 





Amplification of the chromosome locus 11q13 is frequently seen in squamous cell 
carcinomas of the head and neck (HNSCC) and results in overexpression of cortactin, a 
cytoskeletal protein that regulates actin dynamics.  Cortactin overexpression is 
associated with poor prognosis in patients and increased invasion and metastasis in 
vitro.  To investigate the role of cortactin in tumor progression we aimed to develop a 
transgenic model in which epitope-tagged murine cortactin was specifically 
overexpressed in the oral epithelia of C57BL/6 mice by means of the Epstein-Barr viral 
promoter ED-L2 (L2CortFL).  Founder lines were to be crossbred with p53-mutant 
(Trp53R245W) mice to mimic oncogenic progression commonly seen in HNSCC.  
Founder lines containing the L2-Cort or L2-Trp53R245W transgenes were successfully 
developed. However, protein expression of the transgenic cortactin construct or 
overexpression of p53R245W was not detected in the founder animals. Further studies 
will be needed to examine whether tumors originating in the oral epithelium that 
overexpress cortactin are more invasive and metastatic than tumors with normal 









 Each year there are 36,500 newly diagnosed cases of cancer, with 7,880 deaths 
being directly caused by tumors originating in the oral cavity and pharynx (Altekruse SF, 
1975-2007).  Over ninety percent of these oral-pharyngeal cancers arise from the 
squamous epithelia and are classified as head and neck squamous cell carcinomas 
(HNSCC).  The five-year survival rate of HNSCC remains less than 60%, and despite 
advances in diagnosis and management of the disease, these rates have not 
significantly improved in the past 20 years (ACS, 2010; Shiboski et al., 2000). The 
molecular alterations that lead to the progression of HNSCC have been extensively 
studied within the last five years with the goal of exploiting genetic modifications for 
treatment and chemoprevention (Le and Giaccia, 2003).   
 It is known that amplification of the gene which encodes cortactin (CTTN) is 
associated with poor prognosis in patients with HNSCC (Rodrigo et al., 2000). Cortactin 
is a multi-domain actin binding protein which was originally identified as a major target 
of v-Src infected cells (Wu et al., 1991).  Cortactin functions as a scaffolding protein to 
coordinate actin dynamics driving endocytosis, intracellular trafficking, motility, and 
invasion through interactions with actin-related protein (Arp)2/3 complex, either directly 
or indirectly via N-WASp (Daly, 2004). Cortactin is overexpressed in 50% of cell lines 
derived from HNSCC’s (Patel et al., 1996), and is believed to advance tumorigenesis by 
promoting cellular invasiveness and movement.  It is known that upregulation of 
cortactin mRNA causes increased cell motility and invasion in vitro (Huang et al., 1998; 
Patel et al., 1998) and metastasis in nude mice (Li et al., 2001).  However, the genetic 
role of cortactin overexpression in tumor progression and metastasis is not known.   
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 HNSCC is a highly aggressive and invasive disease largely driven by 
overexpression of EGFR (Kalyankrishna and Grandis, 2006). Recently our laboratory 
found a link between CTTN copy number and enhanced tumor cell invasion and motility 
downstream of EGFR through comparison of HNSCC cells with and without 11q13 
amplification (Rothschild et al., 2006). The increase in cell motility demonstrated by cells 
that overexpress cortactin is associated with increased Arp2/3 binding/activation and 
tyrosine phosphorylation of cortactin. Pretreatment of cells with the EGFR inhibitor, 
gefitinib, blocked cortactin tyrosine phosphorylation and cell motility. While these 
experiments indicate that cortactin overexpression directly drives HNSCC motility and 
invasion, validation of the role of cortactin in tumor progression can be best 
accomplished by the use of an in vivo cancer model. To this end, we have produced 
potential transgenic founder mice that express cortactin specifically in the oral cavity 
through use of the Epstein Barr virus ED-L2 tissue-specific promoter.  This promoter 
has been used successfully to target and overexpress cyclin D1, another 11q13 gene 
associated with HNSCC progression, to the oral epithelia of transgenic mice in other 
mouse models of oral cancer (Goessel et al., 2005; Opitz et al., 2002).   
 Mutations in the p53 gene are found in greater than 50% of HNSCC’s, and is 
believed to occur prior to 11q13 amplification in the current model of HNSCC 
progression (Boyle et al., 1993; Le and Giaccia, 2003). In addition, p53 mutations are 
linked to increased mRNA expression of EGFR in HNSCC (Grandis et al., 1998). Mice 
with dominant negative mutations of p53 have been successful in generating 
carcinomas in lung, breast, prostate, head and neck, and skin (Lang et al., 2004; Morris 
et al., 1998; Olive et al., 2004; Wijnhoven et al., 2005; Wu et al., 2002; Zhang et al., 
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2000; Zhang et al., 2006; Zhang et al., 2005). Our model is based on the most common 
p53 mutation seen in HNSCC, an R to W mutation at codon 245 located in the 
transactivation domain of the encoded protein (Petitjean et al., 2007). Like cortactin, 
transgenic mice overexpressing the R245W p53 mutant protein will be generated using 
the ED-L2 promoter.  
 The purpose of this study is to evaluate the role of cortactin overexpression in the 
development of carcinomas of the oral cavity.  Wild type cortactin will be specifically 
expressed only in the oral epithelia via the Epstein Barr virus (EBV) ED-L2 tissue 
specific promoter (Nakagawa et al., 1997).  Founder transgenic mice will be 
backcrossed into a C57BL/6 background, a strain of mice that is associated with tumor 
progression, and then crossed with p53 R245W animals.  The goal of this transgenic 
project is to mimic the genetic environment commonly seen in head and neck cancers 
and then use this model to examine and role of cortactin in disease progression.  We 
hypothesize that overexpression of wild-type cortactin will increase carcinogenesis in 
the oral cavity of oncogenic mice.   
 
Methods 
Generation of L2-Cort and L2-Trp53R245W mice. The FLAG-tagged cytomegalovirus 
(CMV)-driven cortactin expression construct pcDNA3FLAG2AB cortactin (FLAG-Cort) 
(Du et al., 1998) was used as the template for production of the cortactin construct. Site-
directed mutagenesis was performed on Trp53 murine cDNA (p53) to produce an R to 
W mutation at codon 245 (Trp53R245W). FLAG-tagged wild type murine cortactin 
(FLAG-Cort), and (Trp53R245W) were PCR amplified and subcloned into the Epstein-
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Barr virus ED-L2 vector with Mlu1 and Xho1 restriction sites. Generation of L2-Cort and 
L2-Trp53R245W was verified by sequencing. In preparation for microinjection, excess 
plasmid backbone was eliminated by digestion with EcoR1 and Not1 resulting in 3.1Kb 
and 2.5Kb fragments for L2-Cort, and L2-Trp53R245W, respectively. Fragments were 
given to the WVU Transgenic Rodent Facility for transgenic mouse production. Briefly, 
gene fragments were microinjected into the male pronucleus of single-cell embryos 
isolated from pregnant, superovulated FVB females.  Fertilized eggs were re-implanted 
in the oviducts of CD-1 foster females that had been previously mated with 
vasectomized CD-1 males.   
 
Genotyping. Potential founders were screened by PCR analysis from DNA isolated 
from tail tissue. Primers were generated to amplify a 350 Kb fragment within the L2 
promoter since this nucleotide sequence is unique to the transgene and not found within 
the mouse genome. Primers for genotyping were produced by Integrated DNA 
Technologies, Inc. (Coralville, IA) and are as follows:  L2-F 5’-
CTTAACACACCACACAGGTAGCAA-3’, L2-R 5’CTCTTAGTTTCTGGGTGTGA 
GAGGG-3’ Internal control primers were used during genotyping to verify the integrity of 
the PCR reaction. The following primers amplify a 425Kb fragment of the RX gene: RX-
F 5’-GGGAGTAGGGTTACTGGACTGAGGC-3’, RX-R 5’CGAGTATCCCTACTGCCTG 
GAAATC-3’ 
 
RNA isolation and RT-PCR.  Mouse tissues were harvested and stored in RNAlater 
(Qiagen) at 4°C overnight, and moved to -20°C for long-term storage. RNA was purified 
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using an RNeasy Plus kit (Qiagen). Total RNA were solubilized in RNase-free H2O and 
quantified in duplicate by measuring the optical density (OD) at 260 nm. Purity of RNA 
was assured by examining OD260/OD280 ratio.  cDNA was synthsized using SuperScript 
III First-Strand Synthesis Supermix (Invitrogen) according to the manufacturers’ 
protocol. Two microliters of the cDNA reaction mixture was added to a PCR reaction 
with the following primer sets:    P53-F 5’-CACAGTCGGATATCAGCCTAG-3’ P53-R 




Immunohistochemistry. Dissected mouse tongues were cryoprotected in 30% sucrose 
in PBS, oriented in TBS tissue freezing medium, and stored at -80°C until sectioned on 
a cryostat. To block nonspecific labeling, sections were immersed in PBS containing 
0.6% H2O2 and 5% methanol for 1 hour at RT. Samples were washed in PBS and then 
further blocked in PBS containing 5% heat-inactivated normal serum and 0.1% Triton X-
100 at RT for 1-2 hours. Primary antibodies were diluted in PBS containing 4% serum 
and 0.1% Triton X-100. Samples were incubated overnight in the primary antibody 
solution at 4°C. The antibodies used in this study were: p53 (1:1,000, #9802, Cell 
Signaling); p53 (1:500, AB-7, Calbiochem); Cortactin (1:1000, EP1922Y, Novus 
Biologicals); and DDDDK (FLAG) (1:1000, ab21536, Abcam). Slides were rinsed with 
PBS and incubated with appropriate biotinylated secondary antibodies (1:200, Vector 
Laboratories, Burlingame, CA). Slides were then rinsed with PBS or incubated with elite 
ABC reagent (Vector Laboratories) as described by the manufacturer (biotinylated). 
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Immunoreactivity was visualized with 0.05% 3,3 -diaminobenzidine tetrahydrochloride 
(DAB, Sigma) with 0.01% H2O2 in 0.5 M Tris pH 7.65. Slides were counterstained with 
hematoxylin and were digitally photographed on an Olympus ZX70 Provis microscope 
(Olympus, Center Valley, PA, USA) with a 20x/0.70 UPlanApo objective and an 
Optronics MicroFire 1600×1200 color CCD camera (Optronics Inc) using the 
StereoInvestigator imaging package (MBF Bioscience). 
Immunoprecipitations. Freshly disected mouse tissues were homogenized in 500 μl of 
ice-cold lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20 mM HEPES at pH 7.4, 20% 
glycerol, 0.1% Triton X-100, and 10 μM DTT) with a mechanical homogenizer. Clarified 
lysates (500µg) were immunoprecipitated with anti-cortactin (4F11) for 2 hours at 4°C 
before being resolved by SDS-PAGE. Cultured cells were lysed in NP40 Buffer (20 mM 
Hepes-KOH, pH 7.8, 50 mM KCl, 1 mM EDTA, and 1% NP40). Clarified lysates (500 µg) 
were incubated for 2 h at 4°C with 40 µl of EZview Red ANTI-FLAG M2 Affinity Gel 
(Sigma).  Immune complexes were collected by centrifugation, washed twice with NP40 
Buffer, separated by SDS-PAGE, and Western blotted with antibodies as described.  
Cell lines, transfections and Western blotting. HNSCC cell lines UMSCC1 (Jeffery 
Myers, MD Anderson Cancer Center) and 1483 (David Raben, University of Colorado) 
were cultured as previously described (Rothschild et al., 2006).  SYF+/+ (Src+/+Yes-/-Fyn-
/-) cells were obtained from the American Type Culture Collection. For transient 
transfections, 3 x 106 cells were incubated with 2 µg plasmid construct or siRNA.  Cell 
lines were transfected with the Nucleofector I device (Amaxa Biosystems). Western 
blotting of cell lysates was conducted as described (Rothschild et al., 2006).  The 
following antibodies were used: -actin (JLA-20, 1:5,000, Calbiochem); p53 (1:1,000, 
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#9802, Cell Signaling); p53 (1:500, AB-7, Calbiochem); Cortactin (1:1000, 4F11, 
Upstate); and DDDDK (FLAG) (1:1000, ab21536, Abcam).  
 
Immunofluorescence labeling and confocal microscopy. Cells were fixed with fresh 
4% formaldehyde and permeabilized with 0.4% Triton-X/PBS. Primary antibodies were 
diluted in 5% BSA/PBS. Antibodies used were: p53 (1:1,000, #9802, Cell Signaling); 
p53 (1:500, AB-7, Calbiochem); Cortactin (1:1000, 4F11, Upstate); and DDDDK (FLAG) 
(1:1000, ab21536, Abcam).  Secondary antibodies used were Alexa Fluor 405 goat anti-
rabbit and Alexa Fluor 647 goat anti-mouse (Molecular Probes). F-actin was labeled 
with rhodamine-conjugated phalloidin (Molecular Probes).  Cells were mounted in 
Fluoromount-G (Southern Biotech), or ProLong® Gold antifade reagent with 
DAPI (Invitrogen) and imaged with a Zeiss LSM510 confocal microscope using AIM 
software (Carl Zeiss MicroImaging). 
 
L2 luciferase reporter assays.   3x106 cells were transfected with 800 ng (low) or 3.2 
µg (high) of pXP2 or pL2-782, or with 2 µg of pcDNA3-FLIP plasmids and 400 ng (low) 
or 1.6 µg (high) of multimeric NF-kB pGL2 luciferase vector.   1.25 µg of the Renilla 
pRL-TK vector was added to all treatments.  NF-kB pGL2 vector and pRL-TK vectors 
were kind gifts from Christian Stehlik (Northwestern University, Chicago, IL), and pXP2 
and pL2-782 were received from Anil Rustgi (University of Pennslyvania).  pcDNA3-
FLIP plasmids were made as described previously (Chanvorachote et al., 2005). 
Transfections were performed using the Nucleofector I device (Amaxa 
Biosystems).  The following day luciferase activity was determined using a dual-
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luciferase reporter assay system kit (Promega). The activity of the L2 or NF-kB reporter 
luciferase was standardized to that of Renilla luciferase.    
Results 
Experimental rationale and generation of Tg(L2-Cttn)B6 or Tg(L2-Trp53R245W)B6 
mice.  To investigate the role of cortactin in tumor progression in an animal setting, we 
sought to develop transgenic mice overexpressing FLAG-tagged murine cortactin 
specifically in the oral epithelia of C57BL/6 mice. Because we do not anticipate 
overexpression of cortactin alone to drive carcinogenesis, a tumorigenic background 
was devised in order to examine whether tumors that overexpress cortactin are more 
invasive and metastatic. Such a background will be supplied by the construction of 
transgenic mice expressing the dominant-negative mutant p53 protein (R245W) 
specifically in oral epithelia.    Cross-breeding of mice generated will produce animals 
containing p53 dominant-negative driven tumors that overexpress cortactin (see Figure 
1A).  These mice will allow for the direct evaluation and impact of cortactin 
overexpression on motility and invasion in a transgenic oral cancer model. Potential 
founder animals were genotyped using primers specific to the L2 promoter which 
resulted in a ~350 Kb fragment in animals carrying the L2-Cttn or L2-Trp53R245W 
transgenes (Figure 1A, B). To minimize the possibility of false negatives, primers that 
amplify a 425Kb fragment of the mouse genome were also included in all PCR 
genotyping reactions.  One hundred and fifteen, and forty-two potential founders were 
genotyped for the L2-Cttn or L2-Trp53R245W transgene, respectively. Two positive 
animals were identified in each line (Table 1).  Founder animals were backcrossed with 
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C57BL/6 mice, a strain commonly favored for use in transgenic cancer models due to a 
low incidence of spontaneous tumors (Smith et al., 1973).  
 
Characterization of transgenic lines. Lines were characterized phenotypically for 
cancer onset, transgene mRNA transcription and protein expression. One of the Tg(L2-
Cttn)B6 lines (299) exhibited mRNA expression of the transgene in the tongue and 
esophagus (Figure 2A, B).  Within the same animal mRNA expression is not detected in 
the small intestine or liver, validating the tissue-specific expression of the L2 promoter.  
Next we analyzed protein expression of the L2-Cttn transgene 299 line in the mouse 
tongue. Clarified lysates from homogenized tongue tissues were immunoprecipitated 
with and anti-cortactin antibody, and then probed for cortactin expression.   No 
differences are detectable in cortactin protein levels between the Tg(L2-Cttn)B6 mouse 
line and a non-transgene positive matched littermate (B6) (Figure 2C). 
Immunoprecipitation and western blotting with an anti-FLAG antibody were also 
conducted, but we were unable to detect the FLAG-tagged cortactin protein (data not 
shown).  In addition, immunohistochemistry was conducted on frozen tissue sections of 
the tongue (Figure 2D) and esophagus (data not shown). Similar staining is seen in 
Tg(L2-Cttn)B6 and matched littermates, indicating that transgene mRNA expression did 
not result in increased levels of cortactin protein. Similar staining was also seen with 
use of several anti-FLAG antibodies. Importantly, no morphological differences were 
detected in the oral epithelia of 299 line compared to control animals.  
 Tg(L2-Trp53R245W)B6 animals were also characterized for transgene mRNA and 
protein expression. To specifically detect the L2-Trp53R245W transgene from the 
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expression of the endogenous p53 alleles, primers were generated to complement 
unique DNA sequences introduced during generation of the construct. The forward 
primer flanks an altered Xho1 restriction site, and the reverse primer flanks the R245W 
mutation, resulting in specific amplification of the L2-Trp53R245W transgene (Figure 3A, 
B).   One of the Tg(L2-Trp53R245W)B6 lines (634, Table 1) demonstrated tissue-specific 
mRNA expression of the Trp53R245W transgene (Figure 3C) and was further 
characterized for protein expression. Mutant p53 is known to accumulate in cells, unlike 
the wild type counterpart which is expressed at low levels (Iggo et al., 1990; Rotter, 
1983). High levels of p53 in IHC patient samples are used as a predictive marker of p53 
mutant status (Bartek et al., 1991; Soussi and Beroud, 2001).  No differences were 
identified in p53 protein expression in Tg(L2-Trp53R245W)B6  and B6 lines by 
immunohistochemical analysis of mouse tongues (Figure 3D) or esophagus (data not 
shown). In addition, no pathological abnormalities were identified in the Tg(L2-
Trp53R245W)B6  at ages up to 18 months.  
 
Evaluation of L2 promoter activity in HNSCC cell lines. To determine a possible 
mechanism for the undetectable protein expression levels in the Tg(L2-Cttn)B6 or 
Tg(L2-Trp53R245W)B6 mice, we evaluated the activity of the L2 promoter in HNSCC cell 
lines. 1483 and UMSCC1 HNSCC cell lines were transfected with luciferase reporter 
constructs fused to the L2 promoter (pL2-782) or a promoterless (pXP2) sequence. 
Fibroblast cells (SYF+/+) were also transfected and used as a negative control. pL2-782 
activity was higher in the 1483 and UMSCC1 cell lines than the SYF+/+ control (Figure 
4A). Activity of the pXP2 construct was low in all three lines tested. To determine if 
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transfection of increasing amounts of the pL2-782 construct resulted in a corresponding 
increase in L2 promoter activity, lower (lo) and higher (hi) amounts (see Materials and 
Methods) were transfected into 1483, UMSCC1 and SYF+/+ cells (Figure 2B). The 
HNSCC lines tested display a dosage effect, with increasing L2 activities corresponding 
to increased levels of the reporter construct (Fig. 4B). These results suggest that the L2 
promoter is active in the HNSCC lines. However, there is also a marked response to 
increasing amounts of the pXP2 construct in the UMSCC1 cell line, indicating that some 
of these increases may be non-specific. In addition, the activity levels of the L2 
promoter even at high levels (~0.01 RLU) is much lower than endogenous NF-kB 
activity in the same cell lines (~7 RLU) (Figure 4C). While these values cannot be 
directly compared, these results suggest that L2 promoter activity, though specific, is 
very low in HNSCC cell lines.  
 
Detection of L2 driven cortactin and p53R245W protein expression in HNSCC cell 
lines. To determine if the low levels of L2 promoter activity led to a detectable protein 
product in HNSCC cell lines, 1483 cells were nontransfected, or transfected with 
constructs encoding FLAG-tagged cortactin behind a CMV or L2 promoter sequence 
(Figure 5A). Fibroblast cells (SYF+/+) were used as a negative control. Anti-FLAG beads 
were used to immunoprecipitate FLAG-tagged cortactin from clarified lysates. CMV-
driven cortactin expression led to high cortactin protein levels in 1483 and SYF+/+ cell 
lines detected by Western blotting with anti-FLAG and cortactin antibodies (Fig 5A). 
However, cortactin protein levels did not increase over non-transfected controls when 
driven by the L2 promoter construct.  We also evaluated protein expression in the 1483 
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cells by immunofluorescence and confocal microscopy (Figure 5B). Exogenously 
expressed cortactin was detected in cells transfected with the CMV, but not the L2-
driven cortactin constructs.  
 We additionally evaluated protein expression of p53 in the 1483 cell line (Figure 
6). Cells were non-transfected (NT) or transfected with CMV-Trp53R245W or L2-
Trp53R245W, and then labeled with rhodamine phalloidin (red), DAPI (blue), and two anti-
p53 antibodies (a sheep monoclonal (green) and a rabbit monoclonal (purple)). Nuclear 
accumulation of p53 was visualized by confocal microscopy by both antibodies in cells 
with CMV-Trp53R245W.  There was no detectable increase in p53 protein levels in cells 
transfected with L2-Trp53R245W compared to non-transfected controls.  
 
Discussion 
 Transgenic animal models of tissue-specific cancers are valuable tools in gaining 
insight in the molecular mechanisms promoting carcinogenesis and tumor progression.  
Furthermore, the animal strains and the cell lines derived from them serve as potentially 
valuable platforms for measuring new therapies and preventative approaches.  Our 
attempt to generate a transgenic oral cancer model to directly evaluate the impact of 
cortactin overexpression on cancer cell motility and invasion ultimately failed. We were 
able to produce Tg(L2-Cttn)B6 and Tg(L2-Trp53R245W)B6 mouse strains which 
expressed trangene mRNA, but we were unable to detect a transgene-driven protein 
product. In this study we created transgenic lines through pronuclear microinjection of 
mouse embryos with DNA fragments which results in random insertion of the transgene 
DNA into the mouse genome. The number of transgene inserts into the genome or the 
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chromosomal location at which a transgene inserts is completely random with this type 
of approach. Therefore, it is likely in our Tg(L2-Cttn)B6 and Tg(L2-Trp53R245W)B6 lines 
had trangene insertions in areas regulated by chromatin configurations that suppress 
transgene expression, leading to a undetectable protein product.  Higher numbers of 
founder animals would be needed to potentially overcome these effects, and were not 
available to generate for this study due to time and financial restraints. 
 The L2 promoter was unable to produce measurable amounts of cortactin or 
p53R245W protein in HNSCC cell lines. Therefore, we cannot rule out the possibility that 
the transgene fragments themselves are unable to support expression of cortactin or 
p53R245W in a mouse model. However, it is also possible that these transformed cultured 
HNSCC cell lines have lost the expression of the tissue-specific transcription factors 
necessary to activate the L2 promoter. Without an oral epithelial cell line to use as a 
positive control, we cannot determine if this is, in fact, the case.   
 To date, one transgenic mouse model of cortactin has been reported (van 
Rossum et al., 2006). This study aimed to examine the role of cortactin in a breast 
cancer, in which CTTN amplification is associated with increased risk of relapse and 
death (Hui et al. 1998). Mammary gland-targeted overexpression of cortactin alone, or 
in combination with cyclin D1 overexpression, did not result in increased breast tumors 
compared with control mice. However, this study was limited in multiple ways that could 
explain why cortactin had no effect on carcinogenesis. First, the cortactin transgene was 
driven by the mouse mammary tumor virus and cortactin protein expression was only 
detected during lactation. Even if overexpression of cortactin alone could drive 
tumorigenesis, this window of time may be too small to show effects. Secondly, the 
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strain of mice in this study (FVB/N) showed a very high incidence of spontaneous 
mammary tumors (38%), making cortactin-driven tumorigenesis or progression difficult 
to unequivocally assess.  
 Recently, two studies have analyzed cortactin knockout MEFs derived from mice 
harboring floxed cortactin alleles (Cttnflox/flox).  Okabe and colleagues (Tanaka et al., 
2009) found that cortactin depletion did not alter the F-actin architecture, the localization 
of actin binding proteins to actin networks, or cell motility measured by wound healing 
and transwell migration. The other report (Lai et al., 2009) confirmed that cortactin 
knockout MEFs displayed little to no alterations in Arp2/3-mediated actin networks. 
However, cortactin was found to be necessary for random and directional cell migration 
through the modulation of the Rho-GTPase CDC42. The role of cortactin depletion on 
epithelial cell migration or the impact of cortactin knockout on cell migration in  Cttnflox/flox 
mice was not evaluated in either of these studies.  
 Due to the inherent limitations of the current research examining cortactin in an 
animal model and the wealth of research implicating cortactin as an important mediator 
of human disease, additional studies are necessary and warranted to further define the 
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Figure 1. Genotyping of L2 transgenic lines. A) Cartoon of C57BL/6 (B6) transgenic
mouse lines with specific-targeting of p53 Tg(L2-Trp53R245W)B6, and cortactin Tg(L2-
Cttn)B6 to the oral cavity. Crossing these lines will produce mice with targeted
overexpression of both transgenes Tg(L2-Trp53R245W,L2-Cttn)B6. B) Schematic
representation of p53 (L2-Trp53R245W) and cortactin (L2-Cttn) transgenes. The red bar
denotes the area of the transgene amplified in PCR genotyping analysis. C) Genotyping
to identify potential founder animals. PCR reactions were carried out with GoTaq Green
Master mix in the presence of two primer sets: 1) primers design to amplify a 351 kb
fragment within the L2 promoter, and 2) Primers amplifying a 425 Kb fragment of the
murine genome (internal PCR control). No DNA (lane 1), DNA from diluted transgene
fragments (lane 2, 3), DNA isolated from control (lane 3, 4) or experimental mice (lanes
5-8) were added to the PCR master mix described above. Reactions were resolved on a
2% agarose gel and experimental samples were analyzed in duplicate. An animal
carrying the L2-Cttn, or L2-Trp53R245W transgene will display a band and 351Kb and 425



















































Figure 2. Cortactin mRNA and protein expression in L2-Cttn mice. A) Schematic
representation of the flag-tagged cortactin (L2-Cttn) transgene. The yellow bar denotes
the area of the transgene amplified in RT-PCR analysis. B) Tissue-specific expression of
Cttn mRNA in the tongue and esophagus. RNA was isolated from the tissues listed and
RT-PCR was performed. C) Mouse tongues were homogenized and clarified lysates
were evaluated for cortactin protein expression. Cortactin was immunoprecipitated from
Tg(L2-Cort)B6 and littermate control (B6) mice with an anti-4F11 (cortactin) antibody and
then immunoblotted with anti-4F11 antibody. β-actin was used as a loading control for the
total cell lysate (input). D) Immunohistochemistry of cortactin protein expression in
























































Figure 3. p53 mRNA and protein expression in L2-Trp53R245W mice. A) Schematic
representation of the L2-Trp53R245W transgene. The yellow bar denotes the area of the
transgene amplified in RT-PCR analysis. B) Validation of Trp53 mutant-specific DNA
amplification. Primers were generated flanking an altered Xho1 restriction site and the
R245W mutation. A DNA fragment corresponding to 700 kb is only generated with the
construct that contains the modified Xho1 site and R245W mutation. C) Tissue-specific
expression of Trp53R245W mRNA in the tongue and esophagus. RNA was isolated from
the tissues listed and RT-PCR was preformed on Tg(Trp53R245W)B6 mice and littermate
controls (B6). D) Immunohistochemistry of p53 expression in Tg(Trp53R245W)B6 and B6




Table 1. Summary of Transgenic Cortactin and p53R245W
mouse lines.      
Line Tg(L2-Cttn)B6 Tg(Trp53R245W)B6
Mouse ID 299 300 438 634
Generation N5 N3 N2 N2
mRNA 
expression Yes No No Yes


































Figure 4. Analysis of the L2 promoter in HNSCC cell lines. A) pL2-782 luciferase (green)
and the promoterless pXP2 luciferase (blue) activity in HNSCC cells (1483 and
UMSCC1) and fibroblasts (SYF+/+). B) The experiment shown in (A) was repeated with
increasing amounts of the pXP2 or pL2-782 constructs. C) NF-kB luciferase activity in
1483, UMSCC1 and SYF+/+ cells nontransfected (NT) or cotransfected with high (hi) or
low (lo) amounts of FLIP to induce activation of NF-kB. This experiment was used as a



















































Figure 5. Analysis of L2-Cttn protein expression in HNSCC cell lines. A) 1483 and
SYF+/+ cell lines were nontransfected (NT) or transfected with plasmids expressing flag-
tagged cortactin from a CMV (CMV-Cttn) or L2 (L2-Cttn) promoter. Clarified cell lysates
were immunoprecipitated with anti-FLAG beads and then blotted with anti-FLAG and
anti-cortactin antibodies. Total cell lysates were blotted with anti-FLAG, anti-cortactin,
and anti-actin antibodies. C) 1483 cells were nontransfected (NT) or transfected with
CMV-Cttn or L2-Cttn. Cells were fixed, permeablized and labelled with Rhodamine
phalloidin (red), anti-FLAG (blue) and anti-cortactin antibodies (green).
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Figure 6. Analysis of L2-Trp53R245W protein expression in HNSCC cell lines. 1483 cells
were nontransfected (NT) or transfected with plasmids expressing p53R245W from a CMV
(CMV-Cttn) or an L2 (L2-Cttn) promoter. Cells were fixed, permeablized and labelled






 Taken together, the studies presented throughout this dissertation shed new light 
on pathways that control cellular invasion in HNSCC that may contribute to the 
metastatic process. We have demonstrated several novel findings as to how Src kinase 
activity regulates the metastatic phenotype of cancer cells through the formation of 
invadopodia. Saracatinib (AZD0530), a recently developed Src kinase inhibitor currently 
in phase I/II clinical trials (Kopetz et al., 2007) was reported to have anti-invasive effects 
in several model systems (Green et al., 2009; Koppikar et al., 2008; Nozawa et al., 
2008). In Study 1 we show that the Src inhibition by saracatinib prevents the formation 
of invadopodia and related ECM degradation in HNSCC lines and results in decreased 
cell invasion and lymph node metastasis in nude mice. These results point to a model in 
which saracatinib exhibits anti-invasive effects in HNSCC by preventing invadopodia 
formation. These results have subsequently been confirmed in breast cancer models 
using the Src inhibitor dasatinib (Pichot et al., 2009), suggesting that blocking 
invadopodia formation may be a universal mechanism in suppressing invasion in Src-
targeted therapies within multiple tumor types.  
 In Study 2 we further define how Src tyrosine kinase regulates invadopodia 
assembly and maturation. We demonstrate that Src activation is necessary and 
sufficient to target actin-associated proteins. However, regulated WT Src must be 
present for invadopodia to mature into functional matrix-degrading structures (see 
Figure 1). These results are consistent with the scarcity of activating Src mutations in 
human tumors (Summy and Gallick, 2003; Summy and Gallick, 2006). Therefore this 
study is the first to present evidence demonstrating that oncogenic forms of Src require 
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a WT counterpart to elicit full invasive potential, which has been previously overlooked 
in the field.  
 
 We are able to clearly demonstrate in Study 2 that WT Src directs invadopodia 
maturation. However, the mechanism by which this occurs is unknown. Since 
constitutively-active and kinase dead forms of Src do not rescue for WT Src function, it 
is attractive to speculate that cycles of Src activation and inactivation are necessary to 
temporally and spatially regulate the linking of the actin cytoskeleton to the degradative 
(protease activating/delivering) machinery. However, until activation/inactivation tracing, 
such as employed by FRET (fluorescence resonance energy transfer)-base techniques 
are available on a single molecule level, precise mechanistic testing will be difficult to 
achieve. Future studies are also needed to evaluate the targets of WT Src that are 
responsible for mediating preinvadopodia maturation.  
 It is clear that Src activation is tightly linked to phosphorylation of several 
cytoskeletal proteins known to localize to invadopodia sites, including cortactin (see 
Figure 1  Schematic illustrating Src regulation in invadopodia maturation. 
Constituently active Src is necessary and sufficient to target actin-associated proteins 




Study 1, and 2). Thus far, it is not known if Src is directly phosphorylating these targets 
to regulate invasion or if there are intermediate kinases downstream of Src responsible 
for transmitting the Src-generated signals responsible for these effects.  We 
demonstrate that Src kinase activation in concert with WT Src activation/inactivation is 
sufficient to promote and regulate invadopodia dynamics in cell lacking other Src family 
kinases (Yes and Fyn; Study 2). However, we cannot rule out that other Src family 
members can potentially play a redundant role. Several Src family members that are 
overexpressed in human cancers are known to phosphorylate cortactin, including Arg 
and Abl kinases, so future work should aim to understand what role these proteins play 
in Src-mediated invasion programs. Such studies would provide further insight into the 
molecular mechanisms that govern cancer invasion, but from a current therapeutic 
standpoint, results from studies may have minimal impact since most designed Src 
inhibitors to date (including saracatinib) lack strict Src specificity, targeting all of the 
above-mentioned kinases in addition to Src (Lombardo et al., 2004; Manley et al., 
2005).  
 Studies 1 and 2 support a model in which WT Src overexpressed in HNSCC cells 
primes the cell for an invasive phenotype through production of invadopodia. However, 
it is highly likely that Src activation is reliant upon overactivated upstream pathways 
commonly deregulated in HNSCC. Like Src, EGFR is commonly overexpressed in 
HNSCC cases (Grandis and Tweardy, 1993), but activating mutations are rare (Lee et 
al., 2005; Loeffler-Ragg et al., 2006). In Study 3 we demonstrate that treatment of 
HNSCC cells with EGF leads to phosphorylation of cortactin on Src-targeted tyrosine 
residues (Y421) and ERK1/2-targeted serine residues (S405, S418). Using novel 
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phosphorylation-specific antibodies against S405 and S418, we challenge previous 
reports (Martinez-Quiles et al., 2004) suggesting that cortactin serine and tyrosine 
phosphorylation are independent, mutually exclusive events. We show that these 
phosphorylation events can occur simultaneously in Src transformed cells (Study 3). In 
fact, serine and tyrosine phosphorylated cortactin localizes to motile and invasive 
structures such as lamellipodia, invadopodia, and to the invasive fronts of tumor cells in 
vivo (Studies 2 and 3). Therefore, it is highly likely that both serine and tyrosine 
phosphorylation of cortactin are necessary for supporting invasive tumor movement. 
Tyrosine (Study 1 and 2) and serine phosphorylation (Ayala et al., 2008) of cortactin is 
necessary for efficient invadopodia degradation. In addition, we identify S405/418 
phosphorylation as an important mediator of cancer cell motility and adhesion, and a 
novel regulator of lamellipodia dynamics, two cellular functions necessary for efficient 
cell motility.  
 The understanding of tumor initiation and progression has advanced significantly 
through the use of genetically engineered mouse models (Walrath et al., 2010).  
However, animal models of tumor cell invasion and metastasis, the leading cause of 
cancer-associated death, are desperately needed to gain understanding of the 
molecular mechanisms that drive this process and identify potential targets of 
therapeutic intervention. HNSCC is an highly aggressive and invasive disease in which 
mouse models are particularly lacking (Lu et al., 2006). In Study 4 we attempted to 
create a mouse model of oral cancer to determine the role of cortactin in driving 
invasion and metastasis in vivo.  For unknown reasons, the transgene constructs did 
not result in increased protein expression, and our approached ultimately failed. Future 
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studies are required to decipher how cortactin, and other motility related proteins, 
function in vivo during cancer cell invasion and metastasis.  
 Real-time live imaging of cancer cells is another area of emerging research that 
will significantly increase our knowledge of the metastatic process in live animals 
(Timpson et al., 2009). Capturing the movement of cancer cells away from the primary 
tumor, and subsequent invasion into the blood stream is a technically difficult task that 
requires capturing a sporadic event in an inaccessible environment. Intravital imaging of 
GFP-tagged breast tumor demonstrated that cells form invadopodia-like protrusions 
(Yamaguchi et al., 2005). As intravital imaging techniques advance, studies should 
focus on imaging invadopodia specific markers, such as Src and cortactin, to progress 
the identification and function of invadopodia in vivo.  In addition, visual analysis of 
invadopodia-mediated interaction with ECM components would supply a platform for 
testing anti-invasive therapies that have been successful in blocking invadopodia 
formation and cell invasion in cell culture models.  These studies would highly impact 
our understanding of the metastatic process and potentially impact therapeutic 
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Abstract Coordinated regulation of the actin cytoskele-
ton is central to cell motility, invasion and metastasis. Head
and neck squamous cell carcinoma (HNSCC) is a highly
invasive disease displaying frequent lymph node metasta-
sis, compounding patient management. HNSCC
progression is characterized by frequent amplification of
chromosome segments 3q26-29, 8q23-24 and 11q13,
events that are associated with poor patient outcome. The
relative frequency of these amplification events and cor-
relation with invasive disease raises the potential that these
regions harbor actin regulatory genes important in facili-
tating reorganization of the actin cytoskeleton to promote
tumor invasion. Identification of the actin cytoskeletal
regulatory genes located within the 3q26-29, 8q23-24 and
11q13 amplicons will provide an important first step
towards the comprehensive understanding of the molecular
events that govern invasion and metastasis in HNSCC and
other tumors containing these amplifications. We utilized
Ensembl MartView to conduct a gene mining analysis
within chromosome segments 3q26-29, 8q23-24 and 11q13
to identify known and predicted regulators of actin-based
cell movement, tumor invasion and metastasis. All exam-
ined chromosomal regions contain genes known that
regulate the actin cytoskeleton, with several (PI3-kinase
alpha, focal adhesion kinase (FAK) and cortactin) known
to promote invasion in HNSCC and other carcinomas.
Additional genes known to regulate motility and invasion
were also identified. Amplification of chromosome 3q26-
29, 8q23-24 and 11q13 therefore results in known or pre-
dicted overexpression of several key mediators that can act
alone or potentially act in concert to promote actin-based
cell invasion in HNSCC and other cancer types.
Keywords Actin  Gene amplification 
Head and neck squamous cell carcinoma  Invasion 
Metastasis  Motility
Introduction
Head and neck squamous cell carcinoma (HNSCC)
exhibits a propensity for local-regional invasion and cer-
vical lymph node metastasis. Invasive HNSCC complicates
patient management contributing to the damage of sur-
rounding soft tissue structures [1]. Patient outcome directly
correlates with the degree of local and regional invasion
[2]. Although it has long been recognized that invasive
HNSCC is a negative prognostic indicator, the lack of a
universal molecular ‘‘metastasis signature’’ has hampered
the understanding of the signaling pathways that underlie
HNSCC invasion and metastasis [3]. While recent advan-
ces in screening gene expression arrays have begun to
identify candidate genes responsible for regulating motility
and invasion in HNSCC [4, 5], a comprehensive under-
standing of the factors contributing to HNSCC invasion is
still emerging.
Cancer cell motility and invasion involves a complex
and integrated series of events that are primarily controlled
by regulation and reorganization of the actin cytoskeleton
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[6, 7]. Regulation of actin polymerization is responsible for
the formation of protrusive structures that are essential for
tumor cell movement and invasion, including filopodia,
lamellipodia and invadopodia. Formation and turnover of
these structures require the coordinate activity of actin-
binding and modifying proteins [7]. Subsequent stabiliza-
tion of protrusive structures is accomplished by integrin-
mediated adhesion to the extracellular matrix (ECM),
linking the ECM to the actin cytoskeleton and serving the
additional role of coordinating signal transduction events
that regulate cell movement [8]. The proper synchroniza-
tion of these of protrusion and adhesive events is required
for net cell movement from the primary tumor site into
surrounding tissues and vasculature [9].
Signaling pathways involved in mediating chemotatic
cues from the extracellular environment that impact the
actin cytoskeleton to initiate motility have been and con-
tinue to be an area of intense study. Several protein groups
have been implicated in cancer cell motility and invasion,
most notably receptor and non-receptor tyrosine kinases,
integrin-associated proteins and Rho-family GTPases [10–
13]. For protrusive events, the Rho family GTPases Cdc42
and Rac are intimately involved in mediating upstream
signals that ultimately impact the terminal endpoint of
these pathways, centering on activation of the Wiscott-
Aldrich syndrome (WASp) superfamily of actin nucleation
factors [6]. WASp proteins in turn enhance the production
of free barbed ends from existing F-actin filaments at the
cell cortex by activation of the actin related 2/3 (Arp 2/3)
complex [14]. The resulting actin polymerization by Arp2/
3 initiated at the inner face of the plasma membrane pro-
vides the internal force to push the membrane forward and
begin cell movement. Actin protrusion at the cell periphery
is central to the formation of filopodia and lamellipodia
during cell motility, and well as invadopodia during tumor
cell invasion [7]. In addition to cortical actin regulation,
Rho GTPases also govern integrin containing cell-sub-
stratum adhesion turnover, polymerization and contraction
of actin filaments within cytoplasmic stress fiber networks.
Along with actin-based cell protrusion, the turnover of
integrin containing adhesions is central to cell motility and
invasion [15]. Changes in genes utilized in actin-based
motility either by mutation or altered expression levels are
observed in HNSCC and other carcinomas at every step in
these signaling cascades, from transmembrane receptors to
terminal effector proteins [16, 17].
Sequential accumulation of chromosome gains and
deletions are common in HNSCC and assists to drive tumor
progression. Although chromosomal deletions outnumber
amplifications in HNSCC [18], amplification of select
chromosomal segments has been shown to positively cor-
relate with increased regional metastasis [19]. The
cytogenetic alterations associated with HNSCC have been
reviewed elsewhere and have identified several genes with
potential pro-metastatic roles [18, 20]. However, a com-
prehensive analysis of the most frequently amplified
chromosomal segments in HNSCC to identify elevated
gene numbers that participate in actin cytoskeletal
remodeling during motility and invasion has not been
reported. In this review we have analyzed three of the most
commonly amplified chromosomal segments in HNSCC;
3q26-29, 8q23-24, and 11q13 [21] to identify genes known
or predicted to regulate the actin cytoskeleton during
HNSCC motility, invasion and metastasis. Data mining of
the human genome to find actin-cytoskeleton associated or
regulatory genes on these chromosomal segments was
conducted using Ensembl MartView (http://www.ensembl.
org/Multi/martview). The associated Gene Ontology (GO)
[22] terms for the biological processes, molecular functions
and cellular components of all currently recognized gene
products within each chromosomal segment were exported
and reviewed. Genes with GO terms associated with the
actin cytoskeleton, cell motility and invasion were identi-
fied and further investigated by a literature search for
evidence of amplification or protein overexpression in
HNSCC or other carcinomas. Key genes with putative or
demonstrated roles in HNSCC motility and invasion,
known or predicted interactions between different gene
products, and the how such interplay potentially contrib-
utes to HNSCC motility and invasion are presented and
discussed.
Chromosome 3q26-29
Chromosome 3q26-29 has been consistently cited as the
most frequently amplified region in HNSCC, with the
minimal amplified region containing 3q26-27 as deter-
mined by comparative genomic hybridization (CGH) [23].
Amplification of 3q26 in HNSCC is an early aberration and
correlates with the transition to invasive cancer and nega-
tive clinical outcome [19, 24]. Amplification of 3q24-29 is
seen more commonly in human papilloma virus (HPV)
positive HNSCC tumor specimens than HPV negative
samples [25]. There are 448 genes in this region, 17 of
these genes were found to be associated with cell motility
or the cytoskeleton. Five genes in this region are well
characterized with respect to cell migration in HNSCC or
other tumor types and are discussed in detail.
Protein kinase C iota
Protein kinase C (PKC) is a multigene family of phos-
pholipid-dependent serine/threonine kinases consisting of
at least 11 isoforms that are expressed in virtually all cells
and tissue types and are involved in regulation of cellular
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proliferation, differentiation and apoptosis [26]. The PKC
enzyme family is divided into three subgroups: Calcium-
dependent, novel, and the atypical PKCs. Protein kinase C
iota (PKCi) is an atypical PKC isozyme, which is not
dependent on calcium or diacylglycerol for its activation
[27]. PKCi is activated by c-Src and is an upstream acti-
vator of the Rac1/Pak/MEK/ERK signaling cascade, which
is crucial to cell motility [28]. The activation of PKCi has
been linked to nicotine, as has its phosphorylation of cal-
pain 1 and 2, contributing to enhanced cellular migration
and invasion in lung cancer [28]. Although there is no
current evidence directly linking it to HNSCC, PKCi is
overexpressed in non-small cell lung cancer and is a
prognostic indicator of poor survival independent of tumor
stage [29]. In ovarian carcinoma PKCi is overexpressed
more than other PKC isozymes [30] and its expression
correlates with decreased survival time [31]. Based on
these data, the role of PKCi in HNSCC cases with 3q26-29
amplification warrants additional investigation.
Phospholipase D1
Intracellular signaling by phospholipase D (PLD1) has
been of interest as a therapeutic target for inflammation and
tumor metastasis for decades [32]. PLD1 is a phospholi-
pase that generates second messenger lipid products
following the binding of a variety of cell surface ligands
[33]. PLD1 catalyzes the hydrolysis of phopshatidyl cho-
line to choline and phosphatidic acid. Phosphatidic acid
(PA) in turn is hydrolyzed to produce diacylglycerol
(DAG) and lysophosphatidic acid (LPA). LPA is involved
in physiological activities including wound-healing,
inflammation, oncogenesis and metastasis [32]. LPA is a
potent inducer of cell motility by regulating the activation
levels of a number of Rho GTPases (described in further
detail below with regards to autotaxin). PLD1 regulates
actin stress fiber and integrin-containing focal adhesion
organization in fibroblasts during cell movement [34].
PLD1 activates the tyrosine kinase c-Src and mitogen
activated protein kinase (MAPK), two kinases central to
the regulation of tumor cell growth and invasion [35].
PLD1 is overexpressed in breast cancer and is required for
tumor cell invasion [36, 37]. Data from the Human Protein
Atlas (http://www.proteinatlas.org/index.php) indicates
that PLD1 is overexpressed in HNSCC, and future studies
will be valuable in evaluating its role in regulating HNSCC
growth and invasion.
Phosphoinsoitide-3-kinase a subunit (PIK3CA)
Phosphoinositide 3-kinases (PI3Ks) constitute a family of
lipid kinases that play a central role in many cellular
functions associated with malignant behavior, including
control of cell cycle progression, invasion, and survival
[38]. Class I PI3Ks typically contain a 110 kDa catalytic
subunit and an 85 kDa regulatory subunit [39]. PIK3CA
encodes the class I p110a catalytic subunit [40] and is
amplified and overexpressed in HNSCC, correlating with
increased vascular invasion [41]. PIK3CA is a master
regulator for activating Cdc42, Rac and Rho, reorganizing
the actin cytoskeleton to result in the formation of filopo-
dia, lamellipodia and stress fibers utilized during cell
migration [42]. In particular, PI3K catalytic activity is
required for EGF-stimulated actin nucleation during
lamellipodia extension in breast cancer cells [43] and
accelerates heregulin-induced breast cancer invasion [44].
The prevalence of PIK3CA amplification in HNSCC and
its association with the transition from dysplasia to inva-
sive carcinoma [45] make it a prime candidate for anti-
tumor and anti-invasive therapeutic strategies.
Claudin-1
Claudin proteins comprise a growing protein family that
are essential for the formation of tight junctions (TJs) in
epithelial and endothelial cells [46]. TJs are critical for
cell–cell adhesion, functioning to physically fuse the
membrane of adjacent cells together, creating a paracel-
lular seal that regulates the control of solutes between cells
and establishes a diffusion barrier for integral membrane
proteins in the lipid bilayer [46]. TJs are indirectly linked
to the actin cytoskeleton through a series of adaptor and
signaling proteins. Like all claudins, claudin-1 can form
homotypic or heterotypic interactions with other claudin
members as TJs are formed, with the precise combination
of claudin types determining the strength of the junction
[46]. Maintenance of cell–cell adhesion provides resis-
tance to the epithelial to mesechymal (EMT) transition
during neoplastic transformation, and is often associated
with altered claudin expression [47]. Accordingly, loss of
claudin-1 expression is correlated with higher-grade
colorectal carcinoma than cases with normal claudin-1
levels [48]. However, many claudin members, including
claudin-1, display increased expression in HNSCC and
other cancer types [49], suggesting other functions for
claudin proteins besides TJ biogenesis and homeostasis. In
HNSCC, claudin-1 overexpression enhances the activity
and expression of matrix metalloproteinases MT1-MMP
and MMP2, resulting in elevated cleavage of the extra-
cellular matrix protein laminin-5 and increased tumor cell
invasion [50]. While the precise mechanism of how clau-
din-1 regulates MMP activity is currently unclear, the
evaluation of claudin-1 expression on clinical outcome in
HNSCC cases with 3q26-27 amplification may validate the
role of claudin-1 as a pro-invasive biomarker in select
HNSCC cases.




Activated Cdc42-associated kinase 1 (ACK1) is a dual
specificity tyrosine and serine/threonine kinase that is
amplified and overexpressed in HNSCC [51, 52]. ACK1
was initially identified as an interacting protein for GTP-
bound Cdc42 [53], suggesting a role in actin cytoskeletal
regulation. In support of this, ACK1 mediates signaling
events that lead to actin cytoskeletal reorganization. ACK1
indirectly regulates Rho family protein activity by phos-
phorylation and activation of the Rho family guanine
nucleotide exchange factor Dbl [54]. ACK1 also regulates
actin cytoskeletal architecture by directly phosphorylating
p130CAS [55], a protein linked to activation of Rac and
promotion of cell motility and invasion [56]. In addition,
ACK1 phosphorylates WASp on tyrosine and serine resi-
dues, resulting in enhanced stimulation of Arp2/3-mediated
actin nucleation activity in cell extracts [57]. These data
collectively indicate that ACK1 utilizes multiple signaling
pathways in regulating actin cytoskeletal assembly, indi-
cating that carcinoma motility, invasion and metastasis
may be enhanced in tumors containing amplification and
overexpression of ACK1. Direct evidence for ACK1
amplification and overexpression playing a role in tumor
invasion has been recently documented in esophageal and
lung caracinoma, cancers that correlate with adverse
environmental exposure. ACK1 amplification and overex-
pression in these tumors corresponds with poor patient
outcome, as well as stimulating invasion and metastasis in
animal model systems [52]. In addition, ACK1 is activated
downstream of EGFR [58, 59], suggesting that overex-
pression of EGFR in HNSCC may serve to additionally
potentate signaling pathways in tumors with ACK1 over-
expression. Along with its role in regulating tumor cell
motility and metastasis, ACK1 has recently been shown to
promote tumorigenesis in prostate carcinoma by phos-
phorylating the tumor suppressor WW domain containing
oxireductase (Wwox), targeting it for polyubiquitination
and degradation [60]. The multiple roles of ACK1 in tumor
progression may make it a viable candidate for novel
therapeutic development.
Chromosome 8q23-24
Amplification of the 8q region is common in HNSCC, and
has been cited as the second most important early chro-
mosomal event in HNSCC progression [23, 61, 62]. The
most commonly amplified subregion is 8q23-24 [62]. The
oncogenic transcription factor c-myc is located on 8q24,
and HNSCC cases with 8q24 amplification demonstrate
increased c-myc expression that is associated with poor
survival [18, 63]. There are 273 genes within the 8q23-24
region, with 14 associated with actin cytoskeletal regula-
tion, cell motility or invasion. Four of these are either
known or have the potential to regulate HNSCC motility
and invasion and are described below. Table 1 contains
additional relevant genes found in this region
Autotaxin
Autotaxin (ATX) is an extracellular glycoprotein that is a
potent stimulator of tumor cell motility and invasion in a
variety of normal and tumor cell lines [64, 65]. ATX
functions as an extracellular nucleotide pyrophosphatase
and phosphodiesterase (NPP) [66, 67]. The phosphodies-
terase activity of ATX is required for mediating cell
movement [67], and it was later discovered that ATX is
identical to lysophospholipase D, a serum enzyme
responsible for producing LPA in serum [68]. LPA pro-
duced by ATX stimulates cell movement by activating
Rac1 and RhoA and associated actin structures through
engagement of the LPA1 and LPA2 G-protein coupled
receptors [69], creating a potent autocrine loop for main-
taining cell migration. ATX is also a stimulator of
angiogenesis, a factor contributing to its ability to enhance
tumor aggressiveness [70]. ATX overexpression has been
documented in non-small cell lung cancer [71] and its
overexpression correlates with increased invasive potential
in breast carcinoma [72]. While the known data and
characteristics of ATX make it an attractive candidate as a
mediator of HNSCC invasion and metastasis in cases with
8q23-24 amplification, or overexpression of ATX in
HNSCC has yet to be confirmed.
MIM1
Missing in metastasis 1 (MIM1, MTSS1) was initially
named due to the absence of the gene product in metastatic
bladder and prostate cancer cells [73], suggesting that
MIM1 functions as a tumor suppressor. Evaluation of
MIM1 function by structure-function studies indicates that
it serves as a scaffold protein that regulates actin dynamics
and gene transcription [74]. MIM1 binds G- and F-actin
and serves to coordinate actin assembly and lamellipodia
formation through activation of Rac [75]. MIM1 also
interacts with cortactin, enhancing the ability of cortactin
to facilitate Arp2/3 mediated actin assembly while inhib-
iting Arp2/3 activation by N-WASp [76](see below).
Binding of MIM1 to cortactin enhances lamellipodia for-
mation and fibroblast motility initiated by PDGF [75, 76].
PDGF-mediated Src activation leads to tyrosine phos-
phorylation of MIM1, an event essential for the formation
of pro-migratory membranous dorsal waves [77]. Although
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these studies suggest MIM1 expression enhances motility
in cell model systems, MIM1 expression levels vary widely
in different carcinomas [74]. MIM1 expression is down-
regulated in prostate, bladder and gastric cancers but it is
upregulated in basal cell carcinomas [78–80], making the
precise function of MIM1 expression in cancers unclear.
While data on MIM1 amplification and expression in
HNSCC is currently lacking, its presence on chromosome
8q24 suggests that MIM1 overexpression may play a
potential role in enhancing HNSCC invasion in cases with
coamplification of 8q24 and the cortactin locus on 11q13.
FAK
Focal adhesion kinase (FAK, PTK2) is a non-receptor
tyrosine kinase that has been intensively studied with
regards to its role in cell motility and tumor cell invasion
[81, 82]. FAK was initially identified as a v-Src substrate
that localizes to integrin-containing focal adhesions in cell
culture [83, 84]. Integrin or growth factor receptor activation
leads to FAK activation, resulting in autophosphorylation
at tyrosine 397. Phosphorylation at tyrosine 397 creates a
binding site for the SH2 phosphotyrosine binding domain
of activated Src and related tyrosine kinases. The activated
Src/FAK nexus in turn is responsible for the downstream
phosphorylation of the cytoskeletal associated proteins
paxillin and p130 Crk Associated Substrate (CAS), stim-
ulating cell migration [81]. FAK-null cells contain
increased numbers of focal adhesion complexes and are
defective in motility, indicating that one role FAK plays
during motility is to regulate efficient adhesion complex
turnover [85]. It is now clear that FAK exerts many of its
effects on motility through the kinase-independent associ-
ation with a multitude of signaling and effector proteins. Of
note is the ability of FAK to influence activation of Cdc42,
Rac and Rho, assisting in regulating the proper spatial and
temporal regulation of the actin cytoskeleton during cell
movement [82]. FAK also plays an active role in tumor
invasion and invadopodia formation through signaling
pathways involving Src that also activate Rac and Jun
N-terminal Kinase (JNK), leading to the increased
expression of MMP2 and MMP9 [86]. FAK overexpression
been well documented in HNSCC and other tumor types,
corresponding to increased invasive and metastatic poten-
tial [2, 87]. While the FAK locus at 8q24.3 is amplified in
HNSCC cases, FAK gene amplification does not com-
pletely correspond with FAK protein overexpression [88].
FAK overexpression occurs early in HNSCC and is present
at all stages in HNSCC progression, statistically correlating
with lymph node metastases [88]. In HNSCC, disease free
survival seems to be impacted by FAK overexpression
[88], suggesting that FAK may be a valid therapeutic
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downregulated in HNSCC cell lines treated with the Src
kinase inhibitor dasatinib [89], indicating that FAK activity
is indirectly impacted as a result of Src inhibitor therapy in
HNSCC. Effective disruption of FAK signaling by direct
targeting of FAK may be complex, given the kinase-
dependent and -independent roles FAK plays in cell
motility and invasion [90]. However, recent studies dem-
onstrating impaired migration in tumor cells treated with
novel small molecular inhibitors of FAK kinase activity
[91, 92] may validate the further evaluation of these and
related compounds in clinical settings as anti-invasive and
metastatic agents.
DDEF1
Development and differentiation enhancing factor 1
(DDEF1, known as AMAP1, ASAP1 or centaurin beta4) is
a member of the centaurin family of ADP-ribosylation
factor GTPase-activating proteins that regulate the actin
cytoskeleton in cell motility and cancer cell invasion [93–
95]. Activation of PI3-kinase or Src phosphorylation
enhances the ability of DDEF1 to downregulate activated
Arf proteins by the hydrolysis of bound GTP to GDP [96,
97]. Arf proteins are members of the Ras superfamily of
small GTP-binding proteins that function in regulating
vesicle trafficking and cytoskeletal regulation [98]. DDEF1
localizes to the cell periphery within focal adhesions,
where it regulates growth factor induced lamellipodia for-
mation [93]. DDEF1 also interacts directly with FAK and
is involved in the regulation of focal adhesion turnover
during migration [99]. Overexpression of DDEF1 in breast
cancer cells corresponds to an invasive phenotype and
leads to invadopodia formation [100]. DDEF1 expression
is essential for invadopodia formation, where it forms a
trimeric complex with cortactin and paxillin that is required
for extracellular matrix degradation [100]. The presence of
DDEF1 in this complex may regulate endocytosis of
degraded matrix components by localized activation of
Arf6 in cooperation with the membrane deforming Bar
domain of DDEF1 [94]. Targeted disruption of the cort-
actin/DDEF1 binding interface with either cell permeable
peptides or UCS15A, a small molecule inhibitor that
competitively binds to the DDEF1 binding site of cortactin,
inhibits breast cancer invasion and metastasis [101]. These
studies indicate that DDEF1 expression plays a critical role
in tumor cell invasion, particularly in cases where it is
overexpressed. Amplification of the DDEF1 locus on
8q24.21 corresponds with DDEF1 overexpression,
increased motility and higher tumor grade in uveal mela-
noma [102]. The location of DDEF1 on 8q24 as well as its
important role in regulating the actin cytoskeleton and
tumor cell invasion suggest that it likely plays a critical
role in HNSCC invasion.
Chromosome 11q13
Amplification of the 11q13 region has been well recog-
nized as a major event driving HNSCC invasion and
metastasis, occurring in 30–50% of all HNCSS cases [18,
19, 103]. The presence of 11q13 amplification correlates
with decreased disease free survival [104]. The 11q13
amplicon contains 353 genes, with the cell cycle regulatory
protein cyclin D1 the best-characterized amplified gene
product with regards to regulation of HNSCC progression
[18]. In addition to cyclin D1, the 11q13 amplicon contains
several well-characterized genes known to regulate actin-
based motility and invasion that are overexpressed in
HSNCC and other tumor types. Fourteen of these genes are
shown in Table 1; nine are discussed in detail.
CDC42EP2
Cdc42 effector protein 2 (BORG1, CEP2) is a member of a
class of effector proteins initially identified by direct
interaction with activated Cdc42 [105, 106]. Ectopic
expression of CDC42EP in fibroblasts induces long, finger-
like filopodia (pseudopodia) and accumulates into leading
edge lamellipodia [105, 106]. CDC42EP2 expression in
cultured keratinocytes reduces the thickness and organi-
zation of the actin stress fiber network [106], consistent
with changes observed during motility. The changes in F-
actin architecture are attributed to the direct binding of
CDC42EP2 to members of the septin GTPase protein
family [107]. Septins self-polymerize to form multimeric
filaments that further organize into ring-like structures
responsible for binding F-actin bundles at the cell periph-
ery and for the completion of cytokinesis [108].
CDC42EP2 binding to septins disrupts septin organization
[107], providing a mechanism for the observed reduction of
stress fiber thickness and organization in cells with
increased CDC42EP2 expression. While overexpression
occurs in HNSCC [109], a clear role for CDC42EP2 in cell
movement or tumor invasion has yet to be established.
Calpain 1
Calpain 1 (l-calpain, CAPN1) is a member of a 16-gene
superfamily of cysteine proteases responsible for regulating
cell motility and other cellular processes by select cleavage
of adhesion and cytoskeletal protein substrates [110, 111].
Calpain 1 and the related calpain 2 have been the best
characterized members with respect to cell movement,
where the role of calpain 2 has been well established in
regulating motility through the cleavage of several com-
ponents of focal adhesions and the actin cytoskeleton.
Calpain 2 substrates of note include that are involved in
adhesion and/or motility include FAK, cortactin, paxillin,
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spectrin and talin, with cleavage resulting in the disas-
sembly focal adhesion complexes, loss of adhesion to the
substratum, remodeling of the actin cytoskeleton and
increased cellular motility [111]. Studies utilizing knockout
cells or RNA interference indicate that calpain 1 either
does not cleave these substrates or is compensated for by
other calpain forms [112, 113], casting some doubt on the
participation of calpain 1 in cell migration. However, cal-
pain 1 has been shown to be required for lamellipodia
production during the spreading of bovine aortic endothe-
lial cells by activating Rac and Rho to regulate the
production of initial integrin focal contacts [114, 115].
Other studies demonstrate inhibited cell spreading when
calpain 1 is downregulated [112], making the issue difficult
to interpret. In cancer models, a role for calpain 1 in reg-
ulating tumor cell invasion is better established. Calpain 1
has been shown to be critical for breast and colon cancer
cell motility and invasion in the absence of calpain 2
expression [116, 117]. Additional evidence to support a
role for calpain 1 in tumor metastasis comes from work in
basal cell skin carcinoma, a rarely metastatic cancer that is
devoid of calpain 1 whereas metastatic cases exhibit strong
calpain 1 overexpression [118]. While there is no evidence
to date that calpain 1 plays a role in HNSCC, association of
calpain 1 expression in invasive and metastatic tumors
combined with its amplification on 11q13.1 suggest that
calpain 1 overexpression may play an important role in
regulating HNSCC invasion.
Cofilin 1
Cofilin 1 is a member of a family of well-characterized
actin-binding proteins that bind G- and F-actin. A two-fold
overexpression of cofilin has been documented in oral
squamous cell carcinoma and is in accordance with other
cancer types that display increased invasive capacity [7,
119]. Cofilin functions in cell motility and tumor cell
invasion by promoting lamellipodia and invadopodia for-
mation [120, 121]. Mechanistically, cofilin functions by
severing existing actin filaments in response to EGF and
other growth factor stimuli [120]. The severing activity of
cofilin has a dual effect on actin dynamics to promote
cortical actin-based protrusions. Severing increases the
number of available barbed (+) ends allowing for rapid
actin polymerization at the cell cortex independent of
Arp2/3 complex activity. Severing also serves to enhance
the rate of F-actin depolymerization, allowing G-actin
monomers to be utilized in a subsequent round of poly-
merization [7]. Cofilin is regulated by phosphorylation on
serine 3 by LIM and TES family kinases, which inactivates
cofilin’s severing activity [122]. Dephosphorylation of
serine 3 by the phosphatases slingshot, chronophin, type 1,
2A and 2B phosphatase activates cofilin [122]. While this
cycle of cofilin regulation is well established, evidence to
date indicates that cofilin activation in invasive carcinoma
cells is not coupled to dephosphorylation but to hydrolysis
of bound inhibitory phosphatydalinositol-4,5-bisphosphate
(PIP2) by the enzyme phospholipase C (PLC) [123, 124].
The two independent methods of cofilin regulation have
been reconciled to support the presence of a rapidly acti-
vated cofilin pool (by the PIP2/PLC cycle) that contributes
to membrane protrusion and a phosphorylation-regulated
pool that recycles cofilin or confines it to specific subcel-
lular compartments [7]. The overexpression of cofilin in
oral carcinomas makes it likely that cofilin dynamics play a
central role in regulating the actin cytoskeleton during
HNSCC motility and invasion.
FOSL1
The Fos related antigen-1 (fosl1, more commonly known as
Fra-1) is a transcription factor of the Fos family overex-
pressed in HNSCC and other human carcinomas [125,
126]. Fra-1 is a component of the activator protein-1 (AP-
1) transcription complex, a semi-variable family of nuclear
dimeric complexes comprised of either homodimers of the
Jun family of transcription factors, or heterodimers of the
Jun and Fos family [127]. Enhanced activation of AP-1 is
required for tumor promotion, interacting with various
cofactors to regulate the expression of a wide variety of
genes involved in proliferation, angiogenesis, apoptosis,
migration and invasion [126]. Fra-1 expression alone is
sufficient for cellular transformation and anchorage inde-
pendent growth [128], indicating that this component of the
AP-1 complex plays a significant role in cancer. Identified
motility and invasion genes regulated by Fra-1 include the
matrix metalloproteinase MMP-9 and the pro-invasive
transmembrane receptors CD44 and c-MET [129, 130].
Expression and stabilization of Fra-1 is regulated by
MAPK [131, 132], a terminal kinase of the Ras pathway
displaying elevated activity resultant of EGFR overex-
pression. In colorectal carcinoma cells, upregulation of
Fra-1 by MAPK activity results in decreased activation of
RhoA [133], a small GTPase responsible for regulating
cell-substrate adhesion by governing focal adhesion and
stress fiber formation. Reduced RhoA activation by MAPK
is required for subsequent MAPK-induced expression of
the urokinase plasminogen activator receptor (uPAR),
which in turn promotes cell motility through increased
activation of Rac and Arp2/3 complex [133, 134]. Down-
regulation of Fra-1 expression suppresses motility and
invasion [133]. The dependence of Fra-1 on MAPK
activity suggest that therapeutic targeting of MAPK acti-
vating enzymes and other components of the EGFR-Ras
pathway may be valid strategies for reducing Fra-1 levels
in HNSCC and other carcinomas.




The RIN1 gene is amplified to varying degrees in 50% of
cell lines derived from OSCC patients with 11q13 ampli-
fication [135]. The RIN1 protein is an effector molecule
that binds to activated H-Ras and regulates pathways
involved in endocytosis and cell migration [136]. With
regards to migration, RIN1 expression in fibroblasts and
epithelial cells induces changes in actin cytoskeletal
organization through the binding and activation of Abl and
Arg tyrosine kinases [137]. Activation of Abl and Arg as a
result of RIN1 expression increases cell membrane pro-
trusion and enhances cell motility [137]. Mechanistically,
RIN1 expression may enhance cell motility through Abl/
Arg mediated phosphorylation of the adaptor protein CRK
[137], which when phosphorylated increases binding to the
CRK associated substrate CAS [138]. The CAS/CRK
complex subsequently induces motility through activation
of Rac leading to Arp2/3-induced lamellipodia formation
[139]. A second potential mechanism where RIN1 may
promote cell migration is through Abl/Arg-mediated
phosphorylation of cortactin [140], an actin binding and
Arp2/3 activating protein known to promote HNSCC
motility and invasion (see below). The utilization of either
of these pathways downstream of RIN1 to promote motility
in HNSCC or other cancer types has yet to be validated.
Slingshot homolog 3
Slingshot homolog 3 (Slingshot 3, SSH3L or hSSH3L) is a
member of a phosphatase family that serves to regulate
cofilin activation [122]. Slingshot phosphatases selectively
dephosphorylate cofilin on serine 3 resulting in increased
cofilin severing activity and actin depolymerization [141].
While Slingshot-mediated dephosphorylation counteracts
the ability of LIMK and TESK kinases from inhibiting
cofilin, as mentioned above it appears that it is not the
primary mechanism of cofilin regulation utilized during
cell movement. However, LIMK activity is important in
restricting cofilin activity within lamellipodia [123] and
thus elevated slingshot expression could result in increased
activated cofilin levels within the lamellipodial cofilin
pool, potentially accelerating cortical actin remodeling.
Slingshot 3 is unique in that it does not bind actin fila-
ments, as do other Slingshot proteins, and it displays the
weakest cofilin dephosphorylation activity of all family
members [142]. The weak activity of Slingshot 3 towards
cofilin may be beneficial in cases where cofilin and
Slingshot 3 are overexpressed, allowing equilibrium in the
activation state of cofilin to be maintained. The proper
balance in regulating cofilin phosphorylation and activation
is critical for cell movement and invasion, as evidenced by
impaired motility when cofilin is overexpressed at
abnormally high levels or when constitutive active LIMK
is expressed [7]. The modest overexpression of cofilin
coupled with Slingshot 3 overexpression in HNSCC may
therefore provide the ideal dichotomy for maximizing
cofilin activity levels to stimulate motility and invasion.
Coronin 1B
Coronin 1B (coronin-2, coroninSE) is a member of a seven
gene superfamily of actin-binding proteins [143] originally
identified in Dictyostelium, so named due to its localization
in crown-like structures on the dorsal cell surface [144].
Coronin 1B localizes to leading edge lamellipodia, where it
forms homotrimeric complexes that bundle F-actin [143,
145]. Coronin 1B and related coronins bind Arp2/3 com-
plex and inhibit its activation by WASp family proteins
[146, 147]. This binding is regulated by phorbol ester-
mediated activation of PKC isoforms that phosphorylate
coronin on serine residue two, downregulating the binding
of coronin 1B to Arp2/3 complex [147]. Coronin 1B
therefore provides additional regulatory control of Arp2/3-
driven actin polymerization in lamellipodia during cell
movement. In agreement with this, depletion of coronin 1B
in fibroblast cell lines inhibits motility and alters lamelli-
podia actin architecture [148]. Coronin 1B also binds to
and is dephosphorylated by the phosphatase Slingshot
homologue 1L (SSH1L), and is responsible for targeting
SSH1L to lamellipodia where it can dephosphorylate and
activate the F-actin severing activity of cofilin [148]. In this
capacity coronin 1B serves as a molecular bridge with the
ability to accurately coordinate and regulate actin poly-
merization and depolymerization events within
lamellipodia, resulting in optimal lamellipodia dynamics
and cell movement. While direct evidence for the
involvement of coronin 1B overexpression in HNSCC or
any cancer is currently lacking, it is likely that future
studies will evaluate the role of coronin 1B and the impact
of its overexpression on tumor cell movement.
Cortactin
Cortactin (EMS1, amplaxin, SRC8) is an adaptor protein
that is overexpressed at high levels in roughly 30% of
HNSCC cases [149]. Cortactin gene amplification and
overexpression in HNSCC is associated with poor clinical
outcome [150], increased motility and cellular invasion
[151]. Cortactin is found in lamellipodia and invadopodia,
and functions by binding to F-actin and the Arp2/3 com-
plex, stimulating actin nucleation and subsequent
polymerization [152]. Interactions with the commonly
amplified 8q23-24 gene products MIM1 and DDEF1 [76,
101] likely contribute to the ability of cortactin to stimulate
Arp2/3 activity and/or regulate cellular invasion in cases
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where both amplicons are present. In addition to regulating
actin polymerization within lamellipodia, cortactin also
stabilizes the actin networks formed by Arp2/3-driven
polymerization, an activity congruent with the requirement
for cortactin to maintain lamellipodial persistence [153,
154]. While cortactin is not necessary for cells to produce
lamellipodia, it is absolutely required for the formation of
functional (matrix degrading) invadopodia [155, 156].
Cortactin is essential for the establishment of the actin core
within invadopodia, where its recruitment precedes the
localization of the matrix metalloproteinase MT1-MMP to
sites of matrix degradation [155]. Recently, cortactin has
been shown to be required for the secretion of MMP-2 and
MMP-9 in HNSCC, further expanding the role of cortactin
in cancer invasion [156]. Cortactin activity is regulated in
part by phosphorylation resulting from the activation of
EGFR and other receptor tyrosine kinases. Downstream
activation of Src, MAPK and additional cytoplasmic
kinases leads to direct cortactin tyrosine and serine phos-
phorylation at multiple sites [157]. Tyrosine
phosphorylation of cortactin is required for efficient
migration in HNSCC and other carcinomas, and is also
associated with matrix degradation activity at invadopodia
and distant metastasis in animal models [157–159]. Serine
phosphorylation by MAPK has been proposed to regulate
the ability of cortactin to activate N-WASp [160], indi-
cating that Src and MAPK pathways converge to govern
the ability of cortactin to regulate actin polymerization.
Collectively, studies to date point to cortactin as playing a
central role in HNSCC motility and invasion, suggesting
that therapeutic intervention targeting phosphorylation
pathways or binding partners may be warranted means of
controlling local-regional and metastatic spread.
Shank2
Shank2 is a member of a multigene family responsible for
encoding large scaffolding proteins intimately associated
with the inner face of the plasma membrane. Shank2 and
related proteins have been best characterized at the post-
synaptic density in neurons, where they have been shown
to functionally sequester neurotransmitter receptors into
multiprotein complexes, linking them to a wide variety of
cytoplasmic signaling proteins [161]. Expression of
Shank2 and related isoforms are found in epithelial cells,
where they bind and regulate the function of the Na+/H+
exchanger 3 to assist in maintaining salt and water
homeostasis [162]. In oral squamous cell carcinomas
Shank2 is often coamplified and overexpressed with cort-
actin [163] and the two protein products directly interact
[164]. This suggests that Shank2 provides a molecular link
between transmembrane receptors and the actin cytoskel-
eton through cortactin. Shank2 also interacts with sharpin,
a protein of unknown function whose gene is also present
and amplified within the 11q13 region [165]. While the
functional significance of Shank2 overexpression in
HNSCC is currently unclear, an intriguing possibility is
that Shank2 may participate in enhancing cellular invasion
given its association with cortactin and dynamin2 [166],
proteins that are required for invadopodia protrusion and
extracellular matrix degradation [167]. Whether Shank2
serves as a scaffold for coordinating invadopodia function
in this regard in HNSCC or any cancer type has yet to be
resolved.
PAK1
p21-activated kinase 1 (PAK1) is a serine/threonine kinase
that regulates signaling pathways governing motility and
invasion in a variety of human tumor types [168]. Identified
as the first effector protein to interact with activated Cdc42
and Rac [169], PAK1 kinase activity is stimulated by
Cdc42/Rac binding as well as through other activation
mechanisms [168]. One Cdc42/Rac independent mecha-
nism of note is the direct binding of PI3 kinase to PAK1,
resulting in increased PAK1 activity and phosphorylation
of downstream substrates [170]. PAK1 participates in cell
migration by driving lamellipodia formation and regulating
cortical actin cytoskeletal organization [171, 172]. The
ability of PAK1 to influence the cortical actin network is
accomplished by the direct phosphorylation of numerous
actin regulator proteins. Phosphorylation of LIM kinase by
PAK1 promotes LIM kinase activity, leading to cofilin
inactivation and increased lamellipodia protrusion [173].
Elevated expression and/or activation of either PAK1 or
LIM kinase leads to enhanced tumor cell invasion and
metastasis in breast and prostate cancers [174], demon-
strating the importance of this PAK1 pathway in cancer
progression. PAK1 also phosphorylates the p41 subunit of
the Arp2/3 complex, resulting in direct stimulation of actin
nucleation and cell migration independent of other nucle-
ation promoting proteins [175]. The actin bundling protein
filamin is also a PAK1 target, where PAK1-mediated
phosphorylation of filamin is required for lamellipodia
extension [176]. Finally, PAK1 phosphorylates cortactin,
an activity thought to influence the ability of cortactin to
bind F-actin [177]. These studies suggest that PAK1 serves
as a master regulator of cortical actin dynamics leading to
cell migration and tumor cell invasion. While PAK1
overexpression in HNSCC has been demonstrated and
functions downstream of EGFR activity to promote
HNSCC invasion [178], the PAK1 gene on 11q13.5 is not
amplified in OSCC cases that demonstrate amplification of
the 11q13 genes cortactin, cyclin D1 and SHANK2 [163].
These data suggests that gene amplification may not be
responsible for PAK1 overexpression in HNSCC.
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Nevertheless, the central role of PAK1 in motility signaling
combined with its overexpression in HNSCC may warrant
further clinical evaluation and refinement of several
recently described PAK1 inhibitors as potential anti-inva-
sive therapeutic agents [168].
Conclusions and future perspectives
The high degree of invasion and lymph node involvement
that characterizes HNSCC makes its clinical management
difficult. The known gene products to date overexpressed
due to amplification of 3q26-29, 8q23-24, and 11q13 and
allow for extensive pro-migratory and pro-invasive poten-
tial in HNSCC that has been clinically established for
select genes within these amplicons (i.e., PI3Ka, FAK and
cortactin). While the genes listed and described in this
review are not exhaustive with regards to proteins that
regulate actin biology in all cell types, the proteins known
to play central roles in actin regulation and/or participate in
tumor motility in other cancers may be equally important
in HNSCC and therefore should be good candidates for
evaluative roles in invasion. Given the large number
potential genes present within these chromosomal seg-
ments, comprehensive studies will be a challenging task.
As illustrated in Fig. 1, another compounding barrier to
understanding the actin-based factors regulating HNSCC
motility and invasion is the additional complexity that
arises in cases with amplification of two or all three of
these regions, a phenomenon that has been documented in
patients [21]. In such cases the interplay between many of
the gene products from each individual amplicon is largely
unknown in a normal cellular environment, much less in a
tumor setting where additional epigenetic changes come
into play. Studies examining the cross talk of gene products
produced from these three different amplicons, while
complex, would represent a major advancement in our
understanding of the molecular underpinnings utilized
during HNSCC invasion and metastasis. Such work will
require firm clinical and experimental validation to deter-
mine which amplified gene combinations are the most
important and/or commonly utilized during HNSCC inva-
sion. Such mechanistic and preclinical work is prerequisite
for the rational design and development of novel anti-
invasive and -metastatic therapies for the treatment of
HNSCC and other cancer types containing these
amplicons.
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